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Abstract 
 
Drug discovery is reliant on new developments in natural product chemistry as well as advances 
in chemical synthesis. The interconnectivity and interdependence of natural and synthetic 
investigation in drug discovery is evident.  The chemical exploration reported herein elaborates 
the relationship between natural product chemistry and chemical synthesis.  Of particular interest 
are chemicals from organisms residing in less accessible environments, particularly Antarctica 
and endophytic microbial communities.  Degradation via reductive ozonolysis of palmerolide A, a 
macrocyclic polyketide isolated from the Antarctic tunicate Synoicum adareanum, and 
subsequent synthetic preparation of the resulting polyols (1,2,6-hexanetriol and 1,2,3,6-
hexanetetraol) led to a revision in the absolute configuration of the bioactive natural product (7R, 
10R, 11R to 7S, 10S, 11S).  A partial synthesis of palmerolide A (C3-14) was completed using 
Grubb’s 2
nd
 generation catalyst to couple fragments formed using the previously developed 
methodology from the degradation study.  Isolation of indole-pyrimidine containing alkaloids 
meridianins A, B, C, and E from the Antarctic tunicate Synoicum sp. prompted a synthetic 
investigation of psammopemmin A, a related alkaloid from the Antarctic sponge Psammopemma 
sp. resulting in reassignment of the structure of psammopemmin A to that of meridianin A.  Both 
meridianin A and psammopemmin A were synthesized through a Suzuki coupling of the same 4-
indolol nucleophile to the apposite pyrimidine electrophile.   Several synthetic 3-pyrimidylindole 
analogs were also prepared and investigated for central nervous system, antimalarial, and 
cytotoxic activity.  Chemical investigation of extracts from mangrove fungal endophytes that 
displayed antimalarial properties in vitro resulted in the isolation of several potent but cytotoxic 
and cytostatic compounds: cytochalasin D, roridin E, and 12,13-deoxyroridin E. 
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Chapter 1.  Drugs, nature, and synthesis 
 
1.1 Natural products as sources for drugs 
Compounds derived from natural sources are essential for new drug discovery.  According to 
analysis of all drugs approved world-wide from 1981-2006, seventy percent of the new chemical 
entities reported are natural products, derived from natural products, or inspired by natural 
products.
1
  It is not surprising that organisms produce a multitude of bioactive molecules.  
Organisms survive based on their ability to generate and retain chemical diversity at low cost.
2
  
The inherent diversity, selectivity, and potency of natural products ensure their utility in the drug 
discovery and development process.  Both marine
3
 and microbial
4
 environments are sources for a 
wealth of natural products.  At the interface of macro- and microenvironment are microbial 
symbionts, thought to be responsible for producing a number of compounds isolated from marine 
macroorganisms.
5
  The unfathomable diversity intrinsic to marine and microbial environments 
ensures unlimited drug discovery potential. 
 
1.2 Drugs from the sea 
The antecedent search for biologically active compounds from marine sources can be traced, in 
part, to the laboratory of Paul Scheuer, who methodically investigated the chemistry of marine 
invertebrates beginning in the 1950’s.
6
   Since those initial explorations, bioactive drugs derived 
from marine organisms have proven their therapeutic utility.
7
  The potential for marine natural 
products as pharmaceuticals is impressive; many compounds isolated from the marine 
environment have progressed to clinical trials.
8
   To date, one non-peptide drug originating from 
the marine environment has made it to the commercial sector.   
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Ecteinascidin 743 (= ET-743, trabectedin, Yondelis®, 1.1), a tris(tetrahydroisoquinoline), was the 
first marine natural product anticancer drug to be sold commercially.
9
  Originally described by the 
Rinehart group,
10,11
 with simultaneous publication by Wright et al.
12
 from an antiproliferative 
extract of the Caribbean tunicate Ecteinascidia turbinata, ET-743 was isolated in low yields 
(0.0001%) along with several other analogs (ET-729: 1.2; ET-745: 1.3; ET-759A: 1.4; ET-759B: 
1.5; ET-770: 1.6).  ET-743 was found to target DNA transcription by a complex mechanism of 
action involving DNA binding
13
 with an unusual requirement: the cell must possess a proficient 
nucleotide excision repair (NER) system.
14
  This differs from all other known DNA interacting 
agents which require deficient NER systems to exert cytotoxic effects.  Supply problems of ET-
743 were addressed initially with large-scale aquaculture then later alleviated using an efficient 
semisynthetic procedure (see section 1.4.3).  Under the trade name Yondelis®, ET-743 is 
marketed by PharmaMar in partnership with Johnson and Johnson in the European Union as 
treatment for advanced soft tissue sarcoma and is currently in development for ovarian, prostate, 
lung, breast and pediatric cancers. 
 
 
Discodermolide (1.7), a polypropionate-derived polyhydroxy--lactone isolated from the rare 
Bahaman deep-water (300 m) sponge Discodermia dissoluta, is a potent microtubule stabilizing 
agent (MSA).
15,16
  MSA’s impede the cellular cycle by stabilizing microtubules in conditions which 
would normally be destabilizing, effectively disrupting microtubule dynamics.
17 
 Discodermolide 
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was found to stabilize microtubules more potently than taxol
18
 generating immense interest in the 
compound.  Problems with obtaining quantities suitable for preclinical evaluation led to the 
development of efficient gram scale syntheses of discodermolide (see section 1.4.3).  Although 
an extremely promising lead, Phase 1 clinical trials were halted on discodermolide due to lack of 
efficacy at tolerated doses. 
 
 
Initial investigation of the shallow water Japanese sponge Halichondria okadai revealed a 
cytotoxic polyether C38 fatty acid derivative designated okadaic acid (1.8).
19
  Due to remarkable 
antitumor activity demonstrated by H. okadai extracts in vivo, subsequent reinvestigation of 
sponge revealed small quantities of several cytotoxic polyether macrolides, including halichondrin 
B (1.9) which was shown to potently (nanomolar concentrations) inhibit cell growth.
20
  The low 
yields of halichondrins (halichondrin B: 20 g/kg; total halichondrins: ~0.14 mg/kg) from H. okadai 
presented a barrier for preclinical trials.  Fortuitously, a new species of deep-water sponge, 
Lissodendoryx n. sp. 1 from the South Island of New Zealand, was discovered to contain the 
compounds in higher concentrations  (halichondrin B: ~0.4 mg/kg; total halichondrins: ~1.5 
mg/kg).
21
  One metric ton of Lissodendoryx n. sp. 1 was harvested via trawling (80 – 100 m) 
which resulted in isolation of halichondrin B (310 mg), quantities sufficient for preclinical trials.  As 
aquaculture techniques
22
 were in development to provide the gram scale quantities of 
halichondrin B necessary for clinical trials, truncated synthetic halichondrin analogs were found to 
retain the natural product’s potent activity.  Even though halichondrin D had advanced to Phase I 
clinical trials in 2002, focus was directed to the most promising of the truncated synthetic analogs 
(see section 1.4.4). 
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The abovementioned compounds represent a small fraction of marine-derived chemistry 
exhibiting intriguing chemical structure and exciting bioactivity, a majority of which are isolated 
from temperate and tropical waters.  Because marine natural product discovery programs have 
traditionally focused on organisms in tropical and temperate waters, a wealth of cold-water 
organisms remain largely unexplored.
23
  Although understudied, marine invertebrates residing in 
cold water have elaborated many interesting and biologically relevant compounds.  Chapters 2 
and 3 of this dissertation examine some remarkable chemistry isolated from cold-water marine 
invertebrates.  
 
1.3 Drugs from microorganisms 
Microbe-derived drug discovery began in 1928 in the laboratory of Alexander Fleming
24
 when a 
Penicillium mold was observed to kill Staphylococcus aureus, leading to the discovery of the 
antibiotic -lactam, penicillin (1.10).  An abundance of  useful antibiotics derived from microbes 
have been isolated since that initial discovery including streptomycin (1.11), an aminoglycoside 
from Streptomyces griseus, the dichloroacetamide chloramphenicol (1.12) from Streptomyces 
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venezuelae and the tetracyclines from Streptomyces spp., the first of which was named 
chlortetracycline (1.13).  As well as antibiotic activity, microbial secondary metabolites display a 
broad range of biological utility including, but not limited to, immunosuppressant, antitumor, 
insecticidal, heribicidal, and antiparasitic properties.
4
  Calicheamicins, salinosporamides and 
epothilones are notable microbial natural products currently in clinical development possessing 
both interesting structural features in addition to compelling antitumor properties. 
 
 
Calicheamicins, extraordinarily potent antitumor compounds, were isolated from the bacterium 
Micromonaspora echinospora.
25
  Calicheamicin 1
Br
 (1.14) was initially isolated from culture but 
upon refermentation in the presence of sodium iodide,  a similar compound differing only in 
halogenation of the benzene ring was discovered (calicheamicin 1
I
,1.15).
26
  The remarkable and 
complex structure of calicheamicin 1
I
, including four carbohydrate moieties, a hexasubstituted 
benzene ring, an N-O glycosidic bond, a trisulfide, and a bicyclo-enediyne system, was 
determined via spectroscopic techniques in conjunction with noteworthy chemical degradation 
studies (see section 1.4.1).  Antitumor properties of calicheamicin 1
I
 arise from its ability to 
cleave double-stranded DNA.
27
  Although calicheamicin 1
I
 is generally toxic, a prodrug was 
developed by attaching, via calicheamicin’s sulfide linkage, an antibody (anti-CD33 monoclonal-) 
which directs the molecule selectively to certain cancer cells types.  The resulting drug, 
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gemtuzumab ozogamicin, is approved by the Food and Drug Administration (FDA) for the 
treatment of relapsing patients suffering from acute myeloid lymphoma.
28
 
 
 
Exploration of microbial constituents isolated from ocean sediment resulted in the identification of 
a new genus of actinomycetes (Salinospora) which was found to yield a potent proteosome 
inhibitor, salinosporamide A (from S. tropica CNB476, shake flask: 4 mg/L culture media, 1.16).
29
  
Nereus Pharmaceuticals licensed the compound and began industrial scale fermentation after 
modifying the culture media to meet current Good Manufacturing Practice (cGMP) guidelines.
30
  
The company isolated an individual colony of S. tropica CNB476 from the original strain that 
produced more salinoporamide A concomitant with less undesirable analogs.  Researchers at 
Nereus discovered that addition of solid resin (XAD-16) to the culture considerably increased 
quantities of salinosporamide A due to the inherent instability of the -lactone in aqueous solution.  
The fermentation was ultimately optimized to obtain quantities of material suitable for clinical trials 
resulting in about a hundred-fold increase in production of salinosporamide A (fermentor: 360 
mg/L, shake flask: 450 mg/L).  Salinosporamide A completed Phase 1 clinical trials for the 
treatment of multiple myeloma in 2010, just seven years since its discovery. 
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Epothilones, microtublule-stabilizing polyketide macrolides, were isolated from myxobacterium 
Sorangium cellulosum.
31
  Epothilones A (1.17) and B (1.18) were the first non-taxane-based 
MSA’s to be discovered.
32,33 
 Both compounds are at least as potent as taxol in stabilizing 
microtubules.   Gram-scale isolation (4.8 g 1.17; 2.1 g 1.18 from 230 L culture broth) and crystal 
structure of epothilones A and B were subsequently reported.
34
  Due to the excellent potency and 
efficacy of the naturally occurring epothilones many promising, clinically-significant synthetic 
analogs have been also been prepared (see section 1.4.4).
 
 Natural epothilone B as well as five 
synthetic epothilones have completed Phase I clinical trials leading to investigation of several 
(epothilone B and two synthetic derivatives) in Phase II studies to assess efficacy in a variety of 
tumor types.
35
  Phase III clinical trials of epothilone B are currently underway for treatment of 
patients with taxane- and platinum-resistant disease.
36
 
 
 
1.4 Relevance of synthesis in natural product chemistry 
The essential role of synthesis in natural product drug discovery is undeniable.
37
  The structural 
complexity present in many naturally occurring compounds necessitates advanced spectroscopic 
techniques, often times in conjunction with wet chemical methods, to fully elucidate absolute 
configuration.  Derivatization and degradation are common synthetic methods utilized to elucidate 
intricate chemical structures.  Total synthesis, considered to be the ultimate verification of 
structure, is especially useful for validating complex natural products isolated in scarce amounts.  
Because many natural products are found in low abundance, total- and semisyntheses have been 
utilized to alleviate supply problems of clinically promising drugs.  Inspired chemists have 
constructed analogs of biologically active natural products to probe and tailor bioactivity, often 
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times resulting in more potent and/or less toxic derivatives.  The symbiotic relationship between 
natural product chemistry and organic synthesis cannot be overstated.  The value of chemical 
synthesis to identify, supply, and modify compounds originating from natural sources will be 
emphasized in the remainder of this chapter. 
 
1.4.1 Structure elucidation and verification via degradation studies 
Degradation studies of naturally occurring compounds have proved instrumental in the structure 
elucidation and verification of complex molecules.  Degradation studies to determine chemical 
structure were commonplace before the advent of X-ray and nuclear magnetic resonance (NMR) 
spectroscopic techniques (circa 1950’s).
38
  Although not as common as it once was, chemical 
degradation for structure elucidation and verification is still an important part of natural products 
chemistry, evidenced by an extraordinary study in which the structure of calicheamicin 1
 I
 was 
determined.
26
   
 
Spectroscopic analysis of calicheamicin 1
I
 (1.15), a compound displaying activity in biochemical 
induction assays (BIA; used to identify DNA damaging antitumor compounds),
39
 revealed four 
glycosides and one aglycone.  Difficulty further interpreting NMR data due to signal overlap 
prompted degradation studies (Scheme 1.1).  N-acetylated calicheamicin 1
I
 (1.19) was subjected 
to acidic methanolysis yielding, among other products, the methyl glycoside of a 6-
deoxyhexopyranose (1.20; both  and  anomers), the methyl glycoside of an N-acetyl-N-
ethylaminoxylopyranose (1.21; 7/3 mixture of anomers confirmed
40
 by synthesis) and 
hexasubstituted benzene 1.22.  To find degradation products retaining BIA activity, methanolysis 
was performed on a strong cation exchange resin (Dowex) column resulting in thioesters 1.23 
and 1.24 (as well as their anomers) along with the BIA active calicheamicin pseudoaglycone 1.25.  
Structures of 1.23 and 1.24 were determined with NMR analysis.  Mass data indicated that 
fragment 1.25 was the natural product minus ring D and E. Based on careful fast atom 
bombardment mass spectroscopy (FABMS) and NMR examination of 1.25, ring A and B were 
determined to be linked through an unusual N-O glycosidic bond. 
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The arduous task of determining the aglycone structure of 1.25a was completed, in part, with 
thoughtful X-ray, NMR, and FABMS analysis of reaction product 1.26 and deuterated 1.26-d2 
which were recovered from mixtures of PPh3/CH2Cl2/CH3OH and PPh3/CD2Cl2/CD3OD, 
respectively (Scheme 1.2).  The deuterated benzene product (1.26-d2) could only be explained by 
a enediyne biradical cycloaromatization (Bergman cyclization) initiated by the destabilizing effect 
of thiol adding in Michael fashion to the ,-unsaturated ketone (1.25b→1.27).  Because only 
natural and degradation products retaining the endiyne system displayed BIA activity, the endiyne 
moiety was determined to be responsible for the observed DNA-damaging effects.  The 
degradation study revealed that nature has found an elegant way to retain - and discriminately 
liberate - the quite reactive endiyne functionality.  Nicolaou et. al
41
 synthesized calicheamicin 1
I
 
10 
 
and confirmed the proposed structure,  further validating the effectiveness of degradation to 
elucidate complex natural products. 
 
 
1.4.2 Structure verification via total synthesis 
Spectroscopic techniques [NMR, high resolution mass spectroscopy (HRMS)] and chemical 
degradation are quite powerful and allow for structure elucidation of elaborate molecules.  
Structural misassignment in the literature is not uncommon, however, due to investigator error by 
data misinterpretation.  Simple bookkeeping errors
42
 are often responsible for misassignment, 
although structural data from exceptionally complex molecules can lead the most careful scientist 
to the wrong conclusion.  Total synthesis provides an unambiguous means to verify proposed 
structures.  Chemical literature abounds with structures of natural products that have been 
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corrected through total synthesis.
43,44
  The total synthesis of diazonamide A highlights the 
structure reassignment of an exceedingly complex and bioactive marine natural product. 
 
In 1991, diazonamide A (proposed: 1.28; revised: 1.29), an unusual halogenated cyclic peptide 
with potent antitumor properties, was isolated by Clardy and Fenical
45
 from the colonial ascidian 
Diazona anngulata collected in the Philippines.  The compound’s highly intricate structure and 
compelling bioactivity captured the interest of dozens of synthetic research groups which 
culminated, after ten years of investigation - and frustration - in structural reassignment.  When 
first isolated, the structure of diazonamide A could not be elucidated with NMR and HRFABMS 
alone due to a large number of unprotonated carbons and heteroatoms.  Several subunits were 
revealed but their connectivity remained elusive.  Because the compound would not crystallize, X-
ray analysis of diazonamide A was not possible.  Due to similar NMR, ultraviolet (UV), and 
infrared (IR) data between diazonamide A and diazonamide B, X-ray diffraction of the p-
bromobenzamide derivative of diazonamide B (1.30, initially assigned) afforded connectivity of 
the compounds’ subunits.  The conversion of proposed hemiacetal 1.28 to the acetal found in 
1.30 was postulated to occur during the acylation reaction.  The proposed structure for 
diazonamide A (1.28) was synthesized in 2001 by Harran et. al.
46
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Synthesis of the proposed structure of diazonamide A (1.28) began with formation of modified 
dipeptide 1.30 from 1.31, 1.32, and 1.33 (Scheme 1.3).  A pivotal Heck cyclization of 1.30 formed 
1.34 which, after phenol-protection, was dihydroxylated to 1.35.  The diazonamide core (1.36) 
was formed from 1.35 through an acid catalyzed pinacol rearrangement in a near perfect 
stereoselective manner.  After reduction, protecting group manipulation, and selective 
bromination, 1.36 was converted to lactone 1.37 upon treatment with acid.  Lactone opening with 
N-dimethylaluminumtryptamine followed by oxidation furnished 1.38 which was briefly photolyzed 
(350 nm) to afford 1.39 after acetylation.  Oxidation/cyclodehydration of 1.39 formed 
bis(oxazoyl)indole 1.40.  Surprisingly, exposing 1.40 to UV (300 nm) light resulted in the 
formation of 1.41 with the loss of HBr.  With the critical framework synthesized, 1.41 was 
converted to the proposed structure of diazonamide A (1.28) with facile dichlorination and 
removal of protecting groups.  Unfortunately, however, the synthesized compound was quite 
unstable and differed in physical properties with the natural product.   
13 
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Harran et al. re-evaluated the natural product’s physical and experimental data and discovered 
that the natural product did not release valine upon acid digestion nor did spectroscopic data 
support the valine residue.  They theorized the C37 substituent was actually and OH and not an 
NH2.  This change necessitated an alteration elsewhere in the molecule to rectify the molecular 
mass observed.  Reexamination of mass data of natural diazonamide A and crystal structure of 
the p-bromobenzamide derivatve of diazonamide B (1.30) indicated the acetal proposed for 1.30 
was likely retained in natural diazonamide A as opposed to the proposed hemiacetal.  X-ray and 
HRMS suggested the acetal structure was actually a hemiaminal ether in which O3 should be an 
NH leading Harran et al. to propose revised structure 1.29 for diazonamide A.
47
  A year later, 
Nicolaou et al. completed the total synthesis of 1.29 using strategies developed by Harran as well 
as another method differing in order of macrocycle formation finally verifying the revised structure 
as that of natural diazonamide A.
48
 
 
1.4.3 Drug supply by total synthesis and semisynthesis 
Culturable microbes and cultivatable plants are excellent sources for drugs.  However, reliable 
drug supply from natural sources is often hampered by rarity or inaccessibility of the producing 
organism.  Particularly susceptible are drugs from the sea.  Although marine organisms afford a 
wealth of interesting bioactive chemistry, sustainable supply of marine-derived drugs is limited.  
Not only are most marine macroorganisms and their microbial fauna largely unculturable, but 
many marine natural products are found in low natural abundance.  Consequently, large scale 
aquaculture would likely be too inefficient as a viable source of drugs.  Pharmacological 
investigation of discodermolide and ecteinascidin, two promising marine-derived antitumor 
agents, was hindered by lack of adequate supply.  Supply demands were alleviated through total 
synthesis and semisynthesis, respectively.   
 
Several highly efficient syntheses of discodermolide were developed allowing preparation of gram 
quantities sufficient for initial clinical testing.
 49
  Schreiber et al. completed the total synthesis of 
ent-discodermolide (ent-1.7) establishing the absolute configuration of the molecule.
50
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Surprisingly, ent-discodermolide was found to have similar cytotoxic effects as the natural 
product.  Schreiber et al. used the same methodology to synthesize the natural enantiomer.
51
  
The synthesis relied upon the absolute configuration of Roche ester starting material (1.43) which 
was converted to two diastereomers via Roush crotylation (1.44, 1.45)  further elaborated to three 
fragments of discodermolide (1.46, 1.47, 1.48) that were then stitched together to form the natural 
product, effectively completing the divergent/convergent synthesis (Scheme 1.4).  Key reactions 
include Stille-Gennari HWE olefination in the formation of 1.46, Negishi coupling in the formation 
of 1.48, a Nozaki-Kishi coupling of 1.46 and 1.47, and finally enolate alkylations to join 1.48 and 
1.49.  The synthesis was completed in an overall yield of 4.3% (longest linear sequence: 24 
steps). 
 
 
Smith et al. reported the synthesis of discodermolide in 6% overall yield (24 linear steps) which 
resulted in an impressive 1.0 gram of the natural product using a Roche ester-derived aldehyde 
to form fragments which were coupled to generate the natural product, analogous to Schreiber’s 
synthesis.
52
  Paterson et al. employed two synthetic methods to produce discodermolide.  The 
relatively high-yielding (10.3% over 23 steps, longest linear sequence) first generation synthesis 
employed chiral auxiliary groups and reagents to direct stereochemistry.
53
  A second generation 
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synthesis was lower yielding (5.1% over 24 linear steps) but required fewer total steps (35) and 
no chiral auxiliary groups or reagents, depending instead on substrate to control 
stereochemistry.
54
  Novartis Pharma AG, utilizing key steps from syntheses reported by Smith 
and Paterson, completed large scale synthesis of discodermolide in apposite quantities (60 g!) for 
Phase I clinical trials.
55
 
 
Aquaculture provided suitable quantities of ecteinascidin-743 (ET-743, 1.1) for preclinical and 
early Phase clinical trials but yields were variable.  Supply issues plagued development until 
scientists at PharmaMar developed a semisynthesis of ET-743 from cyanosafracin B (1.50, 
Scheme 1.5), a readily available (kilogram scale!) antibiotic from the optimized fermentation broth 
of Pseudomonas fluorescens.
56
 
 
 
Cyanosafracin B (1.50), after protecting group manipulation, was converted to 1.51 though an 
unstable hydoquinone intermediate (Scheme 1.6).  More protecting group manipulation and 
cleavage of the amide by Edman degradation formed amine 1.52.  A key step in the 
semisynthesis was the conversion of amine 1.52 to alcohol 1.53 upon treatment with sodium 
nitrite/acetic acid (NaNO2/AcOH), effectively completing a formal total synthesis by generating an 
intermediate in the total synthesis of ET-743 previously reported by Corey et al.
57
  The remaining 
conversion of 1.53 to ET-743 followed Corey’s protocol.  EDC promoted esterification of alcohol 
1.53, deallylation, and subsequent oxidation of the phenol with (PhSeO)2O resulted in 
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hydroxylated product 1.54.  Quinone methide formation via Swern protocol then liberation of the 
thioether to generate thiolate ion resulted in nucleophilic attack of quinone forming 1.55 after 
acetylation.  Removal of the Troc group, oxidation of the resulting -amino lactone to the -keto 
lactone then treatment with 2-[3-hydroxy-4-methoxyphenyl]ethylamine (1.56) afforded 
stereospecific formation of the spiro tetrahydroisoquinoline 1.57.  Protecting group removal and 
conversion of cyano-group to alcohol with silver nitrate (AgNO3) resulted in the semisynthesis of 
ET-743 (1.1) from cyanosafracin B (1.50).  The initial synthetic work of Corey et al. in combination 
with the ingenuity of Pharma Mar scientists led to the development of gram-scale semisynthesis 
of a rare marine natural product, enabling production of commercial quantities.  
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1.4.4 Synthetic derivatives of natural products as drugs 
The first examples of marine natural product-inspired, clinically useful synthetic derivatives were 
antiviral ara-A (vidarabine, 1.58) and chemotherapy agent ara-C (cytarabine, 1.59).  Both 
compounds owe their structure to sponge-derived bioactive arabinose-containing nucleosides 
isolated by Bergmann in the 1950’s.
58
  More recently it was found that twenty-seven percent of 
the 1184 drugs approved worldwide from 1981-2006 are derived from natural products, including 
semisynthetic derivatives and totally synthetic compounds containing a pharmacophore that is 
natural in origin.
1
  The number jumps to thirty-seven percent if synthetic natural product mimics -  
such as peptidic isosteres - are included in the analysis.  Medicinal chemists, through synthetic 
procedures, tweak already biologically active natural products to identify pharmacophores 
responsible for desired bioactivity, eliminate unneeded or detrimental structural features, and, 
ultimately, optimize pharmacological properties.
59
   Eribulin mesylate and several epothlilone 
analogs are examples of clinically successful synthetic derivatives of natural origin. 
 
 
Using synthetic methods developed by Kishi,
60,61
 several truncated analogs of halichondrin B 
(1.9) were found to be equipotent to the natural product in antitumor assays.
62
  Because obtaining 
halichondrin B from natural sources proved problematic, the truncated analogs, with about 70% 
the molecular mass of the natural compound, were more easily synthesized and thus, an 
attractive alternative.  Further screening by Eisai Company revealed that the truncated 
halichondrin B ketone analog E7389 (ER-086526), later developed as eribulin mesylate (1.60), 
possessed highly potent in vitro and in vivo anticancer activities with a wide therapeutic window in 
vivo.
63
  Eribulin mesylate completed Phase II studies as a monotherapy for refractory breast 
cancer
64
 and showed promising results in patients with advanced breast cancer.
65
  Currently, 
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eribulin mesylate is undergoing Phase III trials as a late-stage treatment for locally recurrent or 
metastatic breast cancer.
66
 
 
 
After completing total synthesis of epothilones A (1.17)
67
 and B (1.18),
68
 Danishefsky et al. 
proceeded to assemble close to fifty epothilone analogs.  Danishefsky discovered that synthetic 
desoxyepothilone B, (KOS-862, epothilone D, 1.61) displayed low in vivo toxicity in contrast with 
epothilone B (highly toxic in mice) while retaining antitumor effects.
69
  Desoxyepothilone B has 
completed Phase II clinical trials for colorectal, gastric, ovary, renal and other cancers.
35
  The 
production and evaluation of over 300 semisynthetic epothilone analogs by researchers at Bristol-
Meyers Squibb led to ixabepilone (BMS-247550, aza-epothilone B, 1.62) the lactam derivative of 
epothilone B which displayed antitumor properties toward a wide range of cancers in Phase II 
trials.
70
  Recently, Phase III clinical trials of combination ixabepilone therapy in the treatment of 
patients resistant to taxol and anthracyclines showed a statistically significant improvement in 
progression-free survival although toxicity was a concern.
36
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1.5 Research objectives 
The interconnectivity and interdependence of natural product chemistry and chemical synthesis in 
drug discovery is demonstrated through the chemical exploration reported herein.  Investigation 
of less accessible and therefore less studied environments, particularly Antarctica and endophytic 
microbial communities, has afforded exciting chemistry and promising biologically active leads.  
Synthetic analogs inspired by Antarctic-derived natural products have displayed promising 
bioactivity.  The chemical investigation, degradation, and synthetic studies presented herein 
dislcose a number of remarkable compounds derived from natural sources as well as synthetic 
operations utilized to study their interesting structure and biological activity. 
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Chapter 2.  Synthetic studies of palmerolide A 
 
2.1 Isolation, structure elucidation, and bioactivity of palmerolide A 
The palmerolides are a family of macrocylic polyketides found in the abundant Antarctic tunicate 
Synoicum adareanum collected at the National Science Foundation’s Palmer Station, on the 
Antarctic Peninsula.
1
  The major metabolite, palmerolide A (2.1), displays 18 nM inhibition of 
UACC-66 melanoma and includes among its biochemical targets the pH regulatory vacuolar-
ATPase (V-ATPase),
2
 for which it is a potent inhibitor (IC50 = 2 nM).  V-ATPases are largely 
responsible for cellular and organellular pH regulation but have been implicated in cancer 
treatment
3
 due in part to the low pH requirement and concomitant overexpression of V-ATPases 
of some cancer cell types.
4
  In ongoing studies at the National Cancer Institute at Frederick,
5
 
palmerolide A induced markers of autophagy and the transcription factor Hypoxia Induction 
Factor-1 (HIF-1), but the mechanism underlying palmerolide A-induced cell death in human 
tumor cells remains unclear.  Palmerolide A remains of interest for development due, in contrast 
to other V-ATPase inhibitors such as bafilomycin (2.2),
6,7
 to its lack of neurotoxicity at therapeutic 
levels.  The microbial community of S. adareanum has been investigated for genes coding for 
polyketide synthases (PKS) in an ongoing effort to characterize bacteria responsible for 
producing polyketide-derived palmerolide A.
8
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The planar structure of palmerolide A was established on the basis of extensive 2D NMR 
experimentation while the stereochemical assignment required a combination of spectroscopic 
and derivatization techniques.
1
  The two secondary alcohols, C7 and C10, were amenable to 
stereochemical analyses by Mosher’s method.
9
  The remaining stereocenters were determined 
relative to C10 using through-space NMR techniques such as Rotating frame Overhauser Effect 
SpectroscopY (ROESY) along with 
n
JCH-based analysis.
10
  Configuration of C19 and 20 relative to 
C7, 10 and 11 was proposed based on NOE data suggesting the macrolide conformed to a 
teardrop-like structure.  The originally proposed structure (1a) was determined to have an 
absolute configuration of 7R, 10R, 11R, 19R, 20R.  The unique and potent bioactivity as well as 
the intriguing structure of palmerolide A has generated considerable interest in developing 
synthetic access to the compound (see section 2.2 for a review).  The molecule’s complexity 
prompted us to perform degradative studies using a chiral pool based strategy
11
 to verify the 
initial stereochemical assignments (see section 2.3) which then led us to synthesize the C3-14 
fragment
12
 (see section 2.4). 
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2.2 Palmerolide A as a synthetic target 
To date, three total syntheses
 
and one structure activity relationship study of palmerolide A have 
been published.  Several partial syntheses as well as a formal total synthesis have also been 
reported. 
 
2.2.1 Total syntheses of palmerolide A 
2.2.1.1 Total synthesis by De Brabander 
De Brabander et al. reported the first total synthesis of ent-palmerolide A in 2007.
13
  His group 
began by synthesizing the originally proposed structure 2.1a.  De Brabander envisioned 
constructing the C1-24 portion (2.3) of palmerolide A with a convergent approach (Scheme 2.1) 
utilizing three main fragments: 2.4 (C9-15), 2.5 (C16-24), and 2.6 (C1-8). 
 
 
Vinyl pinacol borate ester 2.4 was formed from D-arabitol (2.7) through intermediate 2.8 (Scheme 
2.2).   A key step in the formation of fragment 2.5 was the diastereoselective Mukaiyama aldol 
condensation of dienol silyl ether 2.9a and vinyl iodide 2.10 to form 2.11.  Phosphonate ester 2.6 
was synthesized from -valerolactone (2.12).  Coupling fragments 2.4 and 2.5 via Suzuki 
methodology yielded an intermediate that was esterified with 2.6, setting up a ring closing Horner-
Wadsworth-Emmons (HWE) olefination to form macrolactone 2.3.
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Stereoselective reduction of 2.3 gave the preferred C7 epimer.   Curtius rearrangement followed 
by trapping the isocyanate intermediate (2.12a) with Grignard reagent 2.13 completed the 
enamide pendant 2.14 (Scheme 2.3).  Installing the carbamate at C11 followed by protecting 
group removal afforded initially proposed palmerolide A (2.1a).   
 
Differences in the NMR data of synthesized 2.1a and that of natural palmerolide A led De 
Brabander et al. to reevaluate the assignments.  The group was confident in their stereochemical 
assignment of synthetic 2.1a.  Mosher analysis of C7 confirmed the center’s absolute 
configuration.  Stereochemistry at C10 and 11 was derived from D-arabitol.   X-ray analysis of a 
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crystal intermediate containing C19 and 20 corroborated the assignments at those centers.  De 
Brabander then examined the natural product data and found assignments for C7, 10, and 11 
were made on sound evidence.  He also felt that the relative configuration between C19 and 20 
was justifiable but the relative configuration of C19 and 20 to C7, 10, and 11 (founded on ROESY 
analysis) was suspect.  The researchers decided to repeat the synthesis with 2.4, ent-2.5, and 
2.6.  The resulting compound (ent-2.1b) possessed the same absolute configuration at C7, 10, 
and 11 (all R) but opposite configuration at C19 and 20 (now both S) when compared to 2.1a.  
NMR data, as well as thin layer chromatography (TLC) and high performance liquid 
chromatography (HPLC) behavior of ent-2.1b coincided with that of natural palmerolide A.  
Circular dichroism (CD) spectra of the two compounds were mirror images, however, suggesting 
that De Brabander et al. had synthesized the enantiomer of the natural product.  The absolute 
configuration of naturally occurring palmerolide A was revised to 7S, 10S, 11S, 19R, 20R (2.1b). 
 
2.2.1.2 Total synthesis by Nicolaou 
Shortly after De Brabander reported synthesis of revised palmerolide A (ent-2.1b), Nicolaou et al. 
reported a total synthesis of the natural enantiomer (2.1b) along with several stereoisomers 
including the originally proposed structure.
14,15
  Nicolaou’s group also used a convergent, three 
fragment approach to achieve synthesis of the originally proposed structure which could be easily 
amended to synthesize other stereoisomers of palmerolide A.  Using this methodology the group 
was first to synthesize the revised structure, 2.1b, from fragments 2.15, 2.16 and 2.17 (Scheme 
2.4).  By varying the order in which the fragments were combined, Nicolaou was able to 
determine the most efficient method to form the macrocycle was via olefin ring closing metathesis 
(RCM) from 2.18 or Yamaguchi macrolactonization from 2.19.   
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Analogous to De Brabander’s synthesis of fragment 2.5 via stereoselective Mukaiyama aldol 
methodology, Nicolaou synthesized 2.15 using 2.9b and 2.10 (Scheme 2.2) resulting in 
comparable yields and better diastereomeric ratios.  Configuration at C10 and 11 was selectively 
formed by crotylation of 2.20 with diisopinocamphenylborane 2.21 resulting in 2.22 which was 
further elaborated to afford vinyl stannane 2.16 (Scheme 2.5).  Epoxidation of 2.23 then hydrolytic 
kinetic resolution with Jacobsen’s catalyst (2.24) resulted in diol 2.25 and epoxide 2.26 en route 
to 2.17 and ent-2.17, respectively.  
30 
 
 
 
With 2.15, 2.16 and 2.17 in hand, Nicolaou et al. proceeded to assemble the fragments with 
particular focus on efficiency (Scheme 2.4).  Stille coupling of vinyl iodide 2.15 and vinyl stannane 
2.16 then Yamaguchi-type esterification with acid 2.17 furnished 2.18.  Alternatively, esterifying 
2.15 with 2.17 followed by coupling to 2.16 improved yield of 2.18.  Protecting group removal and 
oxidation of 2.18 set up chain elongation via Takai olefination resulting in vinyl iodide 2.26 
(Scheme 2.6).   RCM with Grubbs II catalyst (2.27) proved to be an efficient method to form the 
macrolide which was then coupled to primary enamide 2.28 using Buchwald methodology 
affording the revised structure of palmerolide A (2.1b).  
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Nicolaou et al. found that Yamaguchi macrolactonization was also an effective method to form the 
macrolide portion of palmerolide A (Scheme 2.4).  Less efficient ring closing methods were also 
investigated, including Mitsunobu cylization forming the macrolide at C1-19, intermolecular HWE 
olefination at C2-3, and intermolecular Stille coupling at C15-16. 
 
In 2008, Nicolaou and co-workers reported the synthesis and bioactivity of a multitude of 
palmerolide A stereoisomers and analogs
16
 using strategies developed
 
en route to palmerolide 
A.
14.15
  Along with ent-2.1b, nine diastereomers of palmerolide A, were prepared as were six 
analogs differing only in their amide linkages at C24.  Several deoxygenated derivatives of 
palmerolide A were also synthesized.  From this structure activity relationship (SAR) study, 
Nicolaou inferred the anticancer properties of palmerolide A are most dependent on the enamide 
moiety as changes to the substituents on the ring had less effect on activity.  It was also noted 
that the benzoylamide analog was more potent than 2.1b while removing the C7- hydroxyl group 
had no effect on potency.  Less complex analogs, either equipotent or more so, would be more 
easily accessible and thus more attractive drug leads. 
 
2.2.1.3 Total synthesis by Hall 
In 2009, Hall et al.
17
 reported a third total synthesis of palmerolide A (2.1b) utilizing catalytic 
asymmetric organoboron methodologies developed in their lab.  Using a less modular, but still 
32 
 
convergent, approach compared to those employed by De Brabander and Nicolaou, Hall 
envisioned constructing macrolide 2.29 (Scheme 2.7) from two fragments, the “left” comprising 
C14-24 (2.30) and the “right” (C1-13, 2.31). 
 
Hall began synthesis of 2.30 with an enantioselective E-crotylboration of aldehyde 2.10 with 2.32 
using catalyst 2.33 resulting in alcohol 2.34 in excellent yield, diastereoselectivity, and 
enantiomeric excess (Scheme 2.8).  Successive Wittig olefinations furnished 2.35 which 
underwent Sonogashira coupling and alkyne hydrozirconation yielding fragment 2.30, the “left” 
portion of the macrolide. 
 
 
Synthesis of fragment 2.31 commenced (Scheme 2.9) with an enantioselective hetero [4+2] 
cycloaddition/allylboration of 2.36 and 2.37 by way of Jacobsen designed (Schiff base)chromium 
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(III) catalyst (2.38).   Intermediate 2.39 reacted with another equivalent of 2.36 resulting in alcohol 
2.40a which upon acylation gave 2.40b.  An unprecedented Claisen-Ireland [3,3] rearrangement 
followed (through transition state 2.41) giving 2.42a and finally, after oxidation, 2.42b.  With 
configuration at C7, 10, and 11 set, 2.42b was then elaborated to fragment 2.31, the “right” 
portion of the macrolide. 
 
 
Hall et al. then coupled fragments 2.30 and 2.31 with an sp
2
-sp
3
 B-alkyl Suzuki coupling.  
Yamaguchi macrolactonization completed 2.29.  Hall’s endgame was identical to De Brabander’s 
(Scheme 2.3) converting 2.29 to isocyanate 2.12b and finally enamide 2.14b.  Hall then installed 
the carbamate at C11.  Protecting group removal afforded palmerolide A (2.1b). 
 
2.2.2 Partial syntheses of palmerolide A 
Several approaches to various fragments of palmerolide A have been reported
18-22
 (Scheme 
2.10).   Shortly before DeBrabander published the revised structure of palmerolide A, Kaliappan 
and Gowrisankar reported synthesizing the “northern hemisphere” of originally proposed 2.1a 
comprising C1-9 and C15-21 (2.43).
18
  Notable transformations include using an Evans chiral 
auxiliary to set configuration at C7, a palladium (II) (Pd
II
) catalyzed allylic rearrangement to 
furnish E16 selectively, and olefin cross metathesis (OCM) with Grubb’s 2
nd
 generation catalyst to 
form E2.  Maier et al. constructed the linear fragment C3-23 (2.44) en route to 2.1a.
19
  Key steps 
34 
 
include forming C10 and 11 stereocenters via Sharpless dihydroxylation, Red-Al mediated 
reduction of an alkyne to form E8, and Stille coupling at C15-16.  Chandrasekar et al. synthesized 
the C1-14 fragment (2.45a) of revised palmerolide A (2.1b).
20
  The researchers relied on 
deoxygenative rearrangement of an alkynol, an asymmetric dihydroxylation of the resulting diene 
ester which installed C11 and 12 hydroxyls, and CBS (Corey-Bakshi-Shibata) reduction to 
selectively afford the C7 hydroxyl.  Cantagrel et al. reported the C3-15 (2.46) and C16-23 (2.47) 
fragments of 2.1b.
21
   Significant transformations included an Evan’s chiral auxiliary aldol 
condensation forming C19 and 20 centers, an enatioselective reduction with Noyori’s catalyst to 
set C7 configuration, and a diastereoselective acetylenic Grignard addition forming C10 
configuration.  Dudley et al.
22
 synthesized the C1-15 region (2.45b) of revised palmerolide A 
using an optimized Claisen-type condensation of vinylogous acyl triflates to form the C1-8 subunit 
and appending it to C9-15 via a convergent HWE olefination.  Stereocenters C10 and 11 were 
formed via asymmetric dihydroxylation (AD-mix-.  Configuration at C7 was installed using a 
CBS reduction. 
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2.2.3 Formal total synthesis of palmerolide A 
Formation of an advanced intermediate from Nicolaou’s total synthesis
14,15
 (2.47, Scheme 2.11) 
by Maier and Jagel
23
 was reported culminating in the formal total synthesis of palmerolide A 
(2.1b).  Using methods they had previously reported,
19
 the researchers were able to synthesize 
2.48 which could then be coupled to 2.49 via HWE olefination yielding 2.50.  The macrolide was 
formed via a highly stereospecific Heck cyclization.  Takai olefination then cleavage of silyl 
protecting groups yielded 2.47, completing the formal total synthesis.  
 
 
2.3 Degradation of palmerolide A to confirm absolute configuration 
Naturally occurring palmerolide A was subjected to degradative studies
11
 to verify the 
stereochemical assignments determined by spectroscopic and derivatization techniques.
1
  
Reductive ozonolysis of palmerolide A could be used to cleave the molecule into several polyol 
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fragments.  Comparison of the naturally derived fragments to those synthesized from chiral pool 
starting material would verify the proposed structure.   
 
2.3.1 Ozonolysis of palmerolide A 
Subjecting palmerolide A to ozonolysis followed by reduction with sodium borohydride (Scheme 
2.12) resulted in quantitative yields of hexane-1,2,6-triol (2.51) and hexane-1,2,3,6-tetraol (2.52).  
Specific rotations of -9.0 and -8.1 were recorded for triol 2.51 and tetraol 2.52, respectively.  
Degradation of 2.1a should afford triol R-2.51 as well as (2R,3R)-2.52.  Hexane-1,2,6-triol is 
available commercially but only in racemic form.  (S)-Hexane-1,2,6-triol has been reported,
24
 
having a specific rotation of -3.4.  This was at odds with the rotation of degradation product 2.51 
(i.e. R-2.51 should bear a rotation of +3.4) in sign as well as magnitude prompting us to develop 
chiral pool based syntheses of polyols hexane-1,2,6-triol and hexane-1,2,3,6-tetraol. 
 
 
2.3.2 Synthesis of hexane-1,2,6-triol 
(R)-Hexane-1,2,6-triol (R-2.53) was prepared from the (R)-acetonide of glycerol (2.54, Scheme 
13).  Acetonide 2.54 was oxidized via Swern
25
 protocol.  The resulting aldehyde underwent Wittig 
olefination forming 2.55.
26
 In the course of this preparation, the Wittig product 2.55 was 
reductively ozonolyzed back to 2.54 to confirm that epimerization had not occurred.  Recovered 
2.54, however, was found to have significantly epimerized (ee 56% of original).   
37 
 
 
 
A homologue of 2.54, the acetonide of (R)-butane-1,2,4-triol (R-2.56), after oxidation, could be 
subjected to Wittig olefination to R-2.57 while retaining its optical purity based on a similar 
reductive ozonolysis back to R-2.56 (Scheme 2.14).  A 1,4-reduction of the conjugated ester with 
lithium aluminium hydride (LAH) produced the terminal alcohol R-2.58 in moderate yields.  
Hydrolysis afforded the desired triol R-2.53 under mildly acidic conditions.  Spectral and 
chromatographic data (
1
H NMR, 
13
C NMR, GC/MS, ESI-MS) of (R)-hexane-1,2,6-triol (R-2.53) 
matched that of commercially available (±)-hexane-1,2,6-triol. 
 
The specific rotation of synthetic (R)-hexane-1,2,6-triol (R-2.53, +11.1) was then compared to 
degradation product (2.51, -9.0).  We were satisfied to find the magnitude of the specific rotation 
from the synthetic product more closely matched the degradation product, but were disappointed 
to find the sign of the rotation to be opposite that of the degradation product.  Final verification of 
the C7 configuration was achieved by preparation of (S)-hexane-1,2,6-triol (S-2.53), starting from 
the acetonide of (S)-butane-1,2,4-triol (S-2.56, Scheme 2.14).  Oxidation of S-2.56 to the requisite 
aldehyde was achieved via Swern protocol, avoiding use of Dess-Martin periodinane, a costly 
reagent.  Horner-Wadsworth-Emmons olefination was utilized to form S-2.57 in a more efficient 
manner than the Wittig reaction used to form the R-enantiomer.  As an alternative to the modest 
yielding reduction of R-2.57 with LAH, a two step reduction with diisobutylaluminum hydride 
(DIBALH) to the allylic alcohol then catalytic hydrogenation afforded S-2.58 in better overall yield.   
The specific rotation of the (S)-triol (S-2.53, -11.6) matched the degradation product (2.51, -9.0) 
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obtained from ozonolysis of palmerolide, suggesting the configuration of palmerolide A’s C7 
stereocenter as bearing the S configuration, rather than the originally published 7R. 
 
2.3.3 Synthesis of hexane-1,2,3,6-tetraol 
Stereocenters at C10 and 11 of palmerolide A were analyzed by comparing the degradation 
product tetraol 2.52 to analogs synthesized from the chiral pool.  The configuration at C10 and 
C11 could be explored by synthesis of both (2R,3R)- and (2S,3S)-hexane-1,2,3,6-tetraol (R,R-
2.59 and S,S-2.59, respectively).  Synthesis from either L(+)- or D(−)-2,3-O-Isopropylidene-
threitol (2.60) yielded the desired tetraol in six steps.  Preparation of (2R,3R)-hexane-1,2,3,6-
tetraol (Scheme 2.15) began with the monoacetylation of diol (R,R)-2.60 followed by oxidation of 
the unprotected alcohol via Dess-Martin periodinane.  Immediate Wittig olefination of the 
subsequent aldehyde produced an inseparable mixture of E/Z isomers (2.61).  The desired tetraol 
(R,R)-2.59 was obtained from 2.61 after catalytic hydrogenation, acid hydrolysis, then reduction.  
The specific rotation of (R,R)-2.59 (+9.9) was at odds with the corresponding ozonolysis product 
2.52 (-8.1).    
 
39 
 
 
Preparation of tetraol (S,S)-2.59 was achieved using a slightly different synthetic route starting 
with commercially available (S,S)-2.60 (Scheme 2.16).  Selective benzylation [silver oxide (Ag2O) 
and benzyl bromide]
27
 of (S,S)-2.60 produced the mono-benzylated alchohol which was subjected 
to Dess-Martin oxidation and Wittig olefination to afford alkene 2.62 as a mixture of E/Z isomers.  
E-2.62 could be obtained exclusively using HWE conditions.  Catalytic hydrogenation of 2.62 
yielded the unsaturated and deprotected alcohol 2.63.  Tetraol (S,S)-2.59 was realized by 
reduction with LAH then acid hydrolysis of 2.63.  (S,S)-2.59 displayed a specific rotation of -10.0 
which agreed with that of the degradation product obtained from ozonolysis (-8.1) in sign and 
magnitude inferring the natural product was actually 10S, 11S. 
 
2.3.4 Re-evaluation of absolute configuration 
The results of the degradation study compelled us to re-examine the previously reported
1,28
 data 
from the Mosher’s analysis to establish whether our procedures were in error or the method itself 
failed.  Lab notebooks indicated the correct conversion of the acid chloride stereochemistry to the 
corresponding ester (ie. (R)-acid chloride to (S)-ester).  The esterification of palmerolide A with 
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(R)-methoxytrifluoromethylphenylacetoyl chloride was repeated forming the (S)-MTPA ester 
which was found to bear 
1
H NMR shifts that matched the data originally assigned to the (R)-
MTPA ester.
28
  Thus, the samples or data sets derived from the original MTPA esters were found 
to be mislabelled necessitating a revision to the absolute configuration of palmerolide A at C7 
from R to S.  The C10 configurational assignment was made from the same MTPA products, 
necessitating that we re-evaluate the C7/C10 MTPA diester.  We found that C10 had been 
subject to the same transposition.  Because the C11 configuration is based on 
2
JCH and 
3
JCH 
conformational analysis of the C10/C11 spin system, both C10 and 11 must be revised to the S 
configuration.  In summary, the absolute configuration of palmerolide A should be revised to 7S, 
10S, 11S based on this degradation study and re-evaluation of the Moshers analysis. 
 
2.4 Synthesis of the C3-14 fragment of palmerolide A 
With the correct absolute configuration at C7, 10, and 11 determined, efforts were directed to the 
reconstruction
12
 of palmerolide A using similar synthetic routes as the ones described above 
employed to generate the chiral polyols. The syntheses of the fragments 2.53 and 2.59 were 
modified for coupling using one of the many olefination reactions described in literature.   
 
2.4.1 Julia-Kocienski olefination 
To form the C3-14 segment of the macrolide, we decided that E8-alkene could be formed from an 
aldehyde derived from triol 2.51 coupled to a sulfone derived from tetraol 2.52 based on Julia-
Kocienski protocol.
29
  Compostella et al.
30
 demonstrated that Julia–Kocienski olefination is useful 
in constructing trans-olefins with an -alkoxy aldehyde and an aliphatic sulfone or a -alkoxy 
sulfone (no -elimination observed) and aliphatic aldehyde, but to our knowledge no examples 
exist in which both coupling components contain alkoxy substituents.  Using this methodology, we 
envisioned fragment C3-14 (2.64) could be formed from sulfone 2.65 derived from triol 2.53, 
coupled with aldehyde 2.66, derived from tetraol 2.59 (Scheme 2.17). 
41 
 
 
 
The synthesis of triol 2.53 was modified to generate sulfone 2.65 (C3–8) from alcohol S-2.58 
(Scheme 2.18). Anticipating an olefin ring closing metathesis reaction to form the macrolide 
portion of palmerolide A, intermediate terminal alkene 2.67 was required.  Dess-Martin oxidation 
of S-2.58 followed by Wittig olefination and hydrolysis yielded the desired alkene 2.67.  
Monotosylation followed by silylation of the free secondary alcohol led to sulfone precursor 2.68. 
Treating tosylate 2.68 with 1-phenyl-1H-tetrazole-5-thiol and potassium carbonate under refluxing 
conditions
31
 yielded a thioether intermediate, which was then oxidized with catalytic amounts of 
sodium tungstate, phenylphosphonic acid, methyltrioctylammonium hydrogen sulfate and an 
excess of 30% hydrogen peroxide
32
 to generate sulfone 2.65.  Aldehyde 2.66 was realized by 
Dess-Martin oxidation of 2.63 (Scheme 2.18), an intermediate in the synthesis of (2S,3S)- 
hexane-1,2,3,6-tetraol [(S,S)-2.59]. 
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Attempts at coupling 2.65 and 2.66 using Julia-Kocienski methodology were not successful in our 
hands, yielding low recoveries of unreacted starting material with no evidence of -elimination of 
the tert-butyldimethylsilyl- (TBS-) ether in 2.65.   
 
2.4.2 Grubb’s olefin cross metathesis 
A new route to join fragments derived from 2.53 and 2.59 was devised utilizing olefin cross 
metathesis (OCM).
33
  We chose Grubbs second generation catalyst because Type II/Type III 
cross couplings are predicted to produce moderate to high yields with little to no 
homodimerization.
34
  The new route required that each fragment terminate in an olefin.  The 
synthesis of a fragment bearing the palmerolide A (2.1b) C3-8 centers (e.g., 2.65) was modified 
to produce olefin-metathesis substrate 2.69 (Scheme 2.19).  Benzylation followed by acid 
hydrolysis of intermediate S-2.58 resulted in the formation of diol 2.70.  A one pot protecting 
group manipulation produced secondary acetate 2.71.  Dess-Martin oxidation and Wittig 
olefination resulted in the formation of terminal olefin 2.69.   
 
The fragment bearing the palmerolide A (2.1b) C9–14 segment, 2.72 (Scheme 2.18), was derived 
from aldehyde 2.66 by a Wittig reaction. Combination of olefins 2.69 and 2.72 (Scheme 2.20) 
using Grubbs second generation catalyst (2.27) proceeded smoothly to generate the desired E-
isomer, as predicted, in moderate yields (2.73, C3–14 of palmerolide A) with no recovery of 
homodimers nor unreacted starting material. Steric bulk at both allylic positions in the product 
may explain why Z-2.73 was not observed. One cannot rule out the possibility of E/Z 
isomerization via secondary metathesis of 2.73, which could also explain selective E-isomer 
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formation. The fact that no homodimers were found and only the E-isomer of 2.73 was isolated 
suggests 2.69 and 2.72 may be reacting in a selective type II/type III fashion as postulated by 
Grubbs et al.
34 
However, due to the moderate yield of 2.73 and no evidence of either homodimer, 
it is unclear of which olefin type (II or III) 2.69 and 2.72 should be considered. 
 
 
In summary, 2.73, the C3-14 portion of palmerolide A, was constructed from commercially 
available chiral building blocks S-2.56 and (S,S)-2.60.  The total synthesis of palmerolide A based 
on this chiral pool approach is ongoing and when completed should offer a facile route to a 
multitude of derivatives for use in structure activity relationship (SAR) and structure property 
relationship (SPR) studies. 
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Chapter 3.  Meridianin A and psammopemmin A:  structure investigation 
 
3.1 Indole and pyrimidine containing natural products 
Nitrogen-containing heterocyclic compounds derived from natural sources are abundant in 
structural complexity and bioactivity.  Of particular interest to this study are indole- and 
pyrimidine-containing metabolites derived from marine invertebrates.  Sponges (Porifera) and 
tunicates (Urochordata) have afforded a diverse assortment of biologically promising indole
1
- and 
pyrimidine
2
-containing alkaloids. 
 
Indole alkaloids that bear a nitrogen containing heterocycle at the 3-position have displayed a rich 
array of bioactivity.   Dragmacidin (3.1), a piperazine-linked bisindole alkaloid with cytotoxic 
properties, was isolated from the deep water marine sponge Dragmacidon sp.
3
    The compound 
displayed low in vitro IC50 values toward P-388 (leukemia), A-549 (human lung), HCT-8 (human 
colon), and MDAMB (human mammary) cancer cell lines.  Dragmacidin D (3.2), another 
piperazine-linked bisindole was isolated from the sponge Spongosorites sp.
4
  Dragmacidin D 
exhibited antiviral properties versus feline leukemia virus (FeLV), antitumor properties versus P-
388 and A-549 cancer cells, and also inhibited the growth of the fungal pathogens Candida 
albicans, and Cryptococcus neoformans.  
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Topsentin (3.3),
5
 bromotopsentin (3.4)
5
 and nortopsentins A-C (3.5-3.7),
6
  bis(indolyl)imidazole 
alkaloids isolated from the deep-sea Caribbean sponge Spongosorites ruetzleri exhibit antitumor 
and antiviral activity toward several important targets.  Topsentin displayed activity toward P-338, 
HCT-8, A-549, and T47D (breast) cancer cells in vitro as well as in vivo activity toward P-388 and 
B16 (melanoma) cell lines.  Topsentin and bromotopsentin exhibited in vitro antiviral activity 
toward herpes simplex (HSV-1), Vesivular stomatitis virus (VSV), and coronavirus A-59.  
Nortopsentins A-C (3.5-3.7) displayed inhibitory activity toward P-388 cancer cells.  Semisynthetic 
nortopsentins, dimethylated at the imidazole nitrogens, showed a significant increase in activity 
toward P-388. 
 
 
A multitude of aplysinopsins, tryptophan derivatives bearing an imidazoline moiety, have been 
isolated from sponge genera worldwide.
7
  Aplysinopsins have also been found in corals 
(predominately from the genus Tubastraea) as well as a Tubastraea predator, the mollusk 
Phestilla melanobrachia.  Aplysinopsin (3.8),
8
 initially found in eight Indo-Pacific sponge species, 
has shown anticancer
9
 and antimicrobial properties.
10
  Several aplysinopsins and synthetic 
analogs have also shown activity in serotonin (5-HT) receptor assays.
7
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3.1.1 Indoles and pyrimidines from Southern cold water sponges  
A plethora of discorhabdins, cytotoxic pyrroloiminoquinone alkaloids, have been isolated from 
both temperate and tropical sponges of the family Latrunculiidae.
11
  The cold water sponge 
Latrunculia apicalis, found in McMurdo Sound, Antarctica, has afforded discorhabdin G (3.9)
12
 as 
well as discorhabdin C (3.10, previously reported from New Zealand collected Latrunculia sp.).
13
  
Discorhabdin C is a particularly potent deterrent, defending L. apicalis from predation by the 
spongivorous sea star Perknaster fuscus.  Discorhabdin R (3.11), found to contain a sulfide as 
well as an epoxide, has been isolated from two Antarctic sponges in the Latrunculiidae family 
(Negombata and Latrunculia sp.).
14
 
 
 
The bright red Antarctic sponge Kirkpatrickia variolosa elaborates
 
colorful pigments named 
variolins A (3.12) and B (3.13),
15,16
 aminopyrimidine containing fused tricyclic heteroaromatic 
alkaloids.
 17
   N(3’)-methyl tetrahydrovariolin B (3.14) was also isolated from K. variolosa.  Variolin 
B was shown to be a very potent inhibitor of P-388 cancer cells.  Variolin B was later found to 
inhibit cyclin dependent kinase-2 (CDK2) and CDK3 selectively over CDK4.
18
  Variolin B and a 
synthetic derivative, deoxyvariolin B (3.15), were found to inhibit phosphorylation of histone H1, 
mediated by several CDKs, effectively interrupting the normal progression of the cell cycle.
19
  
These promising findings have prompted PharmaMar, a company specializing in marketing drugs 
derived from marine sources, to assess the variolins in preclinical trials. 
49 
 
 
 
Psammopemmins A-C (3.16-3.18), 4-hydroxyindole alkaloids, were isolated from the Antarctic 
sponge Psammopemma sp.
20
  The 5-(2’-bromo-4-aminopyrimidine) moiety reported in 
psammopemmins is unprecedented in both terrestrial and marine natural products.  No bioactivity 
data was reported for psammopemmins A-C. 
 
 
3.1.2 Indoles and pyrimidines from Southern cold water tunicates 
Aplicyanins A-F (3.19-3.24), tetrahydropyrimidine substituted indoles isolated from the Antarctic 
tunicate Aplidium cyaneum were shown to be cytotoxic and antimitotic.
21
  The absolute 
configuration of the aplicyanins is not known.  Aplicyanin E, when subjected to chiral HPLC, was 
shown to be enantiomerically pure.  Aplicyanins C-F bear a rather uncommon 1N-methoxyindole 
subunit.  Aplicyanins B, D, and F displayed GI50 values in the submicromolar range versus HT-29 
(colon), A-549, and MDAMB cancer cells lines while aplicyanins A, C, and E were far less active.  
The N-acetyl group is clearly crucial for the biological activity observed. 
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The green tunicate Aplidium meridianum, collected in the South Georgia Islands, elaborates 
seven aminopyrimidine containing indole alkaloids, meridianins A-G (3.24-3.30).
22,23
  Meridianins 
A-E were initially screened against murine mamarian adenocarcinoma cells (LMM3).  Meridianins 
B-E displayed micromolar IC50 values against LMM3 cells.  Further biological investigation 
revealed that meridianins A- F were low micromolar inhibitors of various cyclin-dependent kinases 
(CDKs), glycogen synthase kinase-3 (GSK-3), protein kinase A (PKA), as well as other protein 
kinases.
24
  The most potent inhibitors, meridianins B and E, are 4-hydroxyindole indole alkaloids 
differing in bromination pattern.  Meridianins B-F exhibited cytotoxic activity at low micromolar 
ranges.  Meridianin A, however, displayed no cytotoxicity toward HEp-2 (laryngeal carcinoma), 
HT-29, and LMM3 cells at the highest concentration examined. 
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3.2 Review of meridianin syntheses 
The meridianins have attracted significant synthetic interest due to their biological activity as well 
as their unique and relatively simple structure.  Many of the naturally occurring meridianins have 
been synthesized.  Particular attention has been focused on meridianin analogs as well as 
methods to efficiently construct a variety of derivatives for further biological examination. 
 
3.2.1 Synthesis of natural meridianins 
Meridianin D (3.27) and its debromo- analog meridianin G (3.30) were synthesized via coupling of 
2-amino-4-chloropyrimidine (3.31) and the appropriate protected indole boronic acid (3.32) using 
a Suzuki-Miyaura  protocol (Scheme 3.1).
25
 
 
 
Along with the tricyclic core of variolin, the synthesis of meridianins C (3.26), D (3.27), and E 
(3.28) was reported.
26
  A follow up publication described the synthesis of meridianin A (3.24) 
using the same methods.
27
 Heating the suitably functionalized N-tosyl-3-acylindole (3.33) with 
dimethylformamide dimethylacetal (DMF-DMA) afforded enaminone 3.34 (Bredereck protocol,
28
 
Scheme 3.2).  Condensation of 3.34 with guanidine chlorohydrate in the presence of sodium 
carbonate resulted in concomitant detosylation forming meridianins C, D, and intermediate 3.35.  
Debenzylation and debromination of 3.35 with H2 and palladium (Pd) yielded meridianin A.  
Meridian E was formed via selective debenzylation of 3.35 with trifluoroacetic acid (TFA) and 
thioanisole.  Hydrogenation in different solvents formed either meridianin A or E.  In the initial 
report (ref. 26), meridianin E was produced from intermediate 3.35 via hydrogenation (H2, Pd/C, 
EtOH, 88%).  In the follow up report (ref. 27), meridianin E was formed from 3.35 by treatment 
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with TFA and thioanisole (65%) while hydrogenation of 3.35 (H2, Pd/C, EtOAc) resulted in the 
debrominated compound, meridianin A, in 83% yield. 
 
 
Meridianins C, D, and G were synthesized efficiently using a carbonylative alkynylation followed 
by subsequent cyclocondensation.
29
  Carbonylative Sonogashira coupling of 
trimethylsilylacetylene and appropriately functionalized 3-iodoindole 3.36 using Pd(PPh3)2Cl2 
catalyst resulted in trimethylsilylalkynone 3.37 (Scheme 3.3).  Condensation of 3.37 with 
guanidine in the presence of sodium carbonate with concurrent deprotection resulted in 
meridanins C, D, and G.  Absent from the report is any discussion of the reactivity of 4-
hydroxyindoles (or protected forms thereof) toward carbonylative alkynylation. 
 
 
Meridianin G (3.30), referred to in this report as 6-debromomeridianin D, was produced from 3-
cyanoacetylindole (3.38) in four steps (Scheme 3.4).
30
  Treatment of 3.38 with DMF-DMA 
53 
 
afforded enaminonitrile 3.39 which was then condensed with guanidine resulting in 5’-
cyanomeridianin G (3.40).  Base hydrolysis then decarboxylation yielded the desired meridianin 
G. 
 
 
3.2.2 Synthesis and biological activity of meridianin analogs 
Several 3-(5’-(2’amino)pyrimidyl)indole alkaloids were synthesized prior to the discovery of the 
meridianins in 1998.  The first report, in 1967, describes the synthesis of two compounds very 
similar in structure to that of the meridians.   Alkaloids 3.41a and 3.41b were formed by reacting 
3-methylthio-3-(3-indolyl)acrylic acid derivatives (3.42a,b) with guanidine (Scheme 3.5).
31
  In 
1993, the synthesis of over 200 pyrimidine derivatives and their utility in asthma therapy was 
reported.
32
   Enaminone 3.43, 3-methylaniline (3.44), and cyanamide were condensed under 
acidic conditions to form 3.45, in effect, 2’-methylaniline substituted meridianin G (Scheme 3.5).  
Pyrimidylindole 3.45 was found to inhibit histamine release from basophil cells.   Compounds that 
block immunological release of mediators like histamine could be developed into antiasthma 
agents. 
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Several synthetic (bis)indole and pyrazine meridianin analogs constructed using Suzuki 
methodology were found to inhibit growth of a variety of cancer cell lines.
33
  (Bis)indole alkaloid 
3.46 displayed strong activity against IGROV1 (ovarian carcinoma).  The pyrazine-substituted 
indole alkaloids displayed varying amounts of cytotoxicity and selectivity.  N-tosyl indole 3.47 
showed across the board cytotoxicity, inhibiting the growth of every cell line tested.  Alternatively, 
methoxy substituted pyrazine 3.48 specifically and effectively inhibited HOP-92 (non-small lung 
cancer) cells. 
 
 
Iso-meridianins C (3.49) and G (3.50) were prepared by microwave-assisted Fischer indole 
synthesis (Scheme 3.6).
34
  Suitably substituted phenylhydrazine 3.51 (from pyrimidine 3.52) was 
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heated in a conventional microwave oven with zinc chloride (ZnCl2) in a small amount of 
dimethylformamide (DMF) resulting in N-Boc-deprotection and indole formation.  The resulting 
iso-meridianins C and G were devoid of biological activity.  
 
 
An environmentally benign method to construct the 2’-piperidinyl meridianin analog 3.53a and 
related trisubstituted pyrimidines has been described using basic alumina as a solid support as 
well as a catalyst.
35
  Chalcone 3.54, S-benzylthiuronium chloride (3.55) and piperidine dissolved 
in ethanol, concentrated onto basic aluminum and heated intermittently with microwave resulted 
in 3.53a (Scheme 3.7).  Biological activity of 3.53a and other trisubstituted pyrimidines 
synthesized in this study was not reported.  A reaction of the apposite chalcone (3.54) with 
guanidine derivative 56 afforded several similar trisubstituted pyrimidines (3.53b-d, Scheme 3.7) 
that displayed antimalarial properties, inhibiting Plasmodium falciparum in vitro.
36
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Reaction of suitably substituted chalcone 3.57 with guanidine afforded 6’-alkyl substituted 
meridianin analogs 3.58a-c.
37
  When screened for in vivo pregnancy interceptive activity in 
hamsters, 3.58c was 50% effective, whereas 3.58a and 3.58b were devoid of activity. 
 
 
Indoyluracils 3.59 resembling meridians have been synthesized from condensation of 
ureidopropenoate 3.60 (Scheme 3.9).
38
   Using DMF-DMA and a substituted guanidine, 3.60 was 
formed in similar fashion as 3.34 (Scheme 3.2) and 3.39 (Scheme 3.4).  Perplexingly, no mention 
of biological activity, or lack thereof, was reported for these compounds.  The authors note that 
the pyrimidyl N1 could be coupled to a sugar to form novel nucleosides. 
 
 
Using Bredereck methods described in Scheme 3.2,
26,27
 meridianins C (3.26), G (3.30), and 
seven monohalogenated meridianin analogs (3.61a-g) were synthesized from the suitably 
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substituted enaminone 3.34.
39
  In a similar fashion, numerous monohalogenated, N1-alkyl-
substituted meridianin derivatives were constructed from alkylated enaminone 3.62.  The crystal 
structure of N1-methylmeridianin G was obtained to assist in molecular modeling of the 
interaction between merdianin analogs and the adenonsine triphosphate (ATP) pocket of kinases.  
Structure activity relationship studies were ongoing at the time of publication.  No bioactivity data 
is available to date.  Following a Bredereck protocol and bromination at 5’, a Suzuki coupling was 
used to construct 5’-aryl substituted meridianin G derivatives (3.63a-g).
40
  The N1-methyl 
derivatives of 3.63a-g were also synthesized.  The anticancer utility of 3.63a-g was reported in a 
follow up publication.
41
  Screening the compounds against various kinases as well as MCF-7 
(breast) and PA 1 (ovarian) cancer cell lines revealed that N1-methyl 3.63c, N1-methyl 3.63b, 
3.63f, and 3.63g were selectively cytotoxic toward PA 1 cells. Interestingly, none of the active 
compounds displayed any significant kinase inhibition. 
 
 
Several 6’-substituted meridianin C and G analogs were synthesized (Scheme 3.10) via metal-
free alkynylation of indole 3.64 with various -oxo ketene dithioacetals (3.65).
42
  Refluxing 3.64 
and 3.65 in trifluoroacetic acid:dichloromethane (TFA:DCM) resulted in the formation of 
functionalized indole 3.66.  Condensation with guanidine nitrate yielded N1-alkylated-6’-
substituted meridianin derivatives 3.67a-g.   Oxidative debenzylation of 3.67a-d resulted in 6’-
substituted meridianins (3.68a-d).  Biological activity was not reported. 
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Meridianin analogs 3.69a-c as well as a handful of 2’-chloromeridianin derivatives were 
constructed by thermal annulation of nitrosoarenes with 4-ethynylpyrimidines.
43
  Heating a 1:1 
ratio of substituted nitrosoarene 3.70 and 2-amino-4-ethynylpyrimidine (3.71) in toluene resulted 
in the formation of meridianin derivatives 3.69a-c (Scheme 3.11).  At time of publication, 
investigation of the mechanism of the reaction as well as the bioactivity of the compounds 
synthesized was ongoing. 
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3.2.3 Synthesis and biological activity of meriolins 
The remarkable biological activity of the meridianins and the variolins as well as the structural 
commonalities between the two alkaloids prompted interest in synthesizing 3-(2’-aminopyrimidin-
4-yl)-7-azaindole, a structural hybrid later dubbed meriolin 1 (3.70, Fig. 3.1).   
 
 
The first synthesis of 3-(2’-aminopyrimidin-4-yl)-7-azaindole (3.70) was reported along with the 
synthesis of meridianins A, C, D, and E and similarly relied on Bredereck methodology.
27  
 
Analogous to the synthesis of meridianins in Scheme 3.2, meriolin 1 (3.70) was formed through 
condensation of guanidine and azaindolylenaminone 3.71 (Scheme 3.12).  Meriolin 1 was also 
synthesized via condensation of guanidine and trimethylsilylalkynone 3.72 (Scheme 3.12) 
reported in conjunction with the synthesis of meridianins C, D, and G (see Scheme 3.3).
29
  Initial 
screening demonstrated that meriolin 1 inhibits protein kinases hSGK1 and Tie-2 at low 
micromolar levels. 
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The synthesis and biological characterization of fourteen meriolin analogs (meriolins 1-14, 3.70-
3.83) revealed the compounds to be potent CDK inhibitors.
 44,45
   When screened for selectivity 
against thirty-two kinases, meriolins displayed enhanced specificity toward CDKs over variolins, 
especially CDK2 and CDK9.  Upon crystallization of variolin B and meriolin 3 with pCDK2/cyclin 
A, both compounds were found to bind in the ATP binding site of the kinase but in different 
orientations.   Meriolin 3 was found to be forty times more efficient at inhibiting Ewing’s sarcoma 
than the control, roscovitine (a purine analog, 3.84), in xenograft assays.  Meriolin 3 also showed 
nanomolar IC50 values against spheroid and monolayer HCT-116 (colon) cancer cell lines.  SAR 
studies revealed that the 2’-amino group was necessary for CDK inhibition as 2’-
methylthiomeriolin (meriolin 12, 3.81) as well as 2’-H-meriolin (meriolin 13, 3.82) showed a 
significant loss of activity.  Changing the substituent at C4 (R
1
) to a more aliphatic group led to 
increased activity, theorized to be due to favorable interactions with the glycine-rich loop of the 
kinase.  Bulky substitutes at C6 (R
2
) led to less inhibition, perhaps by shielding hydrogen bonding 
interactions between N2, N7 and the kinase.  Meriolins are potent CDK inhibitors as well as 
strong antiproliferatives and warrant further investigation. 
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3.3 Isolation of meridianins A, B, C, and E from Antarctic tunicate Synoicum sp. 
In our ongoing search for bioactive metabolites, we investigated the chemical composition of the 
yellow top tunicate, Synoicum sp.,
46
 collected in the benthos surrounding Palmer Station, 
Antarctica.  The lyophilized tunicate was extracted with polar and nonpolar solvents.  The 
nonpolar extract was subjected to successive medium and high performance liquid (Scheme 
3.13) to yield meridianins A (3.24), B (3.25), C (3.26), and E (3.28).  NMR data of meridianins 
isolated from Synoicum sp. were compared to that of the previously reported meridianins isolated 
from Aplidium meridianum
22
 and found to be congruous. 
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In the process of verifying the structure of the meridianins, it was noted that the physical data 
reported for meridianin A, B, and E bore a striking resemblance to psammopemmin A (3.16), C 
(3.18), and B (3.17), respectively, indole alkaloids isolated from the Antarctic sponge 
Psammopemma sp.
20
  Little difference exists between the reported NMR data of meridianin A and 
psammopemmin A (Table 3.1).  To verify the structure originally proposed for psammopemmin A 
as well as investigate biological activity of the meridianins and analogs thereof, synthetic studies 
were initiated. 
 
 
Table 3.1. 
1
H NMR and 
13
C shifts
a
 of meridianin A (3.24) and psammopemmin A (3.16). 
Position 3.24 H
b 
3.24 H
c
 3.24 C
b 
3.24 C
c
 Position 3.16 H
d
 3.16 C
d
 
4-OH 13.55 (s) 13.57 (s)   4-OH 13.55 (s)  
N1-H 11.71 (brs) 11.76 (brs)   N1-H 11.75 (brs)  
2 8.20 (d) 8.22 (d) 128.5 128.5 2 8.22 (d) 128.3 
3   113.8 114.0 3  113.7 
3a   114.5 114.7 3a  114.3 
4   152.1 152.0 4  152.0 
5 6.36 (dd) 6.36 (dd) 105.6 105.4 5 6.38 (dd) 105.4 
6 6.96 (dd) 6.98 (dd) 124.4 124.4 6 6.98 (dd) 124.3 
7 6.78 (dd) 6.79 (dd) 102.4 102.3 7 6.81 (dd) 102.3 
7a   139.4 139.4 7a  139.2 
2’   161.9 161.7 2’  161.7
e
 
4’   160.6 160.5 4’  160.7
e
 
5’ 7.09 (d) 7.10 (d) 104.5 104.4 6’ 7.12 (d) 104.3 
6’ 8.10 (d) 8.10 (d) 158.5 158.4 N1’-H 8.12 (brd) 158.3
e
 (C5’) 
2’-NH2 6.69 (s, 2H) 6.72 (s, 2H)   4’-NH2 6.68 (brs,2H)  
 a
 in ppm in d6-DMSO. 
 b
isolated from Aplidium meridianum.
22 
 c
isolated from Synoicum sp
 46
 
 d
isolated from Psammopemma sp.
 20
 
 e
assignments may be interchanged.
20
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3.4 Synthesis and biological activity of 3-pyrimidylindoles 
A strategy to couple indoles to amino substituted pyrimidines was developed using Suzuki-
Miyaura protocol to synthesize both meridianin A and psammopemmin A,
47
 as well as 3-
pyrimidyindole analogs.  The compounds were evaluated for biological activity.  
 
3.4.1 Synthesis of meridianin A, 4-methoxymeridianin A, and 5-bromomeridinanin E 
Meridianin A (3.24) was formed in six steps from indolone 3.85 in 17% overall yield (Scheme 
3.14).  The 4-indolol moiety of meridinain A was synthesized by the dehydrogenation of 
commercially available tetrahydroindolone 3.85 using Pd/C in refluxing diisobutyl ketone, a 
modest yielding yet economic reaction.
48 
 The phenol of 4-indolol (3.86) was then masked as a 
silyl ether (3.87).  A two-step, one-pot N1 silylation and bromination
49
 reaction resulted in the 
suitably substituted indole 3.88.  Transmetallation with t-butyllithium then addition of borate 3.89 
generated vinyl borate 3.90 which could be coupled to 2-amino-4-chloropyrimidine using a Suzuki 
protocol resulting in an intermediate (3.91) bearing the 4-hydroxymeridianin skeleton.
25
  
Desilylation with tetra-n-butylammonium fluoride (TBAF) afforded meridianin A (3.24) in good 
yields.   
 
The 4-methoxy analog of meridianin A was synthesized using a route analogous to that producing 
meridianin A (Scheme 3.14).  4-Indolol (3.86) was refluxed with methyl iodide under basic 
conditions to form 4-methoxyindole (3.92).  After silylation and bromination resulting in the 
formation of 3.93, transmetallation followed by addition of 3.89 gave vinyl borate 3.94.  Coupling 
3.94 to 2-amino-4-chloropyrimidine with Pd
0
 resulted in 3-pyrimidylindole 3.95.  Upon treatment 
with TBAF, 4-methoxymeridianin A (3.96) was obtained. 
 
Dibromination of meridianin A (3.24) with pyridinium tribromide
50
 resulted in the formation of 5-
bromomeridianin E (3.97, Scheme 14). 
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3.4.2 Synthesis of psammopemmin A and 2’-chloropsammopemmin A 
Psammopemmin A (3.16) differs from meridianin A (3.24) in connectivity and substitution of the 3-
pyrimidyl- moiety.  Using the Suzuki methodology developed to synthesize meridianin A, we 
needed only to change the pyrimidine coupling partner to afford psammopemmin A.  Synthesis of 
the pyrimidine moiety (Scheme 3.15) began with the amination of 2,4-dichloropyrimidine (3.98) 
followed by iodination to yield 4-amino-2-chloro-5-iodopyrimidine (3.99).
51
  Substitution of the 2’-
chloro group using hydrogen bromide in acetic acid (HBr/AcOH)
52
 resulted in 4-amino-2-bromo-5-
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iodopyrimidine (3.100).  As a general rule, oxidative addition of Pd
0
 to halopyrimidines takes 
place at C4>C2>>C5.
53  
We expected compound 3.100 to couple at C5 rather than C4, however, 
due to the more reactive iodo- substituent. 
 
Vinyl borate 3.90 was then coupled to pyrimidine 3.100 with tetrakistriphenylphospine palladium 
resulting in an intermediate (3.101) bearing the psammopemmin skeleton. 
 
Desilylation of the 
resulting protected 3-(5’-pyrimidyl)-indole using TBAF resulted in very low yields of the 
psammopemmin A free base, 3.102, which was quite unstable under basic conditions. However, 
deprotection of 3.101 with hydrogen fluoride/pyridine (HF·pyridine)
54
 produced the 
psammopemmin A free base cleanly as a white precipitate from the reaction solution.  Forming 
the reported
20
 HX salt of psammopemmin A was problematic and led to decomposition.  
Psammopemmin A hydrochloride (3.103) could be prepared by bubbling HCl gas through a d6-
DMSO solution of 3.102.  Immediately analyzing the sample via NMR was necessary as the 
compound began to decompose after a few hours. 
 
Vinylborate 3.90 was coupled to 4-amino-2-chloro-5-iodopyrimidine (3.99) to form 3.104 which, 
upon deprotection with TBAF in low yields or HF
.
pyr in higher yields, afforded 2’-
chloropsammopemmin A (3.105, Scheme 3.15).  
66 
 
 
 
3.4.3 Structural reassessment of psammopemmin A 
NMR data (Table 3.2) for synthetic psammopemmin A
.
HCl (3.103) and its free base (3.102) were 
then compared to the natural product psammopemmin A (3.16, Table 3.1).  The phenolic 4-OH 
signals differed significantly (3.16:  13.55, s; 3.102:  9.30, s; 3.103:  9.47, vbrs) suggesting 
these protons were in dissimilar electronic environments. However, the 4-OH signal in meridianin 
A (3.24) was identical to that reported for psammopemmin A (3.16, Table 3.1).  The signal for H2 
also differs between reported (3.16:  8.22, d) and synthetic (3.102:  7.27 d; 3.103:  7.33) 
psammopemmin A.  Both meridianin A (3.24) and natural psammopemmin A (3.16) show 
coupling between protons on the pyrimidine ring (3.24: 5’, 6’, d; 3.16: 6’, N1’, d), while there is no 
obvious evidence of N1’-protonation in synthetic psammopemmin A hydrochloride (3.103).  It is 
not clear from the 
1
H NMR spectrum of 3.103 which pryimidyl-nitrogen accepts a proton (N1’ or 
N3’).  The 4’-NH2 signal of 3.102 exists as a very broad signal from  6.2-7.6 (centered around  
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7.00) under H2, 5, 6, and 7 signals and making integration difficult.  The 4’-NH2 signal of 3.103 
appears even more broad ( 6.1-8.5, centered around  7.45).  The rather sharp 4-OH singlet in 
the 
1
H NMR spectrum of 3.102 ( 9.30) significantly broadens as to be almost imperceptible in 
3.103 ( 9.47).   N1’ should be preferentially protonated as proposed in natural product 3.16.  It 
has been demonstrated that monoprotonation of simple 4-aminopyrimidines occurs almost 
completely on N1, para to the amino group.
55
  The 
13
C NMR data for 3.103, however, lacks 
signals for C3, 2’, and 6’, perhaps explained by the rapid proton exchange between N1 and N3 of 
pyridine.  This phenomenon has been reported to occur in 2,4-diaminopyrimidine resulting in two 
carbon signals for C2, 4, 5, and 6.
56
  Unfortunately, 3.103 slowly degrades in d6-DMSO so the 
doubling of those carbons due to proton exchange, if occurring, could not be detected. 
 
Table 3.2. 
1
H and 
13
C NMR shifts
a
 of synthetic psammopemmin A (3.102) and synthetic 
psammopemmin A·HCl (3.103) 
 
Position 3.102 H 3.102 C 3.102 HMBC 3.103 H 3.103 C 
4-OH 9.30 (s)   9.30 (s)  
N1-H 11.29 (brs)   11.29 (brs)  
2 7.27 (d) 123.6  7.33 124.2 
3  105.6 H2, 6’, N1H  not observed 
3a  115.4 H2, 5, 7, N1H, 4-OH  115.2 
4  151.2 H5, 6, 4-OH  151.1 
5 6.38 (d) 103.8 H7, 4-OH 6.48 104.0 
6 6.93 (dd) 122.6  6.90
b
 122.8 
7 6.88 (d) 103.2 H5 6.90
b
 103.2 
7a  138.6 H2, 6  138.6 
2’  148.9   not observed 
4’  163.6 H6’  163.9 
5’  113.0 H6’  113.0 
6’ 7.79 (s) 156.4  7.88 not observed 
4’-NH2 7.00 (vbrs)   7.45  
N1’-H    not observed  
 a
 in ppm in d6-DMSO. 
 b
signals overlap. 
 
 
From comparison of the 
1
H and 
13
C NMR data of 3.16, 3.24, 3.102, and 3.103 we infer that the 
correct structure of psammopemmin A isolated from Psammopemma sp. is the same as that of 
meridianin A (3.24).  The structure of psammopemmin C (3.18) should also be revised to that of 
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meridianin B (3.25) due to the nearly identical 
1
H and 
13
C NMR signals reported.
20,22
  It is also 
likely that the structure of psammopemmin B (3.17) is that of meridianin E (3.28), although the 
NMR data for the two were obtained in different solvents so comparison is difficult. 
 
3.4.4 Synthesis of meridoquin 
Inspired by the meriolins (3.70-3.83), synthetic hybrids of meridianins and variolins (Fig. 3.1), we 
envisioned a meridianin-chloroquine hybrid dubbed meridoquin (3.106, Fig. 3.2).  By combining 
the bioactive meridianin skeleton with characteristics from the widely used antimalarial 
chloroquine (see section 4.2), we hoped to build a new bioactive scaffold as a starting point for 
future studies. 
 
 
Meridoquin (3.106) was achieved using Suzuki methodology to couple a suitably substituted 
indole moiety to the desired pyrimidine (Scheme 3.16).   A low yielding but quick reaction of neat 
diethylamine and 2,4-dichloropyrimidine (3.98) resulted in the formation of 2-chloro-4-N,N-
diethylaminopyrimidine (3.107) as well as the desired 4-chloro-2-N,N-diethylaminopyrimidine 
(3.108).  Construction of the indole coupling partner began with the one pot N1 silylation, 3-
bromination of commercially available 6-chloroindole (3.109) resulting in dihaloindole 3.110.  
Transmetallation of 3.110 with t-butyllithium then addition of 3.89 resulted in intermediate 3.111 
which was immediately coupled to pyrimidine 3.108 using the previously developed Suzuki 
protocol.  Due to the electron withdrawing effects of the ring nitrogens, 4-halopyrimidines are 
exceptionally good electrophiles for use in Suzuki coupling reactions,
53
 explaining the absence of 
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any bisindoles in the reaction mixture.  The indole-pyrimidine coupling product (3.112) was 
observed exclusively.  Desilylation of 3.112 with TBAF afforded meridoquin (3.106). 
 
 
3.4.5 Biological evaluation of 3-pyrimidylindoles 
Serotonin (3.113, 5-hydroxytryptamine, 5-HT) transmission is thought to play a role in central 
nervous system (CNS) disorders.  Compounds that bind to specific serotonin receptor subtypes 
could lead to treatment of CNS diseases.
57
  Selective antagonists of 5-HT2C helped to establish 
the receptor’s role in behaviors such as feeding and anxiety.  Neuropsychiatric disorders such as 
major depression, anxiety, and migraine are currently being treated with 5-HT selective receptor 
ligands while drugs that target 5-HT1A, 5-HT2A, and 5-HT2C receptors are under clinical 
investigation for the treatment of depression, schizophrenia, and anxiety, respectively.  We were 
prompted to examine the binding affinity of several of our 3-pyrimidylindoles to various serotonin 
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receptors due to the structural features (amine-containing indole) common to our compounds and 
serotonin. 
 
 
The binding affinity of meridianin A (3.24), 4-methoxymeridianin A (3.96), synthetic 
psammopemmin A (3.102), and 2’-chloropsammopemmin A (3.105) toward eleven 5-HT receptor 
subtypes was evaluated.
58
  Primary screening was conducted in vitro by measuring the percent 
inhibition of radioligand bound to the receptor in question (% inhibition = 100% - % radioactively 
bound).  Primary assay results are summarized in Table 3.3.  Secondary screening was 
performed in vitro on compounds showing >50% inhibition (highlighted in Table 3.3). 
  
Table 3.3.  Primary screening of 3-pyrimidylindoles for 5-HT binding inhibition.
a
 
 
 
5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT2A 5-HT2B 5-HT2C 5-HT3 5-HT5A 5-HT6 5-HT7 
3.24 81.3 -0.6 57.1 5.1 11.7 103.7 84.9 12.5 21.1 36 6.9 
3.96 83.7 43.8 76 1.6 8 100.3 91.4 -7.5 79.9 12.7 69.8 
3.102 20.3 41.7 58.2 2.2 -11.4 1.4 -13.3 -5.2 0.8 10.8 10 
3.105 10.6 44.1 27.9 -2 4.1 -3.7 -7.2 5.7 8.7 17 12.7 
a% inhibition = 100% - % radioactively bound 
 
Meridianin A significantly inhibited binding of the radioligand to 5-HT1A, 5-HT1D, 5-HT2B and 5-
HT2C in primary screening.  To date, secondary screening using radioligand competition binding 
assays has been carried out on 5-HT1D, 5-HT2B and 5-HT2C.  Secondary screening revealed 
meridianin A did not inhibit binding of 5-HT1D and 5-HT2C with [
3
H]5-carboximidotryptamine and 
[
3
H]mesulergine, respectively.  Meridainin A did, however, inhibit the binding of radioligand 
[
3
H]lysergic acid diethylamide ([
3
H]LSD) with 5-HT2B (Ki = 150 nM, Fig. 3.3). 
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Primary screening of 4-methoxymerididanin A showed the compound inhibited radioligand 
binding to 5-HT1A, 5-HT2B, 5-HT2C and 5-HT5A, and 5-HT7.  Secondary screening toward 5-HT1D 
and 5-HT2C showed 4-methoxymeridianin A did not inhibit binding of the radiolabled compounds.  
Like meridianin A, the 4-methoxy- analog significantly inhibited binding of radioligand [
3
H]LSD 
with 5-HT2B (Ki = 88 nM, Fig. 3.4).  4-Methoxymeridianin A also inhibited, to a lesser extent, 
binding of [
3
H]LSD with 5-HT5A, and 5-HT7 (Ki = 1525 nM, 1985 nM; Fig. 3.5 and Fig. 3.6, 
respectively).  Secondary screening showed psammopemmin A did not inhibit binding of [
3
H]LSD 
to 5-HT1D.  These initial findings show meridianin A is a more selective inhibitor than other 
compounds tested while methylation of the 4-OH group leads to more potent inhibition of 
radioligand binding to 5-HT2B as well as broader but less potent activity versus other receptor 
subtypes. 
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In addition to 5-HT receptors, the binding effects of 3-pyrimidylindoles on other CNS receptors 
and transporters were investigated.  The dopamine active transporter (DAT) was screened for 
radioligand ([
3
H]WIN35428, a synthetic tropane analogous to cocaine) inhibition.  Meridianin A 
was the only compound to display activity in primary and secondary DAT screens (Ki = 2.35 M, 
Figure 3.7).  One compound was also found to inhibit radioligand binding ([
3
H]3-quinuclidinyl 
benzilate, [
3
H]QNB) of the muscarinic acetylcholine receptor (M5): 2’-chloropsammopemmin A (Ki 
= 7.04 M, Figure 3.8). 
2’-Cl-psamm Ameridianin A
 
Malaria is a devastating disease affecting disadvantaged populations worldwide (see Chapter 4).  
Because many current treatments for malaria are losing efficacy due to drug-resistant parasites, 
new drugs are required to overcome resistance.  Toward this end, the potential antimalarial 
activity
59
 and cytoxicity
60
 of meridianin A (3.24), 4-methoxymeridianin A (3.96), synthetic 
psammopemmin A (3.102), 2’-chloropsammopemmin A (3.105) and meridoquin (3.106) were 
investigated.  Meridianin A, 4-methoxymeridianin A, and meridoquin were active against the 
malaria parasite Plasmodium falciparum in initial screening.  Secondary screening was conducted 
to determine IC50 values toward P. falciparum.  Meridianin A was the most potent (IC50 = 12 M) 
but 4-methoxymeridianin A (IC50 = 40 M) and meridoquin (IC50 = 200 M) also displayed some 
antimalarial activity.  Meridianin A was cytotoxic toward A-549 lung cancer cells (IC50 = 15 M) 
but, fortuitously, both 4-methoxymeridianin A and meridoquin displayed no toxic effects at the 
highest concentration examined (IC50 > 420 M and > 333 M, respectively).  Psammopemmin A 
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and its 2’-chloro- analog showed no activity against P. falciparum at the highest concentration 
tested.  The results of this screen are interesting in that 4-OH methylation of meridianin A 
significantly decreases the cytotoxicity of the compound while retaining antiparasitic activity. 
 
In summary, several meridianin and psammopemmin analogs were synthesized and examined 
for biological activity (Figure 3.9).  Meridianin A inhbited binding of [
3
H]LSD to 5-HT2B, inhibited 
radioligand binding to DAT, and inhibited growth of P. falciparum but was, unfortunately, found to 
be cytotoxic.  4-Methoxymeridianin A inhibited binding of [
3
H]LSD with 5-HT2B, 5-HT5A, and 5-HT7, 
inhibited growth of P. falciparum, and displayed no cytotoxic effects.  Meridoquin had moderate 
antimalarial activity and was found to be non-toxic.  Psammopemmin A was devoid of activity but 
its 2’-chloro- analog inhibited radioligand binding of M5. 
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Chapter 4.  Antimalarial natural products 
 
4.1 The malaria dilemma 
Malaria, a devastating infectious disease, was responsible for almost a million deaths and 247 
million reported clinical episodes in 2008.
1
  Malaria is caused by Plasmodium parasites 
transmitted through infected Anopheles mosquitoes.  Many Plasmodium species exist worldwide 
and can infect a variety of vertebrates.  P. falciparum is the most deadly to humans, accounting 
for the majority of malaria-related deaths.  P. vivax causes the most morbidity of the human 
parasites.  P. ovale, and P. malariae are also human pathogens of concern.   
 
The malaria parasite life cycle is complex, involving discreet stages in two hosts.
2
 The bite from a 
malaria infected female Anopheles mosquito transmits sporozoites into a human host which infect 
hepatocytes (liver cells).  The sporozoites mature and release merozoites into the blood 
circulation, invading erythrocytes (red blood cells, RBC).  After developing through ring, 
trophozoite, and schizont stages and asexually multiplying within the RBC’s, mature schizonts 
again rupture, releasing more merozoites that infect additional RBC’s.  Some parasites in the 
RBC’s develop into male and female gametocytes which are passed to a female Anopheles 
mosquito during blood meal.  Sexual reproduction in the mosquito gut forms non-motile zygotes 
which develop into motile ookinetes that move to the midgut wall.  Ookinetes transform into 
oocysts which rupture releasing sporozoites that traverse to the salivary gland of the mosquito.  
The parasite life cycle repeats in a new host when the mosquito takes a human blood meal. 
 
Malaria persists in 108 countries and territories, particularly affecting disadvantaged populations 
in Africa and, to a lesser extent, South East Asia and Latin America.
3
   The most at-risk are young 
children residing in Africa where malaria is responsible for 20% of childhood deaths.  Other at-risk 
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groups include non-immune pregnant women, individuals with human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS), international travelers, and families 
returning to endemic areas after prolonged absence.  International funding for the treatment, 
prevention and eradication of malaria increased to $1.7 billion in 2009 from $300 million in 2003 
fueling noticeable reductions in the malaria burden.  However, current funding falls short of the $5 
billion required annually to fully combat the disease globally.  Although devastating, malaria is 
treatable and preventable. 
 
4.2 Current malaria treatment 
4.2.1 Quinolines, antifolates, and artemisinins 
Europeans learned of the antimalarial properties of South American Cinchona bark (Family: 
Rubiaceae) in the seventeenth century.
4
  The antimalarial constituent of the bark, a quinoline-
containing alkaloid named quinine (4.1), is thought to prevent the parasite from polymerizing 
heme.
5
  As the parasite develops in the RBC, it cannibalizes hemoglobin subsequently releasing 
heme which the parasite converts to hemozoin, a non-toxic crystalline heme polymer. Inhibition of 
heme polymerization results in toxic levels of heme and death of the parasite.  The mechanisms 
by which the parasite polymerizes heme and quinoline-based drugs inhibit the polymerization 
process is not fully understood.  It is clear, though, that quinoline based therapies have been 
quite effective in the treatment of malaria evidenced by the success of chloroquine (CQ, 4.2), a 
synthetic 4-aminoquinoline derivative.
6
   CQ was used extensively, beginning in the 1950’s, to 
cure billions of clinical cases of malaria.  Excellent clinical efficacy, economical syntheses, ease 
of use, and prophylactic properties contributed to the success of CQ and other synthetic quinoline 
derivatives including amodiaquine (4.3) and mefloquine (MQ, 4.4).  The “wonder drug” was 
overused, however, leading to the emergence of chloroquine-resistant parasites.
7
  Other drugs 
targeting different metabolic processes in the parasite were developed to combat resistant 
strains. 
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Drugs that target folate metabolism eradicate Plasmodium parasites by inhibiting the parasite’s 
ability to produce folic acid and thus its ability to biosynthesize pyrimidine, purine, and amino 
acids.  A combination of the antifolate pyrimidine-containing drugs sulfadoxine (4.5) and 
pyrimethamine (4.6) was found to be efficacious in treating uncomplicated CQ-resistant malaria.
8
  
While both compounds show modest antiparasitic properties individually, a synergistic effect is 
observed when combination therapy is administered.  Unfortunately, the switch from CQ to 
sulfadoxine/pyrimethamine (SP) to treat CQ-resistant strains, while initially effective, quickly led to 
the appearance of SP resistant parasites.
9
 
 
 
Artemisinin (4.7), dubbed qinghaosu by the Chinese, is the powerful antimalarial component of 
the Chinese medicinal herb Artemisia annua.
7
  Artemisinin, a unique sequiterpene 1,2,4-trioxane 
lactone, rapidly clears all blood stages of Plasmodium parasitemia through a highly-contested 
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mechanism of action which could involve the peroxide moiety forming radical or ionic 
intermediates.
10
  Poor solubility of the natural product led to semisynthetic derivatives including 
more lipophilic artemether (4.8) and more hydrophilic artesunate (4.9).  In an intriguing effort to 
utilize microbes as an inexpensive producer of artemisinin, the yeast Saccharomyces cerevisiae 
was genetically modified, using genes from A. annua, to produce the artemisinin precursor 
artemisinic acid (4.10).
11
  The precursor can be easily converted to artemisinin and derivatives 
using through economical, well-studied synthetic procedures. Although artemisinin and its 
derivatives are effective single-drug treatments, artemisinin combination therapy (ACT) is 
recommended by the World Health Orgaization (WHO) to delay development of parasite drug 
resistance.  ACT has been reported as 95% effective in curing malaria.
12
  Most malaria-endemic 
countries now use ACT as a first-line treatment for uncomplicated P. falciparum infection.  
Unfortunately, parasites displaying artemisinin resistance have been recently documented on the 
Cambodia-Thailand border.
13
 
 
 
4.2.2 Drug resistant parasites 
Widespread drug resistant malaria is of enormous concern.
14
   Parasites resistant to quinoline-
based drugs and sulfadoxine/pyrimethamine combination therapy have been extensively 
observed.
15
  The more recent emergence of artemisinin combination therapy resistance 
underscores an urgent need for the development of a new class of compounds.  Success of 
future antimalarial drug discovery depends on the ability to identify parasites displaying drug 
resistance
16
 and subsequently screen diverse chemotypes for the ability to inhibit drug resistant 
parasitemia.  Gratifyingly, worldwide awareness of the malaria burden has led to collaborations 
between academic institutions, non-profit organizations, and the pharmaceutical industry.
17
  With 
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the support of international funding from public and private sources, these collaborators are 
working to combat the global malaria burden. 
 
4.3 Natural products as antimalarial leads 
Recent screening of vast synthetic chemical libraries provided by Glaxo Smith-Kline has afforded 
hundreds of potential antimalarial leads.
18,19
  Particularly exciting was the identification of 
nineteen new inhibitors of four validated drug targets as well as fifteen novel malarial protein 
binders.  Researchers hunting for new antimalarial chemotypes commonly depend on synthetic 
combinatorial libraries to generate large numbers of compounds, which supply high throughput 
screening (HTS) operations.
20
  Synthetic chemical libraries, however, simply cannot match the 
diversity and vast “chemical space” found in nature.  One just needs to look in the right place!  
Given that the most widely used and most efficacious malaria therapies were derived from natural 
products, further chemical investigation of natural sources for antimalarial constituents is fully 
warranted.   
 
Plants have proven to be an excellent source of antimalarial alkaloids and terpenes.
21
  Flora used 
in traditional medicine to treat malaria-like symptoms, like Cinchona and Artemisina, are 
particularly well studied.  Less studied but no less promising sources for potential antimalrial 
chemistry are microorganisms and marine macroorganisms.  A number of antimalarial agents 
have been recently identified from marine macroorganisms.
22
  Crambescidin 800 (4.11), 
previously isolated from the Mediterranean red encrusting sponge Crambe crambe,
23
 displayed 
nanomolar activity against CQ-resistant P. falciparum FCR3 in-vitro.
24
  Crambescidins bear a 
complex molecular structure comprised of a pentacyclic guanidine linked by a linear -hydroxy 
fatty acid to a hydroxyspermidine moiety.  Several crambescidin analogs have been prepared that 
show even more promising antimalarial activity. 
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Manzamine A (4.12), initially isolated from an Okinawan sponge Haliclona sp., is an antimalarial 
-carboline alkaloid containing a complicated array of 5-, 6-, 8-, and 13-membered rings.
25
  More 
than sixty related compounds have been isolated from various sponge species.
26
  A single 
intraperitoneal injection of manzamine A was found to clear parasitemina in mice infected with P. 
berghei.
27
  Natural manzamines display toxicity but the semisynthetic derivative, peracylated 8-
hydroxymanzamine A (4.13), has no cytotoxicity at the highest dose tested while retaining 
antiparasitic properties.
28
  Manzamines are purported to have been isolated from a symbiotic 
bacterium suggesting the molecules produced in the sponge are of microbial origin.
29
  If large 
scale fermentation of this microbe is feasible, ample quantities of manzamines would be available 
for further experimentation. 
 
 
Bacteria and fungi produce a wide range of biologically active compounds that possess great 
diversity in chemical structure.
30,31
  Screening microbial extracts has resulted in the discovery of 
many compounds possessing antimalarial activity.  Several microbe-derived natural products 
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display potent and promising antiparasitic activity.  Nostocarboline (4.14), isolated from the 
cyanobacterium Nostoc sp., and synthetic dimers thereof, inhibited P. falciparum in nanomolar 
concentrations.
32
  The compounds are only weakly cytotoxic, the most encouraging possessing a 
selectivity index (SI) of >2,500.  The screening of eighty crude marine-derived bacterial extracts 
led to the identification of salinosporamide A (4.15 see also section 1.3) as a nanomolar in vitro 
inhibitor of human Plasmodium parasites.
33
  The compound also significantly reduced P. yoelii 
parasitemia in mice.  Isolated from the yeast Candida lipolytica,
34
 the indoloquinazoline 
tryptanthrin (4.16) along with several synthetic analogs displayed potent in vitro activity against 
CQ- and MQ-resistant Plasmodium strains.
35
   
 
 
Microbes are an ideal source for novel antimalarial compounds.  Not only do microbes produce 
profound chemical diversity, they are also amendable to large-scale fermentation resulting in 
facile access to compounds with complicated structures.  Complex chemicals are undesirable 
mostly because the malaria burden in underdeveloped nations requires inexpensive treatment.  
However, an abundantly producing microbe could yield complex natural products very cost-
effectively.  Our lab, with international collaboration, has examined a multitude of microorganisms 
for antimalarial constituents with the goal of identifying lead compounds possessing potent 
activity against Plasmodium falciparum. 
 
4.4 Medicines for Malaria Venture project 
4.4.1 MMV project overview 
With funding from Medicines for Malaria Venture (MMV),
36
 we endeavored to examine niche 
environment microbiota for new antimalarial chemotypes.  The planned project would seek to 
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analyze ~70,000 microbes from niche environments worldwide including our own microbial 
libraries at the University of South Florida (USF) as well as the libraries of our academic and 
commercial collaborators.   Our lab supplied 1,000+ Antarctic marine, Florida marine, and Florida 
mangrove microbial endophytes.  Bacterial and fungal endophytes were isolated from samples 
collected on various expeditions to McMurdo Station and Palmer Station, Antarctica as well as 
collecting trips to several locations in Florida waters, including the Florida Keys, the Gulf of 
Mexico, and the Florida Everglades.  Eubacteria (~5,000) isolated from Caribbean marine cave-
dwelling invertebrates were supplied by Magellan BioScience (Todd Daviau and John Cronin).  
City University of Hong Kong (CY, Lilian Vrijmoed) and National Taiwan Ocean University 
(NTOU, Ka-Lai Pang) provided 5,000+ isolates of mangrove endophytes from the coastal region 
of China.  The majority (~55,000) of the microbes analyzed were filamentous fungi isolated from 
various sources, largely plant in origin, collected around the world and housed at Mycosynthetix 
(MSX, Cedric Pearce).  Biological activity screening (section 4.4.2.1) was performed at USF, 
College of Public Health (Dennis Kyle).  Processes involving preparation of extracts, fractionation 
of active samples, as well as analyzing and identifying active components were carried out in our 
lab using the procedures described in section 4.4.2.2. 
 
4.4.2 MMV project methodology 
4.4.2.1 Antimalaria and cytotoxicity assays, prioritization of active extracts 
Primary screening employed a novel luciferase reporter assay that utilizes transgenic blood-stage 
parasites to rapidly identify antimalarial extracts from a 96-well plate format.  The in vitro drug 
luminescence (ITDL) assay
37
 uses Plasmodium falciparum (3D7), transfected with a luciferase 
construct, allowing for an assay with signal to noise ratio better than many currently in use (Sybr 
Green, DAPI, Pico Green).  The assay was designed to reveal activity at “high” concentrations 
(50 g crude extract/mL) and “low” concentrations (5 g crude extract/mL).  Extracts that 
displayed >67% parasite growth inhibition at both high and low concentrations were designated 
“active.”  Extracts that showed >67% inhibition at high concentration but <67% inhibition at low 
concentration were labeled “partially active.” 
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In vitro cytotoxicity of the active extracts toward A-549 human cancer cells allowed for further 
prioritization of antimalarial extracts.  Cytotoxicity was measured at the same “high” and “low” 
concentrations previously described.  Both high and low concentrations were divided into three 
categories: cytotoxic (<75% cell viability), moderately cytotoxic (75-95% cell viability), and non-
toxic (>95% cell viability).  Those extracts that were found “active” in the antimalarial screen and 
“non-toxic” in the cytotoxicity screen were given the highest priority.  Current hit rates are 
summarized in Table 4.1.   
 
 Table 4.1.  Antimalarial and cytotoxic activity of microbial extracts 
 
Origin Extracts 
screened 
Active extracts 
(% of screened) 
Partially active 
extracts 
(% of screened) 
non-toxic 
active extracts 
(% of actives) 
Non-toxic 
partially active 
extracts 
(% of p.a.) 
MSX 24,780
a
 278 (0.9%) 2214 (9%) 108 (39%) 872 (39%) 
CY/NTOU 5192 35 (0.7%) 269 (5%) 10 (29%) 186 (36%) 
USF 1056 3 (0.3%) 40 (4%) 2 (67%) 14 (35%) 
 
a
includes only extracts for which both antimalarial and cytotoxicity data was available. 
 
4.4.2.2 Antarctic microbe cultivation, extraction, and processing  
Tissue from sessile marine invertebrates (i.e. sponges, tunicates, soft corals, etc.) collected in the 
waters surrounding McMurdo Station and Palmer Station, Antarctica were preserved in glycerol 
solution and kept at -80 
o
C during shipment from Antarctica to USF.  Using sterile technique, the 
warmed tissue (5 
o
C) was sectioned into fractions and immediately plated on a Difco marine agar 
dish which was then sealed with parafilm.  The microbes were allowed to grow at 5 
o
C for about 
two weeks.  Sterile loops were used to isolate various microbes growing from the tissue.  The 
agar plates streaked with the new isolates were allowed to grow for an additional two weeks.  
This process was repeated until a pure isolate was obtained.  Each isolate was archived in 
glycerol stock and kept in our microbe library at -80 
o
C. 
 
The isolates were cultured on a small scale to obtain enough biomass for biological analyses.  To 
limit error and speed processing time, all procedures were conducted in a 96-well format.  A 
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custom built media shaker rack containing 96 “wells” of 160 mL capacity each in a 12 column X 8 
row grid was used to culture 88 isolates concurrently (the last column was reserved for controls).  
Difco marine broth (100 mL) was added to each well.  After sterilization, each isolate, either 
directly from the isolation plate or from regrown stock, was transferred via sterile loop to a 
designated well in the shaker rack.  The culture media was allowed to ferment under aeration at 5 
o
C for three weeks.  Acrylic ester resin (XAD-7, 3 g) was then added to each well to collect small 
non-polar and semi-polar organic metaobolites.  Cells were lysed with three successive freeze-
thaw cycles. The resin was then filtered along with any cell mass and washed with water.  The 
filtrate was sterilized and discarded.  The resin and cell mass were then extracted with methanol 
(10 mL) for 24 h and removed via filtration from the methanolic extract.  Concentration of the 
methonolic extract yielded a crude extract for each of the 88 samples cultured.  The extract was 
redissolved in dimethylsulfoxide (DMSO) at 30 mg/mL.  A portion of this solution (150 L) was 
transferred to a 96 well plate and submitted for antimalarial screening.  The remaining DMSO 
solution was transferred to a deep well plate and kept frozen for further testing. 
  
4.4.2.3 Fungi extraction and processing  
Lyophilized fungal cultures were received from City University of Hong Kong (CY) and National 
Taiwan Ocean University (NTOU) in 30 mL falcon tubes.  Each culture was extracted with 
methanol (~15 mL) for at least 24 h.  The methanolic extract was carefully transferred to a clean 
20 mL scintillation vial which was placed in a compartmentalized tray keeping the extractions in a 
96-well format (88 per tray).  Concentration of the methanol extracts under a stream of air 
afforded the dried extract.  Mycosynthetix (MSX) samples were received as solid culture material 
(~5 mL) in 20 mL scintillation vials.  After each sample was extracted with methanol (24 h, 15 
mL), the methanolic extract was subjected to the same concentration protocol used for the CY 
and NTOU samples.  All dried extracts were processed and submitted (30 mg/ mL, DMSO) in 96-
well plates analogous to the procedure developed for the Antarctic microbial extracts.   
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4.4.2.4 Scale up fermentation and fractionation  
Antarctic microbe extracts found active in the antimalarial assay were regrown in 6X1 L cultures 
(Difco marine broth).  After 3 weeks of aerated fermentation, XAD-7 (30 g/L) resin was added to 
extract the small organic metabolites from the media.  Cells were then lysed in three successive 
freeze-thaw cycles.  The resin and cell mass was separated from the broth by filtration, rinsed 
with water, and extracted with methanol.  The methanolic extract was concentrated in vacuo to 
afford the crude scale up extract.  Scaled up fermentations (100X-1000X) were received from CY, 
NTOU, and MSX and extracted exhaustively with methanol.  The methanolic extracts were 
concentrated to afford crude scale up extracts. 
 
Fractionation of the scale up extracts was achieved with normal phase silica gel medium pressure 
liquid chromatography (MPLC).  A portion (400 mg or 2 g) of the extract was fractionated through 
a silica gel cartridge (4g and 40g, respectively) with a gradient of hexane→ethyl 
acetate→methanol generating about ten fractions of increasing polarity.  After concentration, a 
portion of each fraction was redissolved in DMSO (2 mg/ mL) and submitted for biological 
evaluation. 
 
4.4.2.5 Active fractions to pure compounds 
Fractions that remained active in the antimalarial assay were further investigated via nuclear 
magnetic resonance (NMR) spectroscopy and liquid chromatograpy-mass spectrometry (LC-MS).  
Proton (
1
H) NMR spectra were obtained for each active fraction.  Those fractions with interesting 
spectra (i.e. those with downfield signals indicative of heteroatoms and, consequently, functional 
groups) were further analyzed by thin layer chromatography (TLC) and finally purified with high 
performance liquid chromatography (HPLC).  Pure compounds were identified by obtaining 
physical data (
1
H and 
13
C NMR, MS) and searching databases such as AntiMarin for compounds 
with similar or identical data.  Alternatively, partial structures could be elucidated via various 2-D 
NMR techniques [Correlation spectroscopy (COSY), Heteronuclear Single Quantum Coherence 
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(HSQC), Heteronuclear Multiple Bond Correlation (HMBC), etc.] which would be used to narrow 
down potential structures.   
 
4.4.2.6 Protocol validation 
To validate our sample preparation procedures as well as the antimalarial assay, a crude 
Artemisina annua extract
38
 was subjected to our fractionation protocol.  The concentrated 
fractions were then added to a plate containing MSX fractions and submitted for biological 
analysis.  The Artemisina extract fractions were analyzed in an identical manner alongside the 
fungal fractions.  Bioassay results indicated one active Artemisina fraction which, upon NMR and 
LC-MS analyses, was revealed to contain artemisinin. 
 
4.4.3 Antimalarial compounds from endophytic mangrove fungi  
Preliminary results led to isolation of several fungi-derived antimalarial natural products.  Extracts 
from endophytic fungi isolated from mangroves inhabiting coastal China were the first to be 
analyzed.  Scale up fermentation and extraction followed by fractionation of several fungal 
samples afforded two known and, unfortunately, cytotoxic and cytostatic classes of metabolites, 
cytochalasins and trichothecenes. 
 
4.4.3.1 Cytochalasins  
Scale up fermentation of CY-4202 was found to contain cytochalasin D (cytD, 4.17), a 
polyketide
39
 mycotoxin originally isolated
40
 from cultures of Metarrhizium anisopliae and 
Hypoxylon terricola.  Cytochalasin D is a reversible potent inhibitor of actin polymerization and 
thus is used to probe the role of actin in various cell processes.
41
  Physical data (Table 4.2. 
1
H 
and 
13
C NMR data) of cytD isolated from CY-4202 was identical to that previously reported.
42
  An 
LC-MS method was developed to quickly screen fractions for the presence of cytD leading to the 
identification in another cytD-producing coastal China mangrove endopyte, CY-4204, the 
presence of which was further confirmed with 
1
H NMR data.  Several other CY and MSX samples 
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appear to contain cytochalasins as their 
1
H NMR spectra are similar to cytD but LC-MS traces 
differ from cytD.   
 
Cytochalasin D was previously observed to affect development of P. berghei
43,44
 but have had no 
inhibitory effect on P. yoelli.
45
  We found that many of the cytD containing fractions inhibit P. 
falciparum (in vitro) perhaps enhanced by synergistic effects from other compounds in the 
mixture.  Pure cytD also displayed in vitro inhibition of P. falciparum with activity at nanomolar 
concentrations (IC50 = 26 nM).  However, because the compound inhibits actin polymerization 
resulting in cytostasis, cytD is a poor candidate for malaria therapy. 
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Table 4.2. 
1
H and 
13
C NMR shift
a
 comparison of isolated cytochalasin D (4.17) with literature 
values. 
Position ref. 42 H 4.17 H ref. 42 C 4.17 C 
1   173.6 173.7 
3 3.22, m 3.24, m 53.5 53.5 
4 2.84, m 2.84, m 47.0 47.0 
5 2.14, t 2.15, t 50.0 49.9 
6   147.5 147.6 
7 3.80, d  3.80, d  69.8 69.8 
8 2.83, m 2.83, m 32.6 32.6 
9   53.2 53.3 
10 2.65, dd; 2.83, m 2.76, m (2H) 45.3 45.3 
11 0.95, d 0.94, d 13.6 13.6 
12 5.09, s, 5.29, s 5.08, s, 5.29, s 114.5 114.4 
13 5.35, m 5.33, m 134.1 134.1 
14 5.65, dd 5.69, dd 130.6 136.0 
15 2.02, dd, 2.51, dd 2.02, dd, 2.51, dd 37.7 37.7 
16 2.73, m 2.73, m 42.3 42.3 
17   210.2 210.2 
18   77.7 77.7 
19 5.15, dd 5.14, d 127.1 127.0 
20 6.11, dd 6.11, dd 132.3 132.3 
21 5.63, dd 5.62, m 77.3 77.1 
22 1.20, d, 3H 1.20, d, 3H 19.4 19.4 
23 1.51, s, 3H 1.51, s, 3H 24.2 24.2 
1’   137.2 137.2 
2’, 6’ 7.25, m, 2H 7.13, d, 2H 129.1 129.1 
3’, 5’ 7.25, m, 2H 7.28, m, 2H 128.9 128.9 
4’ 7.25, m 7.28, m 127.6 127.6 
OCOCH3   169.7 169.6 
OCOCH3 2.26, s, 3H 2.26, s, 3H 20.8 20.8 
NH 5.53, brs 4.64, brs   
 a
 in ppm in CDCl3. 
 
4.4.3.2 Trichothecenes  
Investigation of scale up fermentation CY-3923 revealed two known tricothecene mycotoxins that 
were in vitro inhibitors of the malaria parasite.  Trichothecenes are tetracyclic sesquiterpenes 
usually containing an epoxide ring.  We found that roridin E (4.18) potently inhibited P. falciparum 
(IC50 < 190 nM) while its deoxy-analog, 12,13-deoxyroridin E (4.19),  displayed less, but still 
significant, inhibition (IC50 = 765 nM).  The compounds were cytotoxic, however, in our initial 
toxicity screen at the lowest dose examined (5 g/mL).  The structures of 4.18 and 4.19 were 
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confirmed upon comparison of 
1
H and 
13
C data with literature values(4.18: Table 4.3, 4.19: Table 
4.4).
46
 
 
 
The antimalarial properties of roridin E and related trichothecenes have been previously 
reported.
47
  Roridin E showed extremely potent activity against P. falciparum (K1, EC50 = 0.3 nM) 
but, unfortunately, similar cytotoxicity (KB, BC1, vero cells: EC50 = 0.8 to1.4 nM).  Interestingly, 
roridin E acetate (4.20) more potently inhibited P. falciparum (K1, EC50 = 0.1 nM) while 
possessing ten- to twenty-fold less cytotoxicity (KB, BC1, vero cells: EC50 = 8.0 to 28.0 nM) than 
roridin E.  This simple addition of an acetate moiety had a profound effect on activity.  Although 
most tricothecenes are cytotstatic or cytotoxic, it is possible that a derivative will be uncovered or 
semisynthetically derived that possesses the excellent antiparasitic properties currently observed 
as well as low or no cytotoxicity.   
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Table 4.3. 
1
H and 
13
C NMR shift
a
 comparison of isolated roridin E (4.18) with literature values. 
Position ref. 46 H 4.18 H ref. 46 C 4.18 C 
2 3.85, d 3.85, d 79.2 79.2 
3 2.09, m; 2.56, m 2.06, m; 2.53, m 35.8 35.8 
4 6.22, m 6.21, dd 74.2 74.2 
5   48.4 48.4 
6   42.7 42.7 
7 1.67, m; 2.06. m 1.67, m; 2.06. m 21.6 21.6 
8 2.02, m; 2.00, m 2.02, m; 2.00, m 27.7 27.6 
9   140.2 140.2 
10 5.48, br d 5.48, d 118.9 118.8 
11 3.92, d 3.90, d 67.2 67.2 
12   65.6 65.6 
13 2.83, d; 3.15, d 2.82, d; 3.14, d 48.1 48.1 
14 0.8, s 0.79, s, 3H 6.7 6.7 
15 3.95, d; 4.32, d 3.93, d; 4.31, d 63.7 63.7 
16 1.72, s 1.71, s, 3H 23.2 23.2 
1’   166.4 166.5 
2’ 5.96, s 5.96, s 117.2 117.1 
3’   159.2 159.2 
4’ 2.53, m 2.53, m 41.2 41.2 
5’ 3.59, m; 3.71, m 3.59, m; 3.70, m 69.6 69.8 
6’   83.9 83.8 
7’ 5.91, dd 5.90, dd 138.0 137.9 
8’ 7.54, dd 7.52, dd 126.6 126.6 
9’ 6.58, dd 6.57, dd 143.6 143.6 
10’ 5.75, d 5.75, d 117.8 117.8 
11’   165.8 165.8 
12’ 2.28, d 2.26, d, 3H 20.3 20.3 
13’ 3.65, m 3.65, m 70.7 70.7 
14’ 1.21, d 1.20, d, 3H 18.3 18.2 
 a
 in ppm in CDCl3. 
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Table 4.4. 
1
H and 
13
C NMR shift
a
 comparison of isolated 12,13-deoxyroridin E (4.19) with 
literature values. 
Position ref. 45 H 4.19 H ref. 45 C 4.19 C 
2 4.45, d 4.48, d 79.0 79.8 
3 1.75, m; 2.56, m 1.77, m; 2.55, m 37.2 37.2 
4 6.26, dd 6.27, m 74.4 74.4 
5   51.0 51.0 
6   42.5 42.5 
7 1.50, m; 1.97, m 1.51, m; 1.96, m 20.9 20.9 
8 2.00, m, 2H 2.00, m, 2H 27.7 27.7 
9   139.8 140.0 
10 5.44, br d 5.45, d 119.1 118.8 
11 3.98, d 4.01, d 67.0 67.1 
12   152.7 152.5 
13 4.70, s; 5.14, s 4.72, s; 5.16, s 105.3 105.5 
14 1.02, s, 3H 1.03, s, 3H 11.3 11.3 
15 3.96, d; 4.28, d 3.96, d; 4.30, d 64.2 64.3 
16 1.68, s, 3H 1.69, s, 3H 23.2 23.3 
1’   166.5 166.6 
2’ 6.02, br s 6.03, s 117.5 117.5 
3’   158.7 158.8 
4’ 2.53, m, 2H 2.53, m, 2H 41.3 41.3 
5’ 3.55, m; 3.65, m 3.56, m; 3.65, m 69.8 69.8 
6’ 3.70, m 3.70, m 83.9 83.7 
7’ 5.90, dd 5.90, d 137.8 137.7 
8’ 7.56, dd 7.56, dd 126.6 126.7 
9’ 6.57, dd 6.58, dd 143.5 143.5 
10’ 5.66, d 5.68, d 117.7 117.8 
11’   165.6 165.7 
12’ 2.25, d, 3H 2.25, s, 3H 20.0 20.0 
13’ 3.64, m 3.64, m 70.6 70.8 
14’ 1.20, d, 3H 1.23, d, 3H 18.3 18.2 
 a
 in ppm in CDCl3. 
 
4.4.4 MMV project outlook 
With preliminary extract screening nearing completion
48
 and fractionation of scale up fermentation 
extracts well underway, we expect to discover many more antimalarial constituents in our 70,000-
strong microbial extract library.  The identification of artemisinin combined with the isolation of 
cytochalsin D and roridin E contributes to the validity of both the isolation procedure as well as 
the antimalarial assay.   Cytotoxicity data for those extracts displaying activity in the malaria 
assay should steer us away from active but toxic extracts resembling the ones discussed herein.  
Further development of LC-MS techniques to identify common toxic compounds like 
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cytochalasins and roridins would speed up identification of compounds we do not want.  The time 
saved would allow us to analyze a greater quantity of promising active extracts increasing the 
chance of drug lead discovery.  A microbe-derived lead compound would then be investigated 
synthetically to identify the pharmacophore, as well as to tailor bioactivity and physical properties, 
analogous to operations that led to the development of clinically successful quinoline and 
artemisinin derivatives. 
 
4.5 References Cited 
 
1. World Health Organization. Fact sheet no. 94. April, 2010 (Geneva, Switzerland). 
 
2.  Tuteja, R. FEBS J. 2007, 274, 4670-4679. 
 
3.  World Health Organization. World Malaria Report 2009; WC 765, NTIS (Geneva, 
 Switzerland). 
 
4.  Rocco, F. Quinine: Malaria and the Quest for the Cure that Changed the World;  Harper 
 Perennial: San Francisco, 2004. 
 
5.  Rathore, D.; Dewal, J.; Nagarkatti, R.; Kumar, S. Drug Discovery Today: Ther. 
 Strategies 2006, 3, 153-158. 
 
6.  Sullivan, D. J.; Gluzman, I. Y.; Russels, D. G.; Goldberg, D. E. Proc. Natl. Acad. Sci. 
 USA 1996, 93, 11865-11870. 
 
7.  Bray, P. G.; Ward, S. A.; O’Niell, P. M. Curr. Top. Mol. Immun. 2005, 295, 3-38. 
 
8 . Bell, D. J.; Nyirongo, S. K.; Mukaka, M.; Zijlstra, E. E.; Plowe, V. P.; Molyneus, M. E.; 
 Ward, S. A.; Winstanly, P. A. PLoS ONE 2008, 3, e1578. 
 
9.  Gatton, M. L.; Martin, L. B.; Cheng, Q. Antimicrob. Agents Chemother. 2004, 48, 2116-
 2123. 
 
10.  O’Niell, P. M.; Barton, V. E.; Ward, S. A. Molecules 2010, 15, 1705-1721. 
 
11.  Ro, D.-K.; Paradise, E. M.; Ouellet, M.; Fisher, K. J.; Newman, K. L.; Ndungu, J. M.; Ho, 
 K. A.; Eachus, R. A.; Ham, T. S.; Kirby, J.; Chang, M. C. Y.; Withers, S. T.; Shiba, Y.; 
 Sarpong, R.; Keasling, J. D. Nature 2006, 440, 940-943. 
 
12.  Kar, S.; Kar, S. Nat. Rev. Drug Discovery 2010, 9, 511-512. 
 
13.  Dondorp, A. M. Nature Rev. Microbiol. 2010, 8, 272–280. 
 
14.  Hayton, K.; Su, X. Z. Curr. Drug Targets Infect. Disord. 2004, 4, 1-10. 
 
15.  Hyde, J. FEBS J. 2007, 274, 4688-4698. 
 
16.  Bacon, D. J.; Jambou, R.; Fandeur, T.; Le Bras, J.; Wongrichanalai, C.; Fukuda,  M. M.; 
 Ringwald, P.; Sibley, C. H.; Kyle, D. E. Malaria Journal 2007, 6, 120. 
95 
 
 
 
17.  Gelb, M. H. Cur. Opin. Chem. Biol. 2007, 11, 440-445. 
 
18.  Fransisco-Javier, G.; Sanz, L. M.; Vidal, J.; de Cozar, C.; Alverez, E.;  Lavandera, J.-
 L.; Vanderwall, D. E.; Green, D. V. S.; Hasan, S.; Brown, J. R.;  Peishoff, C. E.; Cardon, 
 L. R.; Garcia-Bustos, J. F. Nature 2010, 465, 305-310. 
 
19.  Guiguemde, W. A.; Shelat, A. A.; Bouck, D.; Duffy, S.; Crowther, G. J.; Davis, P. H.; 
 Smithson, D. C.; Connelly, M.; Clark, J.; Zhu, F.; Jimenez-Diaz, M. B.; Martinez, M. S.; 
 Wilson, E. B.; Tripathi, A. K.; Gut, J.; Sharlow, E. R.; Bathurst, I.;  Mazouni, F. E.; Fowble, 
 J. W.; Forquer, I.; McGinley, P. L.; Castro, S.; Angulo- Barturen, Ferrer, S.; Rosenthal, 
 P. J.; DeRisi, J. L.; Sullivan, D. J.; Lazo, J. S.; Roos, D. S.; Riscoe, M. K.; Phillips, M. 
 A.; Rathod, P. K.; Van Voorhis, W. C.;  Avery, V. M.,; Guy, R. K. Nature 2010, 465, 311-
 315. 
 
20. Olliaro, P. L.; Yuthavong, Y. Pharmacol. Ther. 1999, 81, 91-110.  
 
21.  Saxena, S.; Pant, N.; Jain, D. C.; Bhakuni, R. S. Curr. Science 2003, 85, 1314- 1329. 
 
22.  Gademann, K.; Kobylinska, J. Chem. Rec. 2009, 9, 187-198. 
 
23. Jares-Erijman, E. A.; Sakai, R.; Rinehart, K. L J. Org. Chem. 1991, 56, 5712- 5715.   
 
24.  Lazaro, J. E. H.; Nitcheu, J.; Mahmoudi, N.; Ibana, J. A.; Mangalindan, G. C.;  Black, 
 G. P.; Howard-Jones, A. G.; Moore, C. G.; Thomas, D. A.; Mazier, D.;  Ireland, C. M.; 
 Concepcion, G. P.; Murphy, P. J.; Diquet, B. J. Antibiot. 2006, 59, 583–590. 
 
25. Sakai, R.; Higa, T.; Jefford, C. W.; Bernardinelli, G. J. Am. Chem. Soc. 1986, 108, 
 6404-6405.  
 
26.  Hu, J. F.; Hamann, M. T.;  Hill, R. T.; Kelly, M. The Manzamine Alkaloids. In The 
 Alkaloids: Chemistry and Biology; Elsevier; 2003, Vol.  60; pp 207–285. 
 
27. Ang, K. K. H.; Holems, M. J.; Higa, T.; Hamann, M. T.; Kara, U. A. K. Antimicrob. Agents 
 Chemother. 2000, 44, 1645-1649. 
 
28.  Shilabin, A. G.; Kasanah, N.;  Tekwani, B. L.;  Hamann, M. T. J. Nat. Prod. 2008, 71, 
 1218-221. 
 
29.  Hill, R.; Hamann, M.T.; Peraud, O.; Kasanah, N. Manzamine-producing actinomycetes. 
 US Patent. WO2003US2423820030801[WO2004013297], 2006. 
 
30.  Demain, A.; Sanchez, S. J. Antibiol. 2009, 62, 5-16. 
 
31. Brase, S.; Encinas, A.; Keck, J.; Nising, C. F. Chem. Rev. 2010, 109, 3903-3990.  
 
32. Barbaras, D.; Kaiser, M.; Brun, R.; Gademann, K. Bioorg. Med. Chem. Lett. 2008, 18, 
 4413-4415.  
 
33. Prudhomme, J.; McDaniel, E.; Ponts, N.; Bertani, S.; Fenical, W.; Jensen, P.; Le Roch, K. 
 PLoS ONE 2008, 3, e2335. 
 
34. Schindler, F.; Zahner, H. Arch. Mikrobiol. 1971, 79, 187-203.   
 
96 
 
 
35. Bhattacharjee, A. K.; Hartell, M. G.; Nichols, D. A.; Hicks, R. P.; Stanton, B.; van Hamont, 
 J.E.; Milhous, W.K. Eur. J. Med. Chem. 2004, 39, 59-67.  
 
36. Medicines for Malaria Ventures grant: MMV08/0105. 
 
37. Franke-Fayard, B.; Djokovic, D.; Dooren, M. W.; Ramesar, J.; Waters, A. P.; Falade, M. 
 O.; Kranendonk, M.; Martinelli, A.; Cravo, P.; Janse, C. J. Int. J. Parasitol. 2008, 38, 
 1651-1662. 
 
38. Artemisina annua extract was generously provided by Jim McChesney, Chromadex, Inc. 
 
39  Schumann, J.; Hertweck, C. J. Am. Chem. Soc. 2007, 129, 9564-9565 
 
40.  Aldridge. D. C., Armstrong, J. J.; Speake, R. N.;  Turner, W. B. J. Chem. Soc: 
 C 1967, 1661- 1676. 
 
41.  Hoppe, H. C.; Joiner, K. A.; Smythe, W. A. Cell Microbiol. 2008, 10, 452-464. 
 
42.  Xu, H.; Fang, W.-S.; Chen, X.-G.; He, W.-Y.; Cheng, K. D. J. Asian Nat. Prod. Res. 2001, 
 3, 151-155. 
 
43. Carrolo, M.; Giordano, S.; Cabrita-Santos, L.; Corso, S.; Vigario, A. M.; Silva, S.; Leiriao, 
 P.; Carapau, D.; Armas-Portela, R.; Comoglio, P. M.; Rodriguez, A.; Mota, M. M. Nat. 
 Med. 2003 9, 1363-1369. 
 
44. Silvie, O.; Franetich, J.-F.; Renia, L.; Mazier, D. TRENDS Mol. Med. 2004,10, 101. 
 
45.  Silvie, O.; Franetich, J.-F.; Renia, L.; Mazier, D.TRENDS Mol. Med. 2004, 10, 97-100. 
 
46. Namikoshi, M.; Akano, K.; Meguro, S.; Kasuga, I.; Mine, Y.; Takahashi, T.; Kobayashi, H. 
 J. Nat. Prod. 2001, 64, 396-398. (
1
H NMR shifts for roridin E are listed in the 
 supporting information). 
 
47. Isaka, M.; Punya, J.; Lertwerawat, Y.; Tanticharoen, M.; Thebtaranonth, Y. J. Nat. Prod. 
 1999, 62, 329-331. 
 
48. We are indebted to numerous researchers (>50!) who contributed to processing the 
 seemingly never ending multitude of samples in both the labs of Bill Baker and Dennis 
 Kyle. 
97 
 
 
 
 
Chapter 5.  Experimental 
 
5.1 General Procedures 
Unless otherwise stated, all experiments were performed under inert atmosphere (nitrogen or 
argon) in oven or flame-dried glassware equipped with a magnetic stir bar and a rubber septum.  
All solvents used were reagent grade.  Anhydrous dichloromethane (DCM) was obtained by 
distillation from calcium hydride (CaH).  Anhydrous tetrahydrofuran (THF) was obtained by 
distillation from sodium/benzophenone.  Dry methanol (MeOH) was obtained by distillation from 
magnesium and iodine (Mg
0
, I2).  All other chemicals were purchased from Sigma-Aldrich and 
were used as received.  Low-temperature baths of -78 °C, -60 °C, and -40 °C were obtained with 
an immersion cooler bath using acetone, chloroform, or acetonitrile, respectively, with dry ice 
(CO2). Thin layer chromatography (TLC) was carried out using Whatman normal phase Silica gel 
60Å Partisil®.
  
TLC plates were visualized with 5% phosphomolybdic acid in ethanol (EtOH) and 
heating and/or UV (254 nm).  Products were chromatographed on a Teledyne Isco Combiflash 
Companion medium pressure liquid chromatography (MPLC) instrument using normal phase 
silica gel cartridges purchased from Teledyne Isco.  Melting points were recorded on an 
Electrothermal Mel-Temp 3.0 instrument.  Specific rotations were measured on an Autopol IV 
automatic polarimeter using Na lamp corrected to 20°C. IR spectra were recorded on a Nicolet 
Avatar 320 spectrometer with a Smart Miracle accessory.  Low-resolution mass spectrometry 
(LRMS) data were recorded on an Agilent LC/MSD VL electrospray ionization mass 
spectrometer.  High resolution mass spectrometry (HRMS) data were obtained on an Agilent 
LC/MSD TOF electrospray ionization mass spectrometer.  
1
H and 
13
C NMR spectra were 
recorded on a Varian 400 MHz or 500 MHz instrument using residual protonated solvent as 
1
H 
internal standard or 
13
C absorption lines of solvents for 
13
C internal standard. NMR data were 
obtained in CDCl3 (Sigma-Aldrich), CD3OD, or d6-DMSO (both from Cambridge Isotope Labs). 
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5.2 Experimental supporting Chapter 2 
5.2.1 Ozonolysis of palmerolide A forming hexane-1,2,3-triol (2.51) and hexane-1,2,3,6-tetraol 
(2.52) 
 
To a solution of palmerolide A (2.1, 8.5 mg, 0.0145 mmol, 1 eq) dissolved in dry methanol, ozone 
was bubbled through at -78
o
C under stirring.  A solution of methanol (1.5 mL) and sodium 
borohydride (10 mg, 0.264 mmol, 18.2 eq.) was added to the solution.  The mixture was warmed 
to room temperature (rt) and stirred for 25 min.  After solvent removal under reduced pressure, 
the resulting residue was chromatographed by silica gel MPLC to yield fragment 2.51 (eluting at 
15% MeOH in chloroform , ~2 mg,  0.0149 mmol, quantitative) and fragment 2.52 (eluting at 20% 
MeOH in chloroform , ~2.5 mg, 0.0165 mmol, quantitative) as colorless oils.  2.51:.  []D
20
  -9.0 (c 
0.100, MeOH); 
1
H NMR (500 MHz, CD3OD)  (multiplicity,  integration): 1.41 (m, 2H); 1.56 (m, 
4H), 3.47 (m, 2H), 3.58 (m, 2H), 3.60 (m); 
13
C NMR (125 MHz, CD3OD)  23.1, 33.8, 34.3, 63.0, 
67.5, 73.3; ESI-MS (m/z) [M+H] = 135.1.  2.52:  []D
20
  -8.1 (c 0.200, MeOH), 
1
H NMR (500 MHz, 
CD3OD)  (multiplicity,  integration): 1.62 (m, 4H), 3.53 (m, 4H), 3.64 (m, 2H); 
13
C NMR (125 
MHz, CD3OD) : 30.3, 30.9, 63.2, 64.7, 72.7, 75.8;  ESI-MS (m/z) [M+H] = 151.1. 
 
5.2.2 Synthesis hexane-1,2,6-triol (2.53) 
 
 
R-2.58 (19 mg, 0.109 mmol) was dissolved in 50% acetic acid:H2O (3 mL).  The solution stirred 
for 20 min. at rt after which the aqueous acid was evaporated under a stream of air.  The resulting 
residue was chromatographed by silica gel MPLC (eluting at 15% MeOH in chloroform) to yield 
R-2.53 as a viscous colorless oil (13.6 mg, 0.101 mmol, 93%).  A similar procedure applied to 40 
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mg (0.230 mmol) of S-2.58 yielded (27.5 mg, 0.205 mmol, 89%) of (S)-hexane-1,2,6-triol (S-
2.53).  R-2.53: []D
20
 +11.1 (c 0.100, MeOH); S-2.53: []D
20
 -11.6 (c 0.100, MeOH); 
1
H NMR (500 
MHz, CD3OD)  1.41 (m, 2H); 1.56 (m, 4H), 3.47 (m, 2H), 3.58 (m, 2H), 3.60 (m, 1H); 
13
C NMR 
(125 MHz, CD3OD)  23.1, 33.8, 34.3, 63.0, 67.5, 73.3; ESI-MS (m/z) [M+H] = 135.1. 
 
5.2.3 Synthesis of (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (2.54) 
 
A stream of ozone was bubbled through a stirring solution of 2.55 (24 mg, 0.112 mmol) in dry 
methanol (3 mL) at -78 
o
C.  A solution of methanol (1.5 mL) and sodium borohydride (20 mg, 
0.518 mmol) was added to the solution.  The mixture was warmed to rt and stirred for 25 min.  
After solvent removal under reduced pressure, the resulting residue was chromatographed by 
silica gel MPLC to yield 2.54 (eluting at 38% ethylacetate (EtOAc):Hexane, 6.5 mg, 0.492 mmol, 
44% yield, 58% ee).  (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol purchased from Sigma-Aldrich: 
[]D
20 
-13.7, (c=0.1, MeOH); 2.54: []D
20
 -7.0, (c=0.1, MeOH); 
1
H NMR (400 MHz, CDCl3)  1.39 
(s, 3H), 1.46 (s, 3H), 3.60 (m), 3.75 (m), 3.81 (m), 4.05 (m), 4.25 (m); 
13
C NMR (100 MHz, CDCl3) 
 25.3, 26.7, 63.0, 65.7, 76.1, 109.4; ESI-MS (m/z) [M+H] = 133.1. 
 
5.2.4 Synthesis of (R)-4-(3-(1,3-dioxolan-2-yl)prop-1-enyl)-2,2-dimethyl-1,3-dioxolane (2.55) 
 
To 20 mL dry DCM at 60 
o
C was added oxalyl chloride (540 mg, 4.16 mmol, 0.36 mL). After 
stirring for 5 min, DMSO (592 mg, 7.57 mmol, 0.54 mL) was added. After stirring 2 min, R-2.56 
(500 mg, 3.78 mmol) dissolved in 3 mL dry DCM was added over a 5 min period.  After stirring for 
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an additional 10 min at 60 
o
C, triethylamine (TEA, 1.91 g, 18.9 mmol, 2.7 mL) was added. The 
mixture was then warmed to rt and partitioned between EtOAc and water. The organic layer was 
collected. The aqueous layer was washed 2X with aliquots of EtOAc. The organic layers were 
combined, dried over anhydrous magnesium sulfae (anhyd. MgSO4), and concentrated to afford 
(S)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (285 mg, 2.19 mmol, 58%). 
 
To a solution of 2-(1,3-Dioxolan-2-yl)ethyltriphenylphosphonium bromide (26 mg, 0.15 mmol, 
dried with heat under vacuum) in dry THF (7 mL) at -78 
o
C was added n-BuLi dropwise until the 
solution turned a dark yellow (1.4 M, 0.22 mL, 0.30 mmol).  After stirring for 15 min., (S)-2,2-
dimethyl-1,3-dioxolane-4-carbaldehyde (dissolved in 1.5 mL  dry THF) was added to the stirring 
solution.  The solution stirred at -78 
o
C for 10 additional minutes then was allowed to warm to rt.  
The mixture was partitioned between diethyl ether (Et2O) and water.  The aqueous layer was 
washed 2X with aliquots of Et2O.  The combined organic layers were dried over anhyd. MgSO4, 
concentrated and chromatographed on silica gel MPLC affording 2.55 as a mixture of E/Z 
isomers as a colerless oil (eluting at 15% EtOAc:hexanes, 24 mg, 0.11 mmol, 75%). 
 
5.2.5 Syntheses of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (2.56) 
 
To a stirring solution of R-2.57 (47 mg, 0.219 mmol) in dry MeOH (5 mL) was added ozone at -78 
o
C.  Sodium borohydride (40 mg, 1.06 mmol), dissolved in 1 mL MeOH was added to the solution.  
The mixture was warmed to rt and stirred for 25 min.  After solvent removal under reduced 
pressure, the resulting residue was chromatographed by silica gel MPLC (eluting at 45% EtOAc 
in hexanes) to yield R-2.56 as a colorless oil (17.5 mg,  0.120 mmol, 55%).  A similar procedure 
applied to 55 mg of S-2.57 (0.258 mmol) yielded 22.6 mg (0.155 mmol, 60%) of S-2.56.  []D
20
R-
2.56: -2.4
o
, 89% ee; S-2.56: +2.4
o
, 97% ee (c 0.100, CHCl3); 
1
H NMR (400 MHz, CDCl3)  
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(multiplicity, J (Hz), integration): 1.36 (s, 3H), 1.42 (s, 3H), 1.82 (dt, 5.8, 5.4, 2H), 2.31 (brs), 3.59 
(dd, 7.8.04, 7.4), 3.80 (t, 5.4, 2H), 4.09 (dd, 8.1, 6.0), 4.27 (m); 
13
C NMR (100 MHz, CDCl3)  
25.7, 26.9, 35.6, 60.6, 69.4, 75.1, 109.1; ESI-MS (m/z) [M+H] = 147.1. 
 
5.2.6 Synthesis of (E)-ethyl 4-(2,2-dimethyl-1,3-dioxolan-4-yl)but-2-enoate (2.57) 
 
To 100 mL dry DCM at 60 
o
C was added oxalyl chloride (866 mg, 6.82 mmol, 0.6 mL). After 
stirring for 5 min, DMSO (668 mg, 8.55 mmol, 0.6 mL) was added. After stirring 2 min, R-2.56 
(500 mg, 3.42 mmol) dissolved in 3 mL dry DCM was added over a 5 min period.  After stirring for 
an additional 10 min at 60 
o
C, TEA (2.08 g, 20.5 mmol, 2.9 mL) was added. The mixture was then 
warmed to rt and partitioned between EtOAc and water. The organic layer was collected. The 
aqueous layer was washed 2X with aliquots of EtOAc. The organic layers were combined, dried 
over anhydrous MgSO4, and concentrated to afford the aldehyde (R)-2-(2,2-dimethyl-1,3-
dioxolan-4-yl)acetaldehyde (458 mg, 3.17 mmol, 93%) as a colorless oil.  A similar procedure was 
applied to S-2.56 (500 mg, 3.42 mmol) resulting in (S)-2-(2,2-dimethyl-1,3-dioxolan-4-
yl)acetaldehyde (480 mg, 3.38 mmol, 99%). 
 
5.2.6.1 Synthesis of R-2.57 
To a mixture of (ethoxycarbonylmethyl)triphenylphosphonium bromide (4.855 g, 11.31 mmol) in 
dry DCM (100 mL) was added triethylamine (TEA, 1.716 g, 2.354 mL, 16.96 mmol) at rt.  After 
mixture stirred under nitrogen for 10 min, (R)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)acetaldehyde (815 
mg, 5.65 mmol) dissolved in 2.5 mL dry DCM was added.  The mixture stirred for 17 h at rt then 
was partitioned between 250 mL diethyl ether: 250 mL H2O.  The organic layer was collected.  
The aqueous layer was extracted with 250 mL diethyl ether.  The organic layers were combined 
and dried over anhydrous MgSO4.  After solvent removal under reduced pressure, the resulting 
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residue was chromatographed by silica gel MPLC (eluting at 20-25% EtOAc in hexanes) to yield 
R-2.57 as a colorless oil (544 mg, 2.54 mmol, 45%).  
 
5.2.6.2 Synthesis of S-2.57 
To a slurry of sodium hydride (NaH, 196 mg  60% in mineral oil, 4.91 mmol) in dry THF (12 mL) at 
0 
o
C and inert atmosphere was added triethyl phosphonoacetate (1.1 g, 4.91 mmol, 0.98 mL). 
After stirring 10 min., (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)acetaldehyde (544 mg, 3.77 mmol) 
dissolved in 2.5 mL dry THF was added.  The mixture stirred an additional 10 min. and was 
partitioned between EtOAc:H2O. The aqueous layer was washed 2X with aliquots of EtOAc.  The 
combined organic layers were dried over anhyd. MgSO4, concentrated and purified via MPLC 
(silica, elution at 25% EtOAc:hexane) to afford 573 mg of S-2.57 (2.68 mmol, 71%).   
 
5.2.6.3 Physical data common to R-2.57 and S-2.57 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration) 1.29 (t, 7.1, 3H), 1.36 (s, 3H), 2.48 
(m, 2H), 3.60 (dd, 8.0, 6.5), 4.06 (dd, 8.0, 6.2), 4.19 (q, 7.1, 2H), 4.20 (m), 5.91 (dt, 15.6, 1.4), 
6.93 (dt, 15.6, 7.1); 
13
C NMR (100 MHz, CDCl3)  14.2, 25.5, 26.8, 36.4, 60.3, 68.8, 74.2, 109.3, 
123.9, 143.7, 166.2; ESI-MS (m/z) [M+H] = 215.1. 
 
5.2.7 Synthesis of 4-(2,2-dimethyl-1,3-dioxolan-4-yl)butan-1-ol (2.58) 
 
To a mixture of R-2.57 (66 mg, 0.308 mmol) in anhydrous THF (7 mL) was added LiAlH4 (35 mg, 
0.924 mmol) under an atmosphere of nitrogen.  The mixture stirred at rt for 2 h.  Potassium 
hydroxide solution (0.1 mL, 1 M) was carefully added to quench the reaction.  After stirring for 10 
min., the mixture was partitioned between DCM:H2O.  The organic layer was collected.  The 
aqueous layer was extracted 2X with DCM.  The organic layers were combined and dried over 
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anhydrous MgSO4.  After solvent removal under reduced pressure, the resulting residue was 
chromatographed by silica gel MPLC (eluting at 38-42% EtOAc in hexanes) to yield R-2.58 as a 
colorless oil (24.1 mg, 0.138 mmol, 45%).  A similar procedure applied to 465 mg (2.17 mmol) of 
S-2.57 yielded 140 mg (0.803 mmol, 37%) of S-2.58.  
1
H NMR (400 MHz, CDCl3)  (multiplicity, 
integration): 1.36 (s, 3H), 1.42 (s, 3H), 1.49 (m, 2H), 1.53 (m, 2H), 1.62 (m, 2H), 3.52 (t, 7.3), 3.67 
(t, 6.4, 2H), 4.06 (m), 4.12 (m); 
13
C NMR (100 MHz, CDCl3)  22.0, 25.7, 26.9, 32.6, 33.2, 62.7, 
69.4, 76.0, 108.7; ESI-MS (m/z) [M+H] = 175.1 
 
5.2.8 Synthesis of hexane-1,2,3,6-tetraol (2.59) 
 
5.2.8.1 Synthesis of (2R,3R)-hexane-1,2,3,6-tetraol (R,R-2.59) 
To a flask containing activated 10% Pd/C (10 mg) and a stir bar was added 2.61 (40 mg, 0.147 
mmol) dissolved in 5 mL EtOH.  A balloon containing H2 gas was affixed to the flask.  The mixture 
stirred for 4 h at rt then was filtered through Ce-Lite.  The filtrate was concentrated to afford the 
intermediate saturated acetal (38 mg, 0.138 mmol, 94%).  The intermediate saturated acetal (37 
mg, 0.135 mmol) was stirred in a solution of 50% acetic acid in water for 2h at 60
o
C.  The solvent 
was then evaporated under a stream of air to yield the diolal (24 mg, 0.126 mmol, 94%).  To a 
solution of the diolal (24 mg, 0.126 mmol, 1.0 eq.) in 4 mL MeOH was added sodium borohydride 
(7.6 mg, 0.202 mmol, 1.6 eq.).  The solution stirred for 2h then was concentrated onto silica and 
chromatographed on MPLC to afford (R,R)-2.59 as a colorless oil (11 mg, 0.073 mmol, 58% yield, 
eluting at 20% MeOH in cholorform). []D
20
 +9.9 (c 0.100, MeOH).  
 
5.2.8.2 Synthesis of (2S,3S)-hexane-1,2,3,6-tetraol (S,S-2.59) 
To a mixture of lithium aluminum hydride (LAH, 8 mg, 0.187 mmol) in dry THF (10 mL) at rt was 
added 2.63 (58 mg, 0.250 mmol) dissolved in 1 mL dry THF.  The mixture stirred for 2h.  TLC 
showed some starting material remained so additional LAH (6 mg, 0.158 mmol) was added.  After 
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20 min., no more starting material remained.  KOH solution (1 M, 0.5 mL) was cautiously added.  
The mixture was diluted with EtOAc, dried over anhydrous MgSO4 and concentrated on to silica.  
After MPLC purification the intermediate diol (eluting at 100% EtOAc, 40 mg, 0.210 mmol, 84% 
yield) was obtained. The intermediate diol was added to a 50% acetic acid in water solution.  The 
mixture stirred for 3h.  The solvent was removed under a stream of air to afford (S,S)-2.59 (11 
mg, 0.073 mmol, 41%) as a viscous colorless oil. []D
20
 -10.0 (c 0.100, MeOH). 
 
5.2.8.3 Physical data common to R,R-2.59 and S,S-2.59 
1
H NMR (400 MHz, CD3OD)  (multiplicity, J (Hz), integration): 1.62 (m, 4H), 3.53 (m, 4H), 3.64 
(dd, 11.1, 4.9, 2H); 
13
C NMR (100 MHz, CD3OD) : 30.3, 30.9, 63.2, 64.7, 72.7, 75.8; ESI-MS 
(m/z) [M+H] = 151.1. 
 
5.2.9 Synthesis of ((4R,5R)-5-(2-(1,3-dioxolan-2-yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 
acetate (2.61) 
 
To a stirring solution of (−)-2,3-O-Isopropylidene-D-threitol (R,R-2.60, 255 mg, 1.54 mmol) in 10 
mL dry DCM at rt under inert atmosphere was added 4-dimethylaminopyridine (DMAP,18 mg, 
0.15 mmol), TEA (155mg, 0.214 mL, 1.54 mmol), and acetic anhydride (158 mg, 0.147 mL, 1.54 
mmol).  The solution stirred for 30 min then was concentrated and subjected to chromatographic 
purification on silica MPLC.  The monoacetate (176 mg, 0.862 mmol, 57%) eluted at 25-30% 
EtOAc:Hex.  To a stirring slurry of Dess Martin periodinane (287 mg, 0.676 mmol) in 10 mL dry 
DCM was added the monoacetate (92 mg, 0.451 mmol) dissolved in 2 mL dry DCM followed by 
pyridine (180 mg, 2.28 mmol).  After 2h at rt, the mixture was quenched by addition of saturated 
sodium bicarbonate (sat. NaHCO3, 5 mL) and 1 M sodium thiosulfate (Na2S2O3) solution (5 mL).  
105 
 
This mixture was allowed to stir until both layers were clear.  The mixture was partitioned 
between EtOAc and water.  The organic layer was collected.  The aqueous layer was extracted 
X2 with aliquots of EtOAc.  The combined organic layers were dried over anhydrous MgSO4 and 
concentrated to yield crude aldehyde (84 mg, 0.415 mmol, 92% yield).  A slurry of (1,3-Dioxolan-
2-ylmethyl)triphenylphosphonium bromide (308 mg, 0.714 mmol,) and potassium tert-butoxide 
(80 mg, 0.714 mmol) in dry THF stirred at rt for 25 min under inert atmosphere.  To the resulting 
dark yellow mixture was added the intermediate aldehyde (84 mg, 0.446 mmol) dissolved in 2 mL 
dry THF.  After stirring for 2.5 h, the dark orange mixture was concentrated then partitioned 
between Et2O and H2O.  The organic layer was collected.  The aqueous layer was extracted 2X 
with aliquots of Et2O.  The combined organic layers were dried over anhydrous MgSO4, 
concentrated, and chromatographed on silica MPLC (eluting at 30% EtOAc:Hex) to yield a 
mixture of E/Z-2.61 (51 mg, 0.187 mmol, 42%) as a colorless oil. 
 
5.2.10 Synthesis of ethyl 3-((4S,5S)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate 
(2.62) 
 
A mixture of (+)-2,3-O-isopropylidene-L-threitol [(S,S)-2.60, 500 mg, 3.08 mmol], benzyl bromide 
(580 mg, 3.39 mmol, 1.1 equiv), and silver oxide (Ag2O, 1.07 g, 4.62 mmol) in dry toluene was 
stirred at rt for 8 h.  The mixture was filtered through a plug of silica and concentrated.  The 
resulting residue was chromatographed on silica (eluting at 35–42% EtOAc in hexanes) to yield 
((4S,5S)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (598 mg, 2.38 mmol, 77%) 
as a colorless oil.   
 
To a stirring slurry of Dess–Martin periodinane (630 mg, 1.49 mmol) in 100 mL dry DCM was 
added ((4S,5S)-5- (benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (342 mg, 1.35 
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mmol) dissolved in 5 mL dry DCM followed by pyridine (534 mg, 0.54 mL, 6.75 mmol).  After 30 
min at rt, the mixture was quenched by addition of satd NaHCO3 (50 mL) and 1 M Na2S2O3 
solution (50 mL).  This mixture was allowed to stir until both layers were clear and was then 
partitioned between EtOAc and water.  The aqueous layer was extracted 2X with aliquots of 
EtOAc.  The combined organic layers were dried over anhydrous MgSO4 and concentrated to 
yield the crude aldehyde (360 mg).  A slurry of (ethoxycarbonylmethyl)triphenyl phosphonium 
bromide (683 mg, 1.59 mmol, 1.1 equiv) and NaH (38 mg, 1.59 mmol, 1.1 equiv) in 50 mL dry 
THF at rt stirred for 4 h.  The crude aldehyde (360 mg, ~1.44 mmol) dissolved in 5 mL dry THF 
was then added.  The mixture stirred for 6 h and was then partitioned with Et2O/H2O.  The organic 
layer was collected.  The aqueous layer was extracted 2X with aliquots of Et2O.  The combined 
organic layers were dried over anhydrous MgSO4 and concentrated under reduced pressure.  
The concentrate was chromatographed by silica gel MPLC (eluting at 15% EtOAc:hexane) to 
afford a mixture of E/Z isomers of conjugate ester 2.62 (298 mg, 0.93 mmol, 69%, two steps) as a 
colorless oil.  The E-isomer could be formed exclusively by substituting (ethoxy-
carbonylmethyl)triphenyl phosphonium bromide with triethylphosphonoacetate (60%, two steps). 
E-2.62: []D
20
 -23.4 (c 1.0, CHCl3); IR (neat)  (cm
-1
): 2988, 1722, 1654, 1090; 
1
H NMR (400 MHz, 
CDCl3)  (multiplicity, J (Hz), integration): 1.29 (t, 6.9, 3H), 1.44 (s, 3H), 1.45 (s, 3H), 3.63 (d, 4.7, 
2H), 3.96 (dt, 8.4, 4.7, 1H), 4.20 (q, 6.9, 2H), 4.43 (ddd, 8.4, 5.6, 1.7, 1H), 4.60 (s, 2H), 6.09 (dd, 
15.7, 1.7, 1H), 6.89 (dd, 15.7, 5.6, 1H), 7.34 (m, 5H). 
13
C NMR (100 MHz, CDCl3) : 14.3, 26.8, 
27.1, 60.7, 69.5, 73.8, 77.6, 79.7, 110.3, 122.7, 127.8 (2C), 127.9, 128.6 (2C), 137.9, 144.2, 
166.1. ESI HRMS [M+Na]
+
 calcd for [C18H24O5Na]
+
: 343.1516, found 343.1510. 
 
5.2.11 ethyl 3-((4S,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)propanoate (2.63) 
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To activated 10% Pd/C (50 mg) was added 2.62 (278 mg, 0.87 mmol) dissolved in 10 mL EtOH.  
A balloon containing H2 gas was affixed to the flask.  The mixture stirred for 12 h at rt, was diluted 
with EtOAc, and filtered through Celite.  The filtrate was concentrated to afford 2.63 as a colorless 
oil (194 mg, 0.84 mmol, 96%).  
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 
1.23 (t, 7.2, 3H), 1.37 (s, 3H), 1.38 (s, 3H), 1.60 (br s), 1.83, (m), 1.94 (m), 2.46 (m, 2H), 3.61 (m), 
3.75 (m), 3.78 (m), 3.89 (dt, 7.7, 3.6), 4.12 (q, 7.2, 2H); 
13
C NMR (100 MHz, CDCl3) : 14.4, 27.2, 
27.5, 28.2, 30.9, 60.6, 62.0, 76.3, 81.2, 109.2, 173.4; ESI-MS (m/z) [M+H] = 233.1. 
 
5.2.12 (S)-5-(2-(tert-butyldimethylsilyloxy)hept-6-enylsulfonyl)-1-phenyl-1H-tetrazole (2.65) 
 
To 1-phenyl-1H-tetrazole-5-thiol (288 mg, 1.62 mmol) and potassium carbonate (K2CO3, 372 mg, 
2.60 mmol) was added 2.68 (215 mg, 0.54 mmol) dissolved in 5 mL dry acetone. The stirring 
mixture refluxed for 20 h and was cooled to rt, and partitioned between Et2O/H2O. The aqueous 
layer was extracted 2X with aliquots of Et2O. The combined organic extracts were dried over 
anhydrous MgSO4, concentrated under reduced pressure, and subjected to silica gel MPLC to 
afford the thioether intermediate as white needles (mp 35–36 
o
C, 174 mg, 0.430 mmol, 80%). To 
the thioether intermediate (103 mg, 0.254 mmol) in 2 mL EtOAc was added H2O2 (86 L 30% 
solution, 26 mg H2O2, 0.762 mmol), sodium tungstate (Na2WO4
.
2H2O, 170 L of a 5 mg/mL 
solution in EtOAc, 0.85 mg, 0.00254 mmol), phenylphosphonic acid (80 L of a 5 mg/mL solution 
in EtOAc, 0.4 mg, 0.00254 mmol), and methyltrioctylammonium hydrogensulfate (Oct3MeNHSO4, 
240 L of a 5 mg/mL solution, 1.2 mg, 0.00254 mmol). After 40 h the reaction was not yet 
complete via TLC so another aliquot of sodium tungstate (0.00254 mmol), phenylphosphonic acid 
(0.00254 mmol), Oct3MeNHSO4 (0.00254 mmol), and (0.762 mmol) was added. This mixture 
stirred another 60 h and was partitioned between EtOAc/ H2O. The organic layer was dried over 
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anhydrous MgSO4, concentrated and chromatographed via silica gel MPLC afford a mixture of 
diastereomers of the partially oxidized sulfoxide (20 mg, 0.05 mmol, 20%) as well as desired 
sulfone 2.65 as a white solid (mp 62–64 
o
C, 48 mg, 0.110 mmol, 43%). []D
20
 +15.6 (c 0.4, 
CHCl3); IR (neat)  (cm
-1
): 3073, 2950, 2934, 2858, 1345, 1254, 1157; 
1
H NMR (400 MHz, CDCl3) 
 (multiplicity, J (Hz), integration): 0.03 (s, 3H), 0.06 (s, 3H), 0.84 (s, 9H), 1.48 (m, 2H), 1.67 (m, 
2H), 2.10 (dt, 7.0, 7.0, 2H), 3.86 (dd, 14.9, 4.6, 1H), 4.00 (dd, 14.9, 6.6z, 1H), 4.48 (m, 1H), 5.00 
(m, 2H), 5.77 (ddt, 16.9, 6.9, 3.9, 1H), 7.64 (m, 5H); 
13
C NMR (100 MHz, CDCl3) : -4.7,-4.1, 18.1, 
23.6, 25.8 (3C), 33.6, 37.1, 62.1, 66.6, 115.4, 125.3 (2C), 129.9 (2C), 131.6, 133.3, 138.1, 154.4; 
ESI HRMS [M+H]
+
 calcd for [C20H33N4O3SSi]
+
: 437.2037, found 437.2024. 
 
5.2.13 ethyl 3-((4S,5R)-5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl)propanoate (2.66) 
 
To a stirring solution of Dess–Martin periodinane (424 mg, 1.02 mmol) in 10 mL dry DCM at rt 
was added 2.63 (198 mg, 0.85 mmol) then pyridine (336 mg, 0.35 mL). The solution stirred for 1 h 
and was then quenched with 5 mL 1 M Na2S2O3 and 5 mL sat. NaHCO3 solution. The mixture 
stirred until both layers were no longer cloudy. The organic layer was concentrated then 
repartitioned in EtOAc/H2O. The organic layer was collected, dried over anhydrous MgSO4, and 
concentrated to yield 2.66 as a colorless oil (150 mg, 0.65 mmol, 76%). []D
20
 -7.4 (c 1.0, CHCl3); 
IR (neat)  (cm
-1
): 2985, 2938,1073, 1731; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), 
integration): 1.19 (t, 7.3, 3H), 1.34 (s, 6H), 1.95 (m, 2H), 2.42 (m, 2H), 3.91 (dt), 4.04 (m), 4.07 (q, 
7.3, 2H), 9.67 (s); 
13
C NMR (100 MHz, CDCl3) : 14.3, 26.4, 27.2, 28.7, 30.4, 60.7, 76.1, 84.7, 
110.1, 172.9, 201.1; ESI HRMS [M+H]
+
 calcd for [C11H19O5]
+
: 231.1227, found 231.1221. 
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5.2.14 (S)-hept-6-ene-1,2-diol (2.67) 
 
To 10 mL dry DCM at -60 
o
C was added oxalyl chloride (787 mg, 6.20 mmol, 0.525 mL).  After 
stirring for 5 min, DMSO (605 mg, 7.75 mmol, 0.55 mL) was added.  After stirring 2 min, S-2.58 
(540 mg, 3.10 mmol) dissolved in 3 mL dry DCM was added over a 5 min period.  After stirring for 
an additional 10 min at -60 
o
C, TEA (1.88 g, 18.6 mmol, 2.6 mL) was added.  The mixture was 
then warmed to rt and partitioned between EtOAc/H2O.  The organic layer was collected.  The 
aqueous layer was washed 2X with aliquots of EtOAc.  The organic layers were combined, dried 
over anhydrous MgSO4, and concentrated to afford the aldehyde (S)-4-(2,2-dimethyl-1,3-
dioxolan-4-yl)butanal (488 mg, 2.83mmol, 91%) as a colorless oil.  
1
H NMR (400 MHz, CDCl3)  
(multiplicity, J (Hz), integration): 1.28 (s, 3H),1.34 (s, 3H),1.58 (m, 4H), 2.44 (dt, 7.3, 1.6, 2H), 
3.45 (t, 7.1), 3.97 (t, 7.1), 4.0 (m), 9.71 (t, 1.6); 
13
C NMR (100 MHz, CDCl3) : 18.4, 25.9, 27.1, 
33.1, 43.8, 69.5, 76.2, 109.1, 202.4.  
 
To a stirring slurry of Ph3PCH3Br (1.95 g, 5.46 mmol) in dry THF (50 mL) at 0 
o
C was added 
potassium bis(trimethylsilyl)amide (KHMDS, 0.5 M in toluene, 10.92 mL, 5.46 mmol) over a 10 
min period.  The mixture was warmed to rt and stirred for 30 min.  The mixture then was cooled to 
0 
o
C and (S)-4-(2,2-dimethyl-1,3-dioxolan-4-yl)butanal (470 mg, 2.72 mmol, 1.0 equiv) dissolved 
in 10 mL dry THF was added over a 10 min period.  The mixture stirred at 0 
o
C for 1.5 h. 
Methanol (0.6 mL) was added to quench the reaction.  The mixture was diluted with Et2O and 
filtered through Celite.  The filtrate was concentrated and chromatographed by silica gel MPLC 
(eluting at 10-12% EtOAc: hexanes) to afford (S)-2,2-dimethyl-4-(pent-4-enyl)-1,3-dioxolane as a 
colorless oil (260 mg, 1.53 mmol, 56%).  
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), 
integration): 1.29 (s, 3H), 1.34 (s, 3H), 1.45 (m, 2H), 1.55 (m, 2H), 2.02 (dt, 6.8, 1.4, 2H), 3.44 (t, 
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7.4), 3.96 (dt, 7.4, 5.8), 3.99 (m), 4.89 (m), 4.94 (m), 5.73 (ddt, 17.2, 6.8, 3.5); 
13
C NMR (100 
MHz, CDCl3) : 25.1, 25.8, 27.1, 33.1, 33.7, 69.6, 76.2, 108.9, 115.0, 138.8.  
 
(S)-2,2-dimethyl-4-(pent-4-enyl)-1,3-dioxolane (233 mg, 1.37 mmol) was stirred in 5 mL 50% 
AcOH:H2O in a flask open to air for 2 h at rt. The solvent was then removed under a stream of air 
to yield diol 2.67 as a colorless oil (164 mg, 1.26 mmol, 92%). []D
20
 -6.5 (c 1.0, CHCl3); IR (neat) 
 (cm
-1
): 3365, 3079, 2935, 1070, 1039; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), 
integration): 1.44 (m, 4H), 1.68 (br s), 2.03 (m, 2H), 2.07 (br s), 3.37 (dd, 10.8, 7.7), 3.59 (dd, 
10.8, 3.0), 3.65 (m), 4.93 (m, 2H), 5.74 (ddt, 17.0, 6.6, 3.5); 
13
C NMR (100 MHz, CDCl3) : 24.9, 
32.7, 33.7, 67.0, 72.3, 115.0, 138.7; ESI HRMS [M+NH4]
+
 calcd for [C7H18O2N]
+
: 148.1332, found 
148.1328. 
 
5.2.15 (S)-2-(tert-butyldimethylsilyloxy)hept-6-enyl 4-methylbenzenesulfonate (2.68) 
 
To a solution of tosyl chloride (265 mg, 1.39 mmol, 1.1 equiv) and DMAP (15 mg, 0.13 mmol) in 9 
mL dry DCM and stirring at 0 
o
C was added 2.67 (164 mg, 1.26 mmol) dissolved in 1 mL dry 
DCM.  The solution stirred for 5 min, then TEA (141 mg, 0.2 mL, 1.39 mmol) was added.  The 
solution stirred at 0 
o
C for 4 h and then rt for 4 h.  The solution was poured into a flask containing 
20 mL ice, 20 mL H2O and 10 mL 2 N HCl.  The resulting mixture was extracted 2X with 50 mL 
aliquots of DCM.  The combined organic layers were dried over anhydrous MgSO4 and 
concentrated under reduced pressure.  The crude concentrate was chromatographed by silica gel 
MPLC to afford the monotosylated alcohol as a colorless oil (315 mg, 1.11 mmol, 88%).  To the 
monotosylated alcohol (150 mg, 0.53 mmol) in 5 mL dry DCM under stirring at 0 
o
C was added 
2,6-lutidine (169 mg, 0.18 mL, 1.58 mmol) then tert-butyldimethylsilyl trifluoromethanesulfonate 
(TBS-OTf, 348 mg, 0.30 mL, 1.32 mmol).  The mixture stirred for 2 h and was partitioned between 
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DCM/H2O. The organic layer was collected. The aqueous layer was extracted 2X with aliquots of 
DCM.  The combined organic extracts were dried over anhydrous MgSO4, concentrated under 
reduced pressure, and subjected to silica gel MPLC to yield 2.68 as a colorless oil (215 mg, 0.53 
mmol, quantitative). []D
20
 -6.0 (c 0.4, CHCl3); IR (neat)  (cm
-1
): 3079, 2952, 2857, 1170; 
1
H 
NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 0.01 (s, 3H), 0.02 (s, 3H), 0.83 (s, 9H), 
1.39 (m, 4H), 2.00 (dt, 6.6, 6.6, 2H), 2.45 (s, 3H), 3.85 (m, 2H), 3.85 (m), 4.96 (m), 5.74 (ddt, 
17.0, 6.6, 3.2) 7.34 (d, 8.0, 2H), 7.79 (d, 8.0, 2H); 
13
C NMR (100 MHz, CDCl3) : -4.8, -4.6, 21.6, 
24.0, 25.7 (3C), 26.9, 33.4, 33.6, 69.8, 73.1, 114.7, 127.9 (2C), 129.8 (2C), 133.0, 138.3, 144.7; 
ESI HRMS [M+H]
+
 calcd for [C20H35O4SSi]
+
: 399.2020, found 399.2032. 
 
5.2.16 (S)-7-(benzyloxy)hept-1-en-3-yl acetate (2.69) 
 
To a stirring solution of 2.71 (66 mg, 0.248 mmol) in 5mL dry DCM at 0 
o
C was added Dess–
Martin periodinane (158 mg, 0.372 mmol) in one portion.  The mixture was warmed to rt and 
stirred for 45 min.  Saturated NaHCO3 (5 mL) and 1.0 M Na2S2O3 (5 mL) was added.  The mixture 
stirred for 5 min then was partitioned between Et2O/H2O. The organic layer was collected, dried 
over anhydrous MgSO4 and concentrated under reduced pressure to yield the aldehyde 
intermediate as a colorless oil (65 mg, 0.248 mmol, quantitative). To a mixture of 
ethyltriphenylphosphonium bromide (89 mg, 0.25 mmol) in 5 mL dry THF at 0 
o
C was added 
KHMDS (0.5 M in toluene, 0.5 mL, 0.25 mmol) dropwise. After 10 min stirring at 0 
o
C, the 
aldehyde intermediate (60 mg, 0.227 mmol) dissolved in 2 mL dry THF was added dropwise. 
After 5 min the reaction was partitioned between Et2O/H2O. The organic layer was collected. The 
aqueous layer was extracted 2X with aliquots of Et2O. The combined organic layers were dried 
over anhydrous MgSO4 and concentrated. The crude residue was chromatographed by silica gel 
MPLC (eluting at 10–13% EtOAc:hexanes) to afford 2.69 as a colorless oil (37 mg, 0.141 mmol, 
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62%). []D
20
 -2.9 (c 0.6, CHCl3); IR (neat)  (cm
-1
): 3035, 2945, 2857, 1745, 1244, 1106; 
1
H NMR 
(400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.40 (m, 2H), 1.61 (m, 4H), 2.04 (s, 3H), 
3.44 (t, 6.6, 2H), 4.48 (s, 2H), 5.14 (dd, 10.6, 1.0), 5.21 (m, 2H), 5.75 (ddd, 17.3, 10.5, 6.4), 7.27 
(m, 1H), 7.31 (m, 4H); 
13
C NMR (100 MHz, CDCl3) : 21.4, 22.0, 29.7, 34.2, 70.3, 73.1, 74.9, 
116.8, 127.7, 127.8 (2C), 128.5 (2C), 136.7, 133.8, 170.7; ESI HRMS [M+Na]
+
 calcd for 
[C16H22O3Na]
+
: 285.1461, found 285.1463. 
 
5.2.17 (S)-6-(benzyloxy)hexane-1,2-diol (2.70) 
 
To a stirring solution of S-2.58 (215 mg, 1.25 mmol) in 5 mL dry THF at rt was added NaH (33 
mg, 1.37 mmol) in one portion.  The mixture bubbled vigorously for 5 min.  After gas evolution 
had subsided, benzyl bromide (257 mg, 1.5 mmol) was added. The mixture stirred for 20 h and 
was partitioned between Et2O/H2O.  The organic layer was collected.  The aqueous layer was 
extracted 2X with aliquots of Et2O. The combined organic layers were dried over anhydrous 
MgSO4 and concentrated. The crude residue was chromatographed by silica gel MPLC (eluting at 
12-14% EtOAc/hexane) to afford the benzylated intermediate as a colorless oil (142 mg, 0.54 
mmol, 43%). The benzylated intermediate was stirred in 2 mL 50% AcOH:H2O in a flask opened 
to air for 3 h. The mixture was then concentrated to afford 2.70 as a colorless oil (125 mg, 0.47 
mmol, 94%). []D
20
 -3.3 (c 1.0, CHCl3); IR (neat)  (cm-
1
): 3382, 2938, 2867, 1456, 1096, 1029; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.44 (m, 2H), 1.59 (m, 4H), 1.91 (br 
s), 2.14 (br s), 3.41 (dd,11.1, 7.6), 3.47 (t, 6.4, 2H), 3.62 (dd, 11.1, 3.0), 3.69 (m), 4.49 (s, 2H), 
7.27 (m), 7.32 (m, 4H); 
13
C NMR (100 MHz, CDCl3) : 22.4, 29.7, 33.0, 67.0, 70.3, 72.4, 73.1, 
127.8, 127.9 (2C), 128.6 (2C), 138.8; ESI HRMS [M+H]
+
 calcd for [C13H21O3]
+
: 225.1485, found 
225.1481. 
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5.2.18 (S)-6-(benzyloxy)-1-hydroxyhexan-2-yl acetate (2.71) 
 
To a stirring solution of 2.70 (100 mg, 0.45 mmol) in 3 mL dry THF at rt was added TEA (54 mg, 
71 mL, 0.54 mmol) followed by chlorotrimethylsilane (53 mg, 63 mL, 0.49 mmol) dropwise.  After 
stirring 25 min, the mixture was diluted with 3 mL dry DCM.  Additional TEA (162 mg, 213 mL, 
0.16 mmol) followed by DMAP (5 mg, 0.045 mmol) was added.  Acetic anhydride (137 mg, 1.34 
mmol) was added to the stirring solution dropwise.  The solution stirred for 1 h then was 
partitioned between Et2O/2 N HCl.  The organic layer was collected.  The aqueous layer was 
extracted 2X with aliquots of Et2O. The combined organic layers were dried over anhydrous 
MgSO4 and concentrated.  The crude residue was chromatographed by silica gel MPLC (eluting 
at 45–65% EtOAc:hexanes) to afford 2.71 as a colorless oil (66 mg, 0.249 mmol, 56%).  Starting 
material (24%) was also recovered.  2.71: []D
20
 -1.0 (c 1.0, CHCl3); IR (neat)  (cm
-1
): 3452, 
2941, 2864, 1735, 1241, 1096; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.42 
(m, 2H), 1.60 (m, 4H), 2.07 (s, 3H), 3.45 (t, 6.3, 2H), 3.61 (dd, 11.5, 6.3), 3.70 (dd, 11.5, 2.5), 
4.48 (s, 2H), 4.89 (m), 7.27 (m), 7.32 (m, 5H); 
13
C NMR (100 MHz, CDCl3) : 21.3, 22.3, 29.7, 
30.4, 65.0, 70.2, 73.2, 75.7, 127.7, 127.8 (2C), 128.6 (2C), 138.7, 171.6; ESI HRMS [M+H]
+
 calcd 
for [C15H23O4]
+
: 267.1591, found 267.1594. 
 
5.2.19 ethyl 3-((4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl)propanoate (2.72) 
 
To a stirring slurry of Ph3PMeBr (414 mg, 1.16 mmo) in 10 mL dry THF at 0 
o
C was added 
dropwise KHMDS (0.5 M in toluene, 2.32 mL, 1.16 mmol).  The mixture was warmed to rt and 
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stirred for 30 min.  The mixture was then cooled back down to 0 
o
C.  Aldehyde 2.66 (150 mg, 0.65 
mmol) dissolved in 3 mL dry THF was then added dropwise.  The reaction was then partitioned 
between Et2O/ H2O. The aqueous layer was extracted 2X with aliquots of Et2O. The combined 
organic layers were dried over anhydrous MgSO4 and concentrated. The crude residue was 
chromatographed by silica gel MPLC (eluting at 12–16% EtOAc/hexanes) to afford 2.72 as a 
colorless oil (91 mg, 0.40 mmol, 62%). []D
20
 -2.3 (c 0.7, CHCl3); IR (neat)  (cm
-1
): 3082, 2985, 
1741, 1167, 1073; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.25 (t, 7.3, 3H), 
1.39 (s, 3H), 1.40 (s, 3H), 1.83 (m),1.96 (m), 2.45 (m, 2H), 3.69 (dt, 8.3, 3.7), 4.00 (dd, 8.3, 1.4), 
4.13 (q, 7.3, 2H), 5.26 (dd, 10.2, 1.4), 5.38 (dd, 17.4, 1.4), 5.80 (ddd, 17.4, 10.2, 7.0); 
13
C NMR 
(100 MHz, CDCl3) : 14.4, 27.0, 27.1, 27.4, 30.9, 60.6, 79.8, 82.6, 109.0, 119.3, 135.2, 173.3; ESI 
HRMS [M+Na]
+
 calcd for [C12H20O4Na]
+
: 251.1254, found 251.1256. 
 
5.2.20 ethyl 3-((4S,5S)-5-((S,E)-3-acetoxy-7-(benzyloxy)hept-1-enyl)-2,2-dimethyl-1,3-dioxolan-
4-yl) propanoate (2.73) 
 
To a solution of 2.69 (20 mg, 0.076 mmol) and 2.72 (17 mg, 0.076 mmol) in dry DCM under 
stirring at rt was added Grubbs second generation catalyst (7 mg, 0.008 mmol).  The solution 
stirred for 48 h then was concentrated and chromatographed by silica gel MPLC (eluting at 25-
30% EtOAc:hexanes) to afford the E isomer 2.73 as a colorless oil, which solidified when placed 
in freezer (14 mg, 0.03 mmol, 40%). []D
20
 -15.6 (c 0.36, CHCl3); IR (neat)  (cm
-1
): 3032, 2988, 
2931, 2867, 1738, 1372, 1241, 1093, 1079, 1022; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, J 
(Hz), integration): 1.22 (t, 7.1, 3H), 1.36 (s, 6H), 1.38 (m, 2H), 1.59 (m, 4H), 1.84 (m, 2H), 2.02 (s, 
3H), 2.41 (m, 2H), 3.43 (t, 6.5, 2H), 3.64 (dt, 7.7, 4.0), 3.97 (dt, 7.7, 7.2), 4.10 (q, 7.1, 2H), 4.47, 
(s, 2H), 5.24 (d, 6.7), 5.60 (dd, 15.6, 7.2), 5.68 (dd, 15.6, 6.7), 7.25 (m), 7.31 (m, 4H); 
13
C NMR 
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(100 MHz, CDCl3) : 14.4, 21.4, 22.0, 27.0, 27.1, 27.4, 29.7, 30.8, 34.3, 60.6, 70.2, 73.1, 73.7, 
79.9, 81.5, 109.1, 127.7, 127.8 (2C), 128.5 (2C), 129.7, 133.2, 138.7, 170.4, 173.3; ESI HRMS 
[M+Na]
+
 calcd for [C26H38O7Na]
+
: 485.2510, found 485.2524. 
 
5.3 Experimental supporting Chapter 3 
 
5.3.1 Isolation of meridianins A (3.24), B (3.25), C (3.26), and E (3.28) from Antarctic tunicate 
Synoicum sp. 
 
Lyophilized Synoicum sp. (192 g), collected at Palmer Station, Antarctica, was extracted 3x24 h 
with 1:1 DCM:MeOH followed by extraction with 1:1 MeOH:H2O (3x24 h).  Concentration of the 
organic filtrate under reduced pressure yielded 21.0 g of lipophilic extract. A portion of this extract 
(4.6 g) was fractionated on MPLC with a gradient of hexane to EtOAc to MeOH.  Fractions eluting 
at 20–50% MeOH:EtOAc were combined (25 mg) and chromatographed via analytical reverse 
phase HPLC (55% MeOH:H2O) to yield meridianins A, B, C, and E. NMR data matched that of 
the previously reported meridianins (Chapter 3, ref. 22). 
 
Meridianin A (3.24), 5 mg, 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration, 
position): 6.36 (dd, 7.3, 0.5, H5), 6.27 (s, 2H, 2’-NH2), 6.79 (dd, 7.5, 0.5, H7), 6.96 (dd, 7.5, 7.3, 
H6), 7.10 (d, 5.4, H5’), 8.10, (d, 5.4, H6’), 8.22 (s, H2), 11.76, (brs, N1-H), 13.57 (s, 4-OH); 
13
C 
NMR (100 MHz, d6-DMSO) : 102.3, 104.4, 105.4, 114.0, 114.7, 124.4, 128.5, 139.4, 152.0, 
158.4, 160.5, 161.7.  
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Meridianin B (3.25), 5 mg, 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration, 
position):  6.51 (d, 1.5, H5), 6.85 (s, 2H, 2’-NH2), 7.00 (d, 1.5, H7), 7.15 (d, 5.4, H5’), 8.18 (d, 5.4, 
H6’), 8.28 (s, H2), 11.90 (brs, N1-H), 14.21 (s, 4-OH).   
 
Meridianin C (3.26), <1 mg, 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration, 
position):  6.49 (s, 2H, 2-NH2), 7.00 (d, 5.3, H5’), 7.29 (dd, 8.5, 1.9, H6), 7.39 (d, 8.4, H7), 8.10 (d, 
5.3, H6’), 8.24 (s, H2), 8.75 (d, 1.9, H4), 11.85 (brs, N1-H). 
 
Meridianin E (3.28), 3 mg, 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration, 
position):  6.37 (d, 8.3, H5), 6.85 (2H, 2’-NH2), 7.19 (d, 8.3, H6), 7.24 (d, 5.4, H5’), 8.18 (d, 5.4, 
H6’), 8.31 (s, H2), 11.92 (brs, N1-H), 13.93 (s, 4-OH). 
 
5.3.2 synthetic meridianin A (3.24) 
 
To a stirring solution of 3.91 (75 mg, 0.15 mmol) in dry THF (2 mL) at rt was added dropwise 
tetra-n-butylammonium fluoride (TBAF, 1.0 M, 0.3 mL, 0.3 mmol).  After 5 min. aqueous sodium 
carbonate (Na2CO3, 2 M, 2 mL) was added.  The mixture was then partitioned between sat. 
ammonium chloride (NH4Cl)/10% MeOH in EtOAc.  The aqueous layer was extracted with 
another aliquot of 10% MeOH in EtOAc.  The combined organic layers were dried over anhyd. 
MgSO4, concentrated, and purified via MPLC (silica, eluting at 10% MeOH:DCM) to afford 
meridianin A.  The compound was recrystallized from MeOH/H2O to yield meridianin A as yellow 
needles (3.24, 30 mg, 0.13 mmol, 87% yield).  Mp =168 
o
C; 
1
H NMR (400 MHz, d6-DMSO)  
(multiplicity, J (Hz), integration): 6.36 (d, 7.6), 6.73 (br s, 2H), 6.79 (d, 7.9), 6.96 (dd, 7.6, 7.9), 
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7.10 (d, 5.4), 8.10 (d, 5.4), 8.21 (d, 2.6), 11.73 (br s), 13.58 (s); 
13
C NMR (100 MHz, d6-DMSO) : 
102.4, 104.4, 105.5, 113.8, 114.4, 124.4, 128.5, 139.3, 152.0, 158.5, 160.5, 161.8; ESI HRMS [M 
+ H]
+
 calculated for [C12H11N4O]
+
:227.0927, found: 227.0929.  
 
5.3.3 4-indolol (3.86) 
 
A stirring mixture of 1,5,6,7-tetrahydro-4H-indol-4-one (3.85, 2.50 g, 18.4 mmol) and 10% Pd/C 
(625 mg) in 2,6-dimethyl-4-heptanone (25 mL) was refluxed (190
o
C) under N2 for 48 h.  The 
mixture was cooled to rt and filtered through Celite.  The filter cake was washed with DCM.  The 
filtrate was concentrated in vacuo.  Kugel-rohr distillation of the concentrate afforded discolored 
4-indolol (150
o
C, 4 torr) which was subjected to MPLC (silica; eluting at 30-35% EtOAc:Hex) to 
yield 3.86 (1.19 g, 9.0 mmol, 49% yield) as a white crystalline solid.  
1
H NMR (400 MHz, d6-
DMSO, not stable in CDCl3)  (multiplicity, J (Hz), position): 6.31 (d, 6.1, H3), 6.43 (m, H5), 6.81 
(m, H6), 6.82 (m, H7), 7.10 (d, 2.4, H2), 9.21 (s, OH), 10.86 (brs, NH); 
13
C NMR (100 MHz, d6-
DMSO) :  98.5, 102.8 (2C), 117.8, 121.8, 122.9, 137.9, 150.5; ESI HRMS [M + H]
+
 calculated for 
[C8H8NO]
+
: 134.0600, found: 134.0600. 
 
5.3.4 4-(tert-butyldimethylsilyloxy)-1H-indole (3.87) 
 
A mixture of 4-indolol (3.86, 1.05 g, 7.89 mmol), tert-butyldimethylsilyl chloride (1.43 g, 9.47 
mmol) and imidazole (1.74 g, 25.3 mmol) was stirred in 25 mL dry DMF at rt under N2 for 1 h.  
The mixture was partitioned (EtOAc:water).  The organic layer was washed with water then dried 
(anhyd. MgSO4), filtered and concentrated under reduced pressure onto silica.  Purification using 
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MPLC (silica; eluting at 18% EtOAC:hexane) afforded 3.87 as a white solid (1.76 g, 7.14 mmol, 
91% yield). Mp=79-80 
o
C; IR (neat)  (cm
-1
): 3399, 3056, 2961, 2928, 1583;  
1
H NMR (400 MHz, 
d6-DMSO, not stable in CDCl3)  (multiplicity, J (Hz), integration, position):  0.19 (s, 6H,Si(CH3)2), 
1.02 (s, 9H, SiC(CH3)3), 6.35 (m, H3), 6.41 (d, 7.5, H5), 6.93 (dd, 7.5, 8.0, H6), 7.02 (d, 8.0, H7), 
7.21 (s, H2), 11.0 (brs, NH); 
13
C NMR (100 MHz, d6-DMSO) : -4.4 (2C), 18.0, 25.7 (3C), 98.3, 
105.4, 107.6, 121.2, 121.5, 123.8, 137.9, 148.1; ESI HRMS [M + H]
+
 calculated for [C14H22NOSi]
+
: 
248.1465, found: 248.1468. 
 
5.3.5 3-bromo-4-(tert-butyldimethylsilyloxy)-1-(triisopropylsilyl)-1H-indole (3.88) 
 
To 3.87 (1.77 g, 7.14 mmol) in 35 mL dry THF under stirring and N2 was added dropwise n-
butyllithium (5.43 mL, 1.6 M in hexanes, 8.76 mmol) at -78 
o
C.  The mixture was warmed to -10 
o
C and stirred for 10 min. before being cooled back to -78 
o
C.  Triisopropylsilyl chloride (1.93 g, 
10.0 mmol, 2.14 mL) was added dropwise.  The mixture was then warmed to 0 
o
C and stirred 
until reaction was complete (via TLC).  The mixture was cooled to -78 
o
C.  N-bromosuccinimide 
(1.72 g, 9.64 mmol) dissolved in dry THF (10 mL) was added to the cooled mixture.  After stirring 
for 2 h at -78 
o
C, the mixture was warmed to rt, diluted with 1% pyridine in hexane and filtered 
through Celite.  Any 3-bromo-4-(tert-butyldimethylsilyloxy)-1H-indole in the mixture will lead to 
decomposition of the desired product upon concentration.  The filtrate was concentrated onto 
neutral alumina and chromatographed on neutral alumina (eluting in hexanes).  Brown impurities 
were removed by further purification via MPLC (silica; eluting at 5% EtOAc:Hex) to afford white 
crystalline solid 3.88 (2.69 g, 5.59 mmol, 78% yield). Mp =107-109 
o
C; 
1
H NMR (400 MHz, CDCl3) 
 (multiplicity, J (Hz), integration, position): 0.35 (s, 6H, Si(CH3)2), 1.08 (s, 9H, SiC(CH3)3), 1.14 
(d, 18H, SiCH(CH3)2), 1.65 (sept., 3H, SiCH), 6.52 (d, 7.7, H5), 6.98 (dd, 7.7, 8.1, H6), 7.07 (d, 
8.1, H7), 7.10 (s, H2); 
13
C NMR (100 MHz, CDCl3) : -3.7 (2C), 13.0 (3C), 18.2 (6C), 18.7, 26.2 
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(3C), 90.6, 107.7, 109.1, 121.0, 122.8, 129.7, 142.7, 149.5; ESI HRMS [M + H]
+
 calculated for 
[C23H41BrNOSi2]
+
: 482.1905, found: 482.1905. 
 
5.3.6 4-(4-(tert-butyldimethylsilyloxy)-1-(triisopropylsilyl)-1H-indol-3-yl)pyrimidin-2-amine (3.91) 
 
To a stirring solution of 3.88 (500 mg, 1.04 mmol) in dry THF (5 mL) at -78
o
C under N2 was added 
dropwise tert-butyllithium (1.6 M in pentane) until the solution remained yellow then and additional 
aliquot (1.4 mL, 2.29 mmol) was added dropwise.  The solution stirred for 15 min.  Neat 2-
Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.89, 324 mg, 1.74 mmol, 0.35 mL) was 
added dropwise.  The mixture stirred for 1 h at -78
o
C and was quenched with sat. NH4Cl.  The 
mixture warmed to rt and was partitioned between Et2O/sat. NH4Cl.  The aqueous layer was 
extracted 2X with EtO2.  The combined organic layers were dried (anhyd. MgSO4), concentrated 
to afford 4-(tert-butyldimethylsilyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-
(triisopropylsilyl)-1H-indole (3.90) which was used immediately in the next reaction without further 
purification. 
 
A stirring mixture of crude 3.90 (1.04 mmol), tetrakis(triphenylphosphine)palladium (100 mg, 0.09 
mmol), and 2-amino-4-chloropyrimidine (113 mg, 0.87 mmol), benzene (25 mL, degassed by 
sparging with N2), methanol (5 mL, degassed), and aqueous sodium carbonate (1.25 mL, 2 M, 
degassed) was refluxed under N2 for 24 h.  The mixture was allowed to cool to rt, diluted with 
EtOAc and dried with anhyd. MgSO4.  The filtrate was concentrated onto silica and purified via 
MPLC (silica, eluting at 40% EtOAc:hexane) to afford 3.91 (200 mg, 0.40 mmol, 46 % yield).  
Mp=83-85 
o
C; 
1
H NMR (500 MHz, CDCl3)  (multiplicity, J (Hz), integration, position): 0.10 (s, 6H, 
Si(CH3)2), 0.90 (s, 9H, SiC(CH3)3), 1.17 (d, 18H, 7.6, SiCH(CH3)2), 1.73 (sept., 7.6, 3H, SiCH), 
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5.01 (brs 2’NH), 5.04 (brs, 2’NH), 6.63 (d, 7.8, H5), 7.05 (dd, 7.8, 8.1, H6), 7.15 (d, 8.1, H7), 7.22 
(d, 5.3, H5’), 7.69 (s, H2), 8.19 (d, 5.3, H6’); 
13
C NMR (125 MHz, CDCl3) : -0.4 (2C), 12.8 (3C), 
18.2 (6C), 18.6, 26.0 (3C), 107.9, 110.9, 113.4, 118.4, 120.7, 122.5, 133.7, 144.2, 149.5, 156.6, 
162.5, 163.1; ESI HRMS [M + H]
+
 calculated for [C27H45N4OSi2]
+
: 497.3126, found: 497.3116. 
 
 
5.3.7 4-methoxy-1H-indole (3.92) 
 
A stirring mixture of K2CO3 (3.9g, 28.5 mmol), 3.86 (380 mg, 2.85 mmol), and iodomethane 
(4.05g, 28.5 mmol, 1.8 mL) in dry acetone (10 mL) under N2 was refluxed for 6 h.  The mixture 
was then cooled to rt, and partitioned between EtOAc/H2O.  The aqueous layer was extracted 2X 
with aliquots of EtOAc.  The combined organic layers were dried over anhyd. MgSO4, 
concentrated, and purified via MPLC (silica, eluting at 22% EtOAc:Hex) to afford 3.92 (326 mg, 
2.22 mmol, 78% yield).  Mp=66 
o
C;  
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 
3.98 (s, 3H), 6.55 (d, 7.7, 1H), 6.68 (m, 1H), 7.05 (d, 8.2), 7.12 (m, 2H), 8.16 (br s);
 13
C NMR (100 
MHz, CDCl3) : 55.3, 99.5, 99.8, 104.4, 118.5, 122.61, 122.72, 137.18, 153.33; ESI HRMS [M + 
H]
+
 calculated for [C9H10NO]
+
: 148.0757, found: 148.0757.  
 
5.3.8 3-bromo-4-methoxy-1-(triisopropylsilyl)-1H-indole (3.93) 
 
To 3.92 (275 mg, 1.87 mmol) in 7.5 mL dry THF under stirring and N2 was added dropwise n-
butyllithium (1.58  mL, 1.6 M in hexanes, 2.52 mmol) at -78 
o
C.  The mixture was warmed to -10 
o
C and stirred for 10 min. before being cooled back to -78 
o
C.  Triisopropylsilyl chloride (0.5 g, 
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2.62 mmol, 0.56 mL) was added dropwise.  The mixture was then warmed to 0 
o
C and stirred 
until reaction was complete (via TLC).  The mixture was cooled to -78 
o
C.  N-bromosuccinimide 
(0.45 g, 2.52 mmol) dissolved in dry THF (10 mL) was added to the cooled mixture.  After stirring 
for 2 h at -78 
o
C, the mixture was warmed to rt, diluted with 1% pyridine in hexane and filtered 
through Celite.  Any 3-bromo-4-methoxy-1H-indole in the mixture will lead to decomposition of the 
desired product upon concentration.  The filtrate was concentrated onto neutral alumina and 
chromatographed on neutral alumina (eluting in hexanes).  Brown impurities were removed by 
further purification via MPLC (silica; eluting at 5% EtOAc:Hex) to afford white crystalline solid 3.93 
(610 mg, 1.60  mmol, 85% yield). Mp =65 
o
C; 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), 
integration): 1.06 (d, 7.4, 18H), 1.71 (sept., 7.6, 3H), 3.84 (s, 3H), 6.61 (d, 7.6,), 7.10 (d, 8.2,), 
7.13 (dd, 8.24, 7.6), 7.26 (s);  
13
C NMR (100 MHz, d6-DMSO) : 11.9 (3C), 17.76 (6C), 55.24, 
89.5, 101.1, 107.3, 118.0, 123.4, 129.4, 141.4, 153.0; ESI HRMS [M + H]
+
 calculated for 
[C18H28BrNOSiNa]
+
: 404.1016, found: 404.1025. 
 
5.3.9 4-(4-methoxy-1-(triisopropylsilyl)-1H-indol-3-yl)pyrimidin-2-amine (3.95) 
 
To a stirring solution of 3.93 (350 mg, 0.91 mmol) in dry THF (4.5 mL) at -78
o
C under N2 was 
added dropwise tert-butyllithium (1.6 M in pentane) until the solution remained yellow then and 
additional aliquot (1.2 mL, 2.0 mmol) was added dropwise.  The solution stirred for 15 min.  Neat 
2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.89, 340 mg, 1.82 mmol, 0.37 mL) was 
added dropwise.  The mixture stirred for 1 h at -78
o
C and was quenched with sat. NH4Cl.  The 
mixture warmed to rt and was partitioned between Et2O/sat. NH4Cl.  The aqueous layer was 
extracted 2X with EtO2.  The combined organic layers were dried (anhyd. MgSO4), concentrated 
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to afford 4-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-indole 
(3.94) which was used immediately in the next reaction without further purification. 
 
A stirring mixture of crude 3.94 (0.91 mmol), tetrakis(triphenylphosphine)palladium (104 mg, 0.09 
mmol), and 2-amino-4-chloropyrimidine (118 mg, 0.91 mmol), benzene (25 mL, degassed by 
sparging with N2), methanol (5 mL, degassed), and aqueous sodium carbonate (1.25 mL, 2 M, 
degassed) was refluxed under N2 for 24 h.  The mixture was allowed to cool to rt, diluted with 
EtOAc and dried with anhyd. MgSO4.  The filtrate was concentrated onto silica and purified via 
MPLC (silica, eluting at 40% EtOAc:hexane) to afford 3.95 (205 mg, 0.52 mmol, 57 % yield).  Mp 
=106 
o
C; 
1
H (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration): 1.11 (d, 7.5, 18H), 1.74 
(sept., 7.5, 3H), 3.86 (s, 3H), 6.33 (br s, 2H), 6.71 (d, 7.7), 7.16 (m, 3H), 7.77 (s), 8.16 (d, 5.2); 
13
C NMR (100 MHz, d6-DMSO) : 12.0 (3C), 17.9 (6C), 55.0, 102.0, 107.5, 110.2, 117.4, 118.5, 
123.1, 133.0, 143.1, 153.3, 157.0, 161.14, 163.2; ESI HRMS [M + H]
+
 calculated for 
[C22H33N4OSi]
+
: 397.2418, found:397.2418. 
 
5.3.10 4-methoxymeridianin A (3.96) 
 
To a stirring solution of 3.95 (80 mg, 0.2 mmol) in dry THF (2 mL) at rt was added dropwise TBAF 
(1.0 M, 0.2 mL, 02 mmol).  After 5 min. aqueous Na2CO3 (2 M, 2 mL) was added.  The mixture 
was then partitioned between sat. NH4Cl and EtOAc.  The aqueous layer was extracted 2X with 
aliquots of EtOAc.  The combined organic layers were dried over anhyd. MgSO4, concentrated, 
and purified via MPLC (silica, eluting at 10% MeOH:DCM) to afford 4-methoxymeridianin A (3.96, 
30 mg, 0.13 mmol, 87% yield).  Mp =213-215 
o
C; 
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J 
(Hz), integration):  3.87 (s, 3H), 6.27 (brs, 2H), 6.64 (d, 7.2), 7.08 (m), 7.09 (m), 7.25 (d, 5.3), 7.84 
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(d, 2.6), 8.15 (d, 5.3), 11.64 (brs); 
13
C NMR (100 MHz, d6-DMSO) : 55.0, 101.2, 105.6, 109.6, 
114.5, 115.4, 122.7, 127.5, 138.8, 153.3, 157.0, 161.8, 163.1. M; ESI HRMS [M + H]
+
 calculated 
for [C13H13N4O]
+
: 241.1084, found: 241.1084. 
 
5.3.11 5,7-dibromomeridianin A (3.97) 
 
To a stirring solution of meridianin A (3.24, 5 mg, 0.022 mmol) in 2.0 mL dry DCM was added 
AcOH (0.2 mL) and pyridinium tribromide (14 mg, 0.044 mmol).  The mixture stirred for 5.5 h.  
Na2S2O3 (5% aqueous, 10 mL) and 10 mL EtOAc was added.  The aqueous layer was washed 
2X with aliquots of EtOAc.  The combined organic layers were dried over anhyd. MgSO4, 
concentrated to afford crude  3.96 (5 mg, 0.013 mmol, 58% yield). 
1
H NMR (400 MHz, d6-DMSO) 
 (multiplicity, J (Hz)): 6.97 (s, 2H), 7.27 (d, 5.4), 7.46 (s), 8.21 (d, 5.4), 8.38 (s), 11.24 (brs), 
15.10 (s); ESI-MS (m/z) [M+H] = 382.9 (50%), 384.9 (100%), 386.9 (45%).  
 
5.3.12 4-amino-2-chloro-5-iodopyrimidine (3.99) 
 
In a flask sealed with a rubber stopper, 2,4-dichloropyrimidine (3.98, 1 g, 6.76 mmol) was stirred 
in 29% NH4OH (20 mL) for 12 h.  The solvent was removed in vacuo.  The crude product was 
chromatographed via MPLC (silica) to afford 2-amino-4-chloropyrimidine (400 mg, 3.0 mmol, 
eluting at 6% MeOH:CHCl3, 44% yield) and 4-amino-2-chloropyrimidine (454 mg, 3.5 mmol, 
eluting at 10% MeOH:CHCl3, 52% yield).   
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N-iodosuccinimide (2.7 g, 12.0 mmol) and 4-amino-2-chloropyrimidine (1.3 g, 10.0 mmol) were 
stirred in AcOH (30 mL) at 60-75 
o
C for 3 h.  After solvent removal in vacuo, the residue was 
partitioned between 5% Na2S2O3 and CHCl3.  The organic layer was washed with sat. NH4Cl, 
dried over anhyd. MgSO4 and chromatographed via MPLC (silica, eluting at 45% EtOAc:hexane) 
to afford 3.99 (1.45 g , 5.67 mmol, 57% yield).  
1
H NMR (400 MHz, CDCl3)  (multiplicity, 
integration): 8.38 (s,), 5.65 (br s, 2H); 
13
C NMR (100 MHz, CDCl3) : 74.4, 160.5, 163.1, 163.9.  
The NMR data are consistent with literature values (Chapter 3, ref. 51). 
 
5.3.13 4-amino-2-bromo-5-iodopyrimidine (3.100) 
 
4-amino-2-chloro-5-iodopyrimidine
 
(3.99, 0.73 g, 2.86 mmol) in 33% HBr:AcOH was stirred for 1 h 
then refluxed for an additional hour.  The mixture cooled to rt.  Solvent was removed in vacuo.  
Water was added to the concentrate.  The solid was collected via filtration and dried under 
vacuum affording 3.100 (0.74 g, 2.46 mmol, 86% yield).  Mp= 189-190
o
C; IR (neat)  (cm
-1
):  
3330, 3168, 3009, 1633, 1549; 
1
H NMR (400 MHz, CDCl3)  (multiplicity, integration): 5.78 (2H, 
brs, NH2), 8.31 (s, H6);
 13
C NMR (100 MHz, CDCl3) : 75.4, 152.1, 162.8, 163.9; ESI HRMS 
[M+H]
+
 calculated for [C4H4BrIN3]
+
: 299.8629, found: 299.8626. 
 
5.3.14 2-bromo-5-(4-(tert-butyldimethylsilyloxy)-1-(triisopropylsilyl)-1H-indol-3-yl)pyrimidin-4-
amine (3.101) 
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To a stirring solution of 3.88 (470 mg, 0.98 mmol) in dry THF (5 mL) at -78
o
C under N2 was added 
dropwise tert-butyllithium (1.6 M in pentane) until the solution remained yellow then and additional 
aliquot (1.3 mL, 2.15 mmol) was added dropwise.  The solution stirred for 15 min.  Neat 2-
Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.89, 364 mg, 1.96 mmol, 0.4 mL) was 
added dropwise.  The mixture stirred for 1 h at -78
o
C and was quenched with sat. NH4Cl.  The 
mixture warmed to rt and was partitioned between Et2O:sat. NH4Cl.  The aqueous layer was 
extracted 2X with EtO2.  The combined organic layers were dried (anhyd. MgSO4), concentrated 
to afford crude 3.90 which was used immediately in the next reaction without further purification. 
 
A stirring mixture of crude 3.90 (0.98 mmol), tetrakis(triphenylphosphine)palladium (104 mg, 0.09 
mmol), and 4-amino-2-bromo-5-iodopyrimidine (3.100, 283 mg, 0.98 mmol), benzene (25 mL, 
degassed by sparging with N2), methanol (5 mL, degassed), and aqueous sodium carbonate 
(1.25 mL, 2 M, degassed) was refluxed under N2 for 24 h.  The mixture was allowed to cool to rt, 
diluted with EtOAc and dried with anhyd. MgSO4.  The filtrate was concentrated onto silica and 
purified via MPLC (silica, eluting at 18% EtOAc:hexane) to afford 3.101 (252 mg, 0.44 mmol, 45% 
yield from 3.88).  Mp = 131-133
o
C; IR (neat)  (cm
-1
): 3351, 3130, 2951; 
1
H NMR (400 MHz, 
CDCl3)  (multiplicity, J (Hz), integration, position): 0.09 (s, 6H, Si(CH3)2), 0.83 (s, 9H, SiC(CH3)3), 
1.16 (d, 18H, SiCH(CH3)2), 1.69 (sept, 3H, SiCH), 5.25 (brs, 2H, NH2), 6.54 (d, 7.1, H5), 7.04 (dd, 
7.9, 8.1, H6), 7.07 (s, H2), 7.15, (d, 8.1, H7), 7.95 (s, H6’);   
13
C NMR (100 MHz, CDCl3) : -4.1 
(2C), 13.0 (3C), 18.3 (6C), 18.4, 25.8 (3C), 107.9, 109.0, 109.3, 114.1, 121.7, 123.2, 130.3, 
143.9, 149.6, 150.3, 156.2, 163.9; ESI HRMS [M + H]
+
 calculated for [C27H44N4OSi2]
+
: 575.2232, 
found: 575.2248. 
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5.3.15 synthetic psammopemmin A (3.102) 
 
To 3.101 (50 mg, 0.087 mmol) in 1.0 mL acetonitrile (dried over 4Å molecular sieves) and 0.1 mL 
pyridine (dried over 4Å molecular sieves)  was added 50 µL hydrogen fluoride
.
pyridine (70% as 
HF, 30% as pyridine).  After 30 min. the starting material had completely dissolved.  After 1 h, a 
precipitate had formed.  The mixture stirred for 11 additional h at rt.  The precipitate was collected 
via filtration and washed with acetonitrile.  Drying the precipitate under high vacuum resulted in 
3.102 as a tan powder (15 mg, 0.049 mmol, 56%).  IR (neat)  (cm
-1
): 3429, 3313, 3163, 3015;  
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), integration, position): 6.38 (d, 7.1  H5), 6.88 
(d, 8.3, H7), 6.93, (dd, 8.3, 7.1, H6), 7.27 (s, H2), 7.79 (s, H6’), 9.30 (s, OH), 11.29 (brs, NH);    
13
C NMR (100 MHz, d6-DMSO) : 103.2, 103.8, 105.6, 113.0, 115.4, 122.6, 123.6, 138.6, 148.9, 
151.2, 156.4, 163.6; ESI HRMS [M + H]
+
 calculated for [C12H10BrN4O]
+
: 305.0033, found: 
305.0033. 
 
5.3.16 synthetic psammopemmin A
.
HCl (3.103) 
 
In a 3mm NMR tube, HCl gas was bubble through 3.102 (5 mg) in d6-DMSO (200 L) for 1 min to 
form 3.103.  Because 3.103 is not stable, 
1
H and 
13
C NMR data were obtained immediately (see 
Table 3.2 for NMR data). 
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5.3.17 5-(5-(4-(tert-butyldimethylsilyloxy)-1-(triisopropylsilyl)-1H-indol-3-yl)-2-chloropyrimidin-
 4-amine (3.104) 
 
To a stirring solution of 3.88 (200 mg, 0.42 mmol) in dry THF (5 mL) at -78
o
C under N2 was added 
dropwise tert-butyllithium (1.6 M in pentane) until the solution remained yellow then and additional 
aliquot (0.57 mL, 0.92 mmol) was added dropwise.  The solution stirred for 15 min.  Neat 2-
Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.89, 155 mg, 0.83 mmol, 0.17 mL) was 
added dropwise.  The mixture stirred for 1 h at -78
o
C and was quenched with sat. NH4Cl.  The 
mixture warmed to rt and was partitioned between Et2O/sat. NH4Cl.  The aqueous layer was 
extracted 2X with EtO2.  The combined organic layers were dried (anhyd. MgSO4), concentrated 
to afford crude 3.90 which was used immediately in the next reaction without further purification. 
 
A stirring mixture of crude 3.90 (0.42 mmol), tetrakis(triphenylphosphine)palladium (49 mg, 0.04 
mmol), and 4-amino-2-chloro-5-iodopyrimidine (3.99, 106 mg, 0.42 mmol), benzene (10 mL, 
degassed by sparging with N2), methanol (2.0 mL, degassed), and aqueous sodium carbonate 
(0.5 mL, 2 M, degassed) was refluxed under N2 for 24 h.  The mixture was allowed to cool to rt, 
diluted with EtOAc and dried with anhyd. MgSO4.  The filtrate was concentrated onto silica and 
purified via MPLC (silica, eluting at 18% EtOAc:hexane) to afford 3.104 (123 mg, 0.23 mmol,  
56% yield).  Mp = 83-85 
o
C;  
1
H NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration, 
position): 0.10 (s, 6H, Si(CH3)2), 0.83 (s, 9H, SiC(CH3)3), 1.16 (d, 7.3, 18H, SCH(CH3)2), 1.71 
(sept, 7.3, 3H, SiCH), 5.40 (brs, 2H, H2), 6.55 (d, 7.8, H5), 7.05 (dd, 7.8, 8.2, H6), 7.09 (s, H2), 
7.16, (d, 8.2, H7), 8.02 (s, H6’);   
13
C NMR (100 MHz, CDCl3) : -4.3 (2C), 12.8 (3C), 18.1 (6C), 
18.2, 25.6 (3C), 107.7, 108.9, 109.1, 113.5, 121.6, 123.0, 130.2, 143.7, 149.4, 156.1, 158.6, 
164.1; ESI HRMS [M + H]
+
 calculated for [C27H43ClN4OSi2Na]
+
: 553.2556, found: 553.2540.  
128 
 
 
5.3.18 2’-chloropsammopemmin A (3.105) 
 
T o a stirring solution of 3.104 (35 mg, 0.066 mmol) in dry THF (1 mL) was added dropwise TBAF 
(123 L, 1.0 M, 0.132 mmol).  After 8 min. the solution turned brown and 2 M Na2CO3 (1 mL) was 
added.  The mixture was then partitioned between EtOAc:H2O.  The organic layer was collected, 
dried over andhyd. MgSO4 and chromatographed on MPLC (silica, eluting at 10% MeOH:DCM) to 
afford 3.105 (5 mg, 0.019 mmol, 29% yield).  Alternative procedure:  To 3.104 (80 mg, 0.15 
mmol) in 1.0 mL acetonitrile (dried over 4Å molecular sieves) and 0.1 mL pyridine (dried over 4Å 
molecular sieves)  was added 125 µL hydrogen fluoride
.
pyridine (70% as HF, 30% as pyridine).  
After 30 min. the starting material had completely dissolved.  After 1 h, a precipitate had formed.  
The mixture stirred for 11 additional h at rt.  The precipitate was collected via filtration and 
washed with acetonitrile.  Drying the precipitate under high vacuum resulted in 3.105 as a tan 
powder (20 mg, 0.048 mmol, 32%).  
1
H NMR (400 MHz, d6-DMSO)  (multiplicity, J (Hz), 
integration, position): 6.39 (d, 7.3, H5), 6.89 (d, 8.3, H7), 6.90 (vbrs, 2H, 4’NH2), 6.92, (dd, 7.3, 
7.8, H6), 7.27 (s, H2), 7.87 (s, H6’), 9.30 (s, OH), 11.28 (brs, NH);    
13
C NMR (100 MHz, d6-
DMSO) : 103.1, 103.8, 105.6, 112.6, 115.5, 122.6, 123.7, 138.6, 151.2, 156.4, 157.0, 164.0; ESI 
HRMS [M + H]
+
 calculated for [C12H10ClN4O]
+
: 261.0538, found:261.0536. 
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5.3.19 meridoquin (3.106) 
 
To 3.112 (62 mg, 0.136 mmol) in 1 mL dry THF under Ar and stirring was added TBAF (0.14 mL, 
0.14 mmol, 1.0 M in THF).  After 5 min., the reaction was complete.  Sodium carbonate (1 mL, 2.0 
M) was added and the mixture was partitioned between EtOAc/H2O.  The aqueous layer was 
washed 2X with EtOAc aliquots.  The combined EtOAc extracts were dried over anhyd. MgSO4 
and purified via MPLC (silica, eluting at 35% EtOAc:hexane) to afford 3.106 (35 mg, 0.116 mmol, 
86%).  Mp = 166 
o
C; 
1
H NMR (500 MHz, CDCl3)   (multiplicity, J (Hz), integration): 1.29 (t, 6.9, 
6H), 3.75 (q, 6.9, 4H), 6.78 (dd, 5.3, 2.1), 7.24 (d, 8.6), 7.43 (dd, 2.1, 2.1), 7.83 (s), 8.27 (dd, 5.3, 
2.1), 8.45 (d, 8.6), 8.60 (br s).  
13
C NMR (125 MHz, CDCl3) : 13.2 (2C), 42.1 (2C), 104.3, 111.2, 
116.5, 121.9, 123.1, 124.2, 126.5, 128.7, 137.2, 156.9, 161.1, 161.7; ESI HRMS [M + H]
+
 
calculated for [C16H18ClN4]
+
: 301.1215, found: 310.1220. 
 
5.3.20 2-chloro-4-N,N-diethylaminopyrimidine (3.107) and 4-chloro-2-N,N-diethylamino-
 pyrimidine (3.108) 
 
At rt, neat diethylamine (2 mL) was slowly added to 2,4-dichloropyrimidine (3.98, 500 mg, 3.38 
mmol).  The mixture stirred for 1 min., was diluted with EtOAc and concentrated onto silica.  
Purification via MPLC (silica, gradient from 0 to 35% EtOAc:hexane) afforded 4-chloro-2-N,N-
diethylaminopyrimidine (3.108, eluting at 12% EtOAc:Hex, 54 mg, 0.44 mmol, 13% yield) and 2-
chloro-4-N,N-diethylaminopyrimidine (3.107, eluting at 26% EtOAc:hexane, 372 mg, 2.0 mmol, 
59% yield). 
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4-(N,N-diethyl)-2-chloroaminopyrimidine (3.107):  viscous colorless liquid, solidifies in freezer; 
1
H 
NMR (400 MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.18 (t, 7.0, 6H), 3.48 (br s, 4H), 6.26 
(d, 5.9), 7.96 (d, 5.9); 
13
C NMR (125 MHz, CDCl3) : 12.5, 42.4, 100.9, 156.5, 160.7, 161.7; ESI 
HRMS [M + H]
+
 calculated for [C8H13ClN3]
+
: 186.0793, found: 186.0794. 
 
2-(N,N-diethyl)amino -4-chloropyrimidine (3.108):  viscous colorless liquid; 
1
H NMR (400 MHz, 
CDCl3)  (multiplicity, J (Hz), integration): 1.19 (t, 7.1, 6H), 3.61 (q, 7.1, 4H), 6.44 (d, 4.7), 8.14 (d, 
4.7);  
13
C NMR (100 MHz, CDCl3) : 12.9, 42.0, 108.0, 158.7, 160.9, 161.0 ;ESI HRMS [M + H]
+
 
calculated for [C8H13ClN3]
+
: 186.0793, found: 186.0791. 
 
5.3.21 3-bromo-6-chloro-1-(triisopropylsilyl)-1H-indole (3.110) 
 
To 6-chloroindole (3.109, 1.0 g, 6.6 mmol) in 20 mL dry THF under stirring and N2 was added 
dropwise n-butyllithium (5.6 mL, 1.6 M in hexanes, 8.91 mmol) at -78 
o
C.  The mixture was 
warmed to -10 
o
C and stirred for 10 min. before being cooled back to -78 
o
C.  Triisopropylsilyl 
chloride (1.78 g, 9.24 mmol, 1.96 mL) was added dropwise.  The mixture was then warmed to 0 
o
C and stirred until reaction was complete (via TLC).  The mixture was cooled to -78 
o
C.  N-
bromosuccinimide (1.59 g, 8.91 mmol) was added to the cooled mixture in one portion.  After 
stirring for 2 h at -78 
o
C, the mixture was warmed to rt, diluted with 1% pyridine in hexane and 
filtered through Celite.  The concentrate filtrate was purified via MPLC (silica; eluting in hexane) to 
afford white crystalline solid 3.110 (2.26 g, 5.87 mmol, 89% yield). Mp = 52 
o
C; 
1
H NMR (400 
MHz, CDCl3)  (multiplicity, J (Hz), integration): 1.15 (d, 7.6, 18H), 1.67 (q, 7.6, 3H), 7.18 (dd, 8.3, 
1.4), 7.22 (s), 7.46 (d, 1.4), 7.48 (d, 8.3).  
13
C NMR (100 MHz, CDCl3) : 12.7 (3C), 18.0 (6C), 
93.6, 113.8, 119.9, 121.3, 128.6, 128.7 130.4, 140.4; ESI HRMS [M + H]
+
 calculated for 
[C17H26BrClNSi]
+
:386.0701, found: 386.0698. 
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5.3.22 4-(6-chloro-1-(triisopropylsilyl)-1H-indol-3-yl)-N,N-diethylpyrimidin-2-amine (3.112) 
 
To a stirring solution of 3.110 (200 mg, 0.52 mmol) in dry THF (5 mL) at -78 
o
C under inert 
atmosphere was added dropwise tert-butyllithium (1.6 M in pentane) until the solution remained 
yellow then and additional aliquot (0.350 mL, 0.57 mmol) was added dropwise.  The solution 
stirred for 15 min.  Neat 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (194 mg, 1.04 
mmol, 0.21 mL) was added dropwise.  The mixture stirred for 1 h at -78 
o
C and was quenched 
with sat. NH4Cl.  The mixture warmed to rt and was partitioned between Et2O:sat. NH4Cl.  The 
aqueous layer was extracted 2X with EtO2.  The combined organic layers were dried (anhyd. 
MgSO4), concentrated to afford crude 6-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-
(triisopropylsilyl)-1H-indole which was used immediately in the next reaction without further 
purification. 
 
A stirring mixture of crude 6-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-
(triisopropylsilyl)-1H-indole (0.52 mmol), tetrakis(triphenylphosphine)palladium (35 mg, 0.03 
mmol), and 2-(N,N-diethyl)amino-4-chloropyrimidine (283 mg, 0.29 mmol), benzene (5 mL, 
degassed by sparging with N2), methanol (1 mL, degassed), and aqueous sodium carbonate 
(0.25 mL, 2 M, degassed) was refluxed under N2 for 2 h.  The mixture was allowed to cool to rt, 
diluted with EtOAc and dried with anhyd. MgSO4.  The filtrate was concentrated onto silica and 
purified via MPLC (silica, eluting at 18% EtOAc:hexane) to afford 3.112 (82 mg, 0.179 mmol, 
62%).  Mp = 126 
o
C; 
1
H NMR (400 MHz, CDCl3)   (multiplicity, J (Hz), integration): 1.18 (d, 7.4, 
18H), 1.29 (t, 7, 6H), 1.72 (sept., 7.3, 3H), 3.76 (q, 7.3, 4H), 6.80 (d, 5.5),  7.22 (dd, 8.7,  1.8), 
7.49 (d, 1.8), 7.88 (s), 8.26 (dd, 5.4), 8.46 (d, 8.7);  
13
C NMR (100 MHz, CDCl3) : 12.7 (3C), 13.3 
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(2C), 18.06 (6C), 42.04 (2C), 104.3, 113.8, 118.0, 121.7, 122.8, 127.4, 128.1, 133.8, 142.4, 
157.1, 161.2, 161.6; ESI HRMS [M + H]
+
 calculated for [C25H38ClN4Si]
+
: 457.2549, found: 
457.2569. 
 
5.4 Experimental supporting Chapter 4 
 
5.4.1 Isolation of cytochalasin D (4.17)  
 
Lyophilized 2L scale up fermentation of CY 4202 was exhaustively extracted with methanol (3 X 
24h).  The combined, filtered methanolic extracts were concentrated under reduced pressure.  A 
portion of this extract (2 g) was fractionated on silica MPLC (40g column, gradient: hexane→ethyl 
acetate→methanol) to afford fractions A-F, eluting in increasing polarity.  A portion (50 mg) of 
antimalarial fraction C (250 mg) was further purified on HPLC (Sunfire Prep OBO, 10X250 mm) 
with an isocratic solvent system (1% MeOH:CHCl3).  A large UV active peak eluting at 4.4 min. 
was found to be cytochalasin D (18 mg).  ESI-MS (m/z) [M+H] = 508.3; 
1
H and 
13
C NMR data are 
presented in comparison with literature values in Table 4.2.  
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5.4.2 Isolation of roridin E (4.18) and 12,13-deoxyroridin E (4.19). 
  
Lyophilized 2L scale up fermentation of CY 3923 was exhaustively extracted with methanol (3 X 
24h).  The combined, filtered methanolic extracts were concentrated under reduced pressure.  A 
portion of this extract (2 g) was fractionated on silica MPLC (40g column, gradient: hexane→ethyl 
acetate→methanol) to afford fractions A-F, eluting in increasing polarity.  The antimalarial fraction 
D (52 mg) was further purified on HPLC (Sunfire Prep C-18, 10X250 mm) with an isocratic 
solvent system (30% water:MeOH, 0.1% TFA).  A UV (254 nm) active peak eluting at 30 min. was 
found to 12,13-deoxyroridin E (4.19, 3.3 mg) but the major component of the mixture was not 
isolated and was thought to have degraded in the acidic solution.  Another portion of the original 
extract (2g) was carefully fractionated on silica MPLC (40g column) with a gradual gradient (50% 
EtOAc:hexane→100%EtOAc).  Fractions of a strong UV active (254 nm) peak that eluted at 90% 
EtOAc:hexane were analyzed via 
1
H NMR which revealed pure roridin E (4.18, 40 mg).    
1
H and 
13
C NMR data are presented in comparison with literature values in Table 4.3 (4.18) and Table 
4.4 (4.19). 
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1H NMR spectrum (400 MHz, CDCl3) of  2.68
13C NMR spectrum (100 MHz, CDCl3) of  2.68
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1H NMR spectrum (400 MHz, CDCl3) of  2.69
13C NMR spectrum (100 MHz, CDCl3) of  2.69
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1H NMR spectrum (400 MHz, CDCl3) of  2.70
13C NMR spectrum (100 MHz, CDCl3) of  2.70
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1H NMR spectrum (400 MHz, CDCl3) of  2.71
13C NMR spectrum (100 MHz, CDCl3) of  2.71
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1H NMR spectrum (400 MHz, CDCl3) of  2.72
13C NMR spectrum (100 MHz, CDCl3) of  2.72
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1H NMR spectrum (400 MHz, CDCl3) of  2.73
13C NMR spectrum (100 MHz, CDCl3) of  2.73
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1H   ppm mult J(Hz)
8     5.68    dd 7.2, 15.6
9     5.60    dd 6.7, 15.6
1H NMR spectrum (400 MHz, CDCl3,expanded) of  2.73
Coupling simulation of H8 and H9 reveals E-configuration
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13C NMR spectrum (100 MHz, d6-DMSO) of  meridianin A isolated from 
Synoicum sp.  (3.24)
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gHSQC spectrum (400 MHz, d6-DMSO) of meridianin A (3.24) from Synoicum sp.
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1H NMR spectrum (400 MHz, d6-DMSO) of meridianin B (3.25) from Synoicum sp.
1H NMR spectrum (400 MHz, d6-DMSO) of meridianin C (3.26) from Synoicum sp.
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1H NMR spectrum (400 MHz, d6-DMSO) of meridianin E (3.28) from Synoicum sp.
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1H NMR spectrum (400 MHz, d6-DMSO) of synthetic 3.24
13C NMR spectrum (100 MHz, d6-DMSO) of  synthetic 3.24
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13C NMR spectra (100 MHz, d6-DMSO, expanded) of 
meridianin A isolated from Synoicum sp. (3.24) and
synthetic meridianin A(3.24)
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1H NMR spectrum (400 MHz, d6-DMSO) of  3.86
13C NMR spectrum (100 MHz, d6-DMSO) of  3.86
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1H NMR spectrum (400 MHz, d6-DMSO) of  3.87
13C NMR spectrum (100 MHz, d6-DMSO) of  3.87
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1H NMR spectrum (400 MHz, CDCl3) of  3.88
13C NMR spectrum (100 MHz, CDCl3) of  3.88
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1H NMR spectrum (400 MHz, CDCl3) of  3.91
13C NMR spectrum (100 MHz, CDCl3) of  3.91
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1H NMR spectrum (400 MHz, CDCl3) of  3.92
13C NMR spectrum (100 MHz, CDCl3) of  3.92
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1H NMR spectrum (400 MHz, d6-DMSO) of 3.93
13C NMR spectrum (100 MHz, d6-DMSO) of 3.93
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1H NMR spectrum (400 MHz, d6-DMSO) of 3.95
13C NMR spectrum (100 MHz, d6-DMSO) of 3.95
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1H NMR spectrum (400 MHz, d6-DMSO) of 4-methoxymeridianin A (3.96)
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13C NMR spectrum (100 MHz, d6-DMSO) of 4-methoxymeridianin A (3.96)
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1H NMR spectrum (400 MHz, d6-DMSO) of 5-bromomeridianin E (3.97)
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1H NMR spectrum (400 MHz, CDCl3) of  3.100
13C NMR spectrum (100 MHz, CDCl3) of  3.100
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1H NMR spectrum (400 MHz, CDCl3) of  3.101
13C NMR spectrum (100 MHz, CDCl3) of  3.101
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1H NMR spectrum (400 MHz, d6-DMSO) of synthetic psammopemmin A (3.102)
13C NMR spectrum (100 MHz, d6-DMSO) of synthetic psammopemmin A (3.102)
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1H NMR spectra (400 MHz, d6-DMSO) of 
synthetic psammopemmin A (102) and
synthetic psammopemmin A·HCl (103)
1H NMR spectra (400 MHz, d6-DMSO, expansion) of
synthetic psammopemmin A (102)
synthetic psammopemmin A·HCl (103)
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13C NMR spectra (100 MHz, d6-DMSO) of 
synthetic psammopemmin A (102) and
synthetic psammopemmin A·HCl (103)
13C NMR spectra (100 MHz, d6-DMSO, expansion) of
synthetic psammopemmin A (102)
synthetic psammopemmin A·HCl (103)
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1H NMR spectra (400 MHz, d6-DMSO, expansion) of 
meridianin A from Synoicum sp. (3.24) and
synthetic psammopemmin A·HCl (102)
13C NMR spectra (100 MHz, d6-DMSO, expansion) of
meridianin A from Synoicum sp. (3.24) and
synthetic psammopemmin A·HCl (102)
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(courtesy of R. J. Capon)
400 MHz 1H NMR spectrum of meridianin A (1) from Synoicum sp.
(d6-DMSO, 25 
oC)
1H NMR Comparison of meridianin A (24) and natural psammopemmin A (3.16)
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100 MHz 13C NMR spectrum of meridianin A (3.24)  from Synoicum sp.
(d6-DMSO, 25 
oC)
(courtesy of R. J. Capon)
13C  NMR Comparison of meridianin A (3.24) and natural psammopemmin A (3.16)
of natural psammopemmin A (3.16)
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1H NMR spectrum (400 MHz, CDCl3) of  3.104
13C NMR spectrum (100 MHz, CDCl3) of  3.104
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1H NMR spectrum (400 MHz, CDCl3) of  3.105
13C NMR spectrum (100 MHz, CDCl3) of  3.105
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1H NMR spectrum (400 MHz, CDCl3) of  3.106
13C NMR spectrum (100 MHz, CDCl3) of  3.106
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1H NMR spectrum (400 MHz, CDCl3) of  3.107
13C NMR spectrum (100 MHz, CDCl3) of  3.107
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1H NMR spectrum (500 MHz, CDCl3) of  3.108
13C NMR spectrum (125 MHz, CDCl3) of  3.108
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1H NMR spectrum (500 MHz, CDCl3) of  3.110
13C NMR spectrum (125 MHz, CDCl3) of  3.110
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1H NMR spectrum (500 MHz, CDCl3) of  3.112
13C NMR spectrum (125 MHz, CDCl3) of  3.112
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Appendix C:  NMR data supporting Chapter 4 
 
1
H and 
13
C NMR spectra (CDCl3) of cytochalasin D (4.17) .......................................................... 193 
1
H and 
13
C NMR spectra (CDCl3) of roridin E (4.18) .................................................................... 194 
1
H and 
13
C NMR spectra (CDCl3) of 12,13-deoxyroridin E (4.19) ................................................ 195 
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1H NMR spectrum (500 MHz, CDCl3) of  cytochalasin D (4.17)
13C NMR spectrum (125 MHz, CDCl3) of cytochalasin D (4.17)
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1H NMR spectrum (500 MHz, CDCl3) of  roridin E (4.18)
13C NMR spectrum (125 MHz, CDCl3) of  roridin E (4.18)
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